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ABSTRACT 
 
Over the past two decades, drug delivery systems have become a subject of 
major interest in the pharmaceutical industry for the treatment of different diseases, 
such as cancer, viral infections, and genetic disorders. A wide range of compounds 
show high binding affinity and great potential in in vitro non-cellular assays through 
direct interacting with molecular targets. However, many compounds show low 
potency in cell-based assays due to their limited delivery across the cell membrane. 
The physicochemical properties of several compounds, such as size, poor water 
solubility, hydrophobic nature, and negative charge, limit their cellular uptake 
significantly. Thus, there is an urgent need in design and synthesis of novel molecular 
transporters for efficient delivery of effective compounds to cellular targets.   
The recent growth of nanotechnology products will expand the current 
resources of therapeutics for the pharmaceutical industry in the next few years. The 
use of nanotechnology in drug delivery is widely expected to change the future of the 
pharmaceutical and biotechnology industries. The application of nanotechnology in 
drug delivery has led to the discovery of nano Drug Delivery Systems (nano-DDS).  
Nanocarriers exhibit unique properties and take advantage of specific 
physiochemical behavior of nanoparticles. Properties such as, magnetism, 
conductivity, melting and boiling points, and chemical and biological reactivity 
become different at nano scale due to the quantum mechanical behavior of extremely 
small structures at molecular dimensions. Furthermore, nanoparticles behave 
 
 
differently since they take advantage of extraordinary high surface area to mass ratio, 
leading to increased surface interactions and distinct biological performance. 
Nanoparticles have the potential to be manipulated through changing their size, 
electronic, and hydrophobic nature. Employing nanosized carriers offer several 
advantages, including enhanced intracellular delivery of poorly water-soluble drugs, 
targeted delivery, transporting relatively large biologically important molecules across 
the cell membrane, delivery of a combination of drugs to overcome drug resistance, 
and transporting drugs through challenging epithelial and endothelial barriers.  
Thus, design and development of nano-sized pharmaceutical carriers has 
become attractive for chemists, biologists, and physicists. Functionalized Nano-DDS 
are designed to deliver and release cargo drugs intracellularly more efficiently than the 
currently available systems, leading to the enhanced drug tissue bioavailability and 
eventually therapeutics efficacy. 
Among all nano-DDS, Cell-Penetrating Peptide (CPP)-mediated intracellular 
DDS has been widely used for the enhanced delivery of water insoluble drugs, 
negatively charged molecules (e.g., DNA, siRNA, phosphopeptides), and proteins. 
However, the application of (CPP)-mediated intracellular DDS in in vivo models has 
been challenging due to their inherent toxicity to normal cells and organs. Several 
studies have been performed to facilitate the intracellular delivery of a wide range of 
low-molecular weight and macromolecular drugs using carriers through the cell 
cytoplasm bypassing the endocytic pathway to avoid lysosomal degradation. In this 
process, although the drug is delivered into cytoplasm protected, it still needs to be 
transported to a certain organelles, such as mitochondria or nuclei, where therapeutic 
 
 
function occurs. Several CPPs promote the delivery of drugs through receptor-
mediated endocytosis. However, this mechanism requires high affinity between the 
drug-carrier complex and the target in the cell membrane for endocytosis. This process 
will be followed by energy-dependant formation of endosomes. However, this method 
suffers from entrapment and release challenges. After delivery of the molecular cargo 
into cells through endocytic pathway, and its entrapment in endosome, the cargo 
molecules or drug may end up in lysosome and degraded by the lysosomal enzymes. 
Thus, a limited amount of the drug can reach the cytoplasm because of inadequate 
endosomal escape and lysosomal degradation. As a result, although numerous CPPs 
exhibit promising results in in vitro assays, they fail in vivo because of the poor 
bioavailability.  
Furthermore, the nuclear delivery of cargo drugs with known CPPs has been 
unsuccessful. The nucleus of a cell is an important target for drug delivery systems, 
due to presence of the genetic information and transcription machinery. An efficient 
cellular uptake of the drug is highly desired in nucleus where it can interact with 
nucleic acids. The nuclear targeting delivery is challenging. The designed drug-CPP 
complex must meet several requirements for nuclear delivery including efficient cell 
internalization by receptor-mediated endocytosis (RME), escaping 
endosomal/lysosomal pathways, acquiring a nuclear localization signal to 
communicate with nuclear pore complexes, and eventually, being sufficiently small to 
enter the nuclear membrane. Not many CPPs have been found efficient for the nuclear 
delivery applications.   
 
 
CPPs can be classified into two major classes, linear and cyclic CPPs. Most 
reported CPPs are linear peptides that are flexible in solution and contain up to 10 
amino acids. However, cyclization of peptides has been employed as a strategy to 
generate constrained structures. The rigidity imposed by cyclization reduces the 
flexibility and causes the system to adopt a restricted numbers of molecular 
conformations. Peptide cyclization has become a unique approach to generate 
conformations not available to linear peptides. Cyclic and linear peptides containing 
an equal number of similar amino acids create different geometries leading to different 
affinities for similar targets. Furthermore, cyclic CPPs containing specific amino acids 
have shown to have a different cellular uptake mechanism compared to linear CPPs. 
While most of the linear CPPs undergo endocytosis pathways in cellular uptake, some 
of the cyclic CPPs have endocytosis-independent uptake and target nucleus. Thus, 
cyclic peptides can be designed to be used as nuclear delivery vehicles of anticancer 
compounds targeting DNA. Functionalizing cyclic peptides with tumor targeting 
moieties can be used as a strategy for selective cancer cell targeting and improving 
nuclear targeting of anticancer drugs. 
Cyclic CPPs can be also covalently conjugated to active drug cargos to 
generate prodrugs. Prodrugs are chemically modified analogs of an active metabolite 
that can improve pharmacokinetics and pharmacodynamics (PK/PD) properties of the 
drug. Prodrug strategy could offer several advantageous, such as enhancing water 
solubility, drug delivery, and chemical stability, and reducing toxicity. However, 
chemical transformation to the active drug is required in the presence of different 
intracellular enzymes to convert prodrugs to their corresponding pharmacologically 
 
 
potent moieties in in vivo systems. Cyclic peptide-drug conjugates can be used as 
alternative prodrug approach for improving delivery of compounds with limited 
cellular uptake. 
This dissertation focuses on a class of cyclic peptides as intracellular molecular 
transporters that can be used as prodrugs or peptide-capped gold nanoparticles. We 
hypothesized that the combination of alternate hydrophobic tryptophan and positively 
charged arginine or lysine residues in the sequence of the cell-penetrating cyclic 
peptide was critical for improving the cell-penetrating properties of the system. 
Furthermore, the presence of arginine and tryptophan facilitated the formation of gold 
nanoparticles. The molecular transporting efficiency of the peptide alone and peptide-
capped gold nanoparticles was evaluated for a broad range of molecular cargos 
including anti-HIV drugs, anticancer agents, and negatively charged phosphopeptides.  
The cyclic peptides containing alternate tryptophan and arginine residues and 
their corresponding peptide-capped gold nanoparticles enhanced the delivery of water 
insoluble drugs and negatively charged biologically important molecules. A broad 
range of parameters including concentration, toxicity, time, and different sequences of 
amino acids were explored to optimize the cellular uptake. Several characterization 
methods were used to determine the interaction between drugs and carrier through the 
formation of the complex. Different methods were also used to investigate the 
mechanism of the cellular uptake. 
This work presents examples where prodrugs containing linear peptides are 
compared with their corresponding cyclic peptides in terms of biological properties 
 
 
and in delivery of different drugs. For example, cyclic peptides containing certain 
amino acids generated gold nanoparticles more efficiently compared to their 
corresponding linear peptides. Moreover, cyclic peptide capped gold nanoparticles 
exhibited higher molecular transporting potency when compared with the linear 
counterparts. This dissertation will be discussed in four manuscripts: 
The objective of Manuscript І (published in Molecular Pharmaceutics 2013, 
10(5), 2008-2020) was to evaluate a cyclic octapeptide containing arginine and 
tryptophan for their ability to transport negatively charged phosphopeptides. 
Phosphopeptides are important compounds for studying protein-protein interactions. 
Phosphopeptides suffer from their limited cellular uptake due to the presence of 
negatively charged phosphate group in their structure. The hypothesis of this 
manuscript is that cyclic peptide [WR]4 containing positively charged arginine can 
interact with negatively charged cell-impermeable phosphopeptides and improve their 
cellular uptake. Furthermore, the positively charged arginine and hydrophobic 
tryptophan can interact with negatively charged and hydrophobic residues in the cell 
membrane phospholipids and improve cell permeability of phosphopeptides. The 
cellular uptake of several biologically important phosphopeptides such as 
GpYLPQTV, NEpYTARQ, AEEEIY GEFEAKKKK, PEpYLGLD, pYVNVQNNH2, 
and GpYEEI was evaluated in the presence and absence of [WR]4. The cyclic peptide 
enhanced the cellular uptake of all phosphopeptides significantly in human leukemia 
cells (CCRF-CEM) after 2 h incubation. Confocal microscopy studies in live cells 
confirmed that the mixture of F′-PEpYLGLD and [WR]4 was localized in cells and 
showed higher cellular uptake than the phosphopeptides alone. Several tools including 
 
 
Transmission Electron Microscopy (TEM) and Isothermal Calorimetry (ITC) were 
used to understand the interaction between the drug and carrier. TEM results showed 
that the phosphopeptide-drug complex (PEpYLGLD-[WR]4) formed specific nano-
sized structures with the 125 × 60 nm dimensions. The ITC investigation proved an 
exothermic interaction driven by entropy. The result of this paper showed that the 
presence of the cyclic peptide enhanced the cellular uptake of phosphopeptides 
significantly. To this end, it was discovered that [WR]4 can be employed as a cellular 
delivery tool of negatively charged phosphopeptides through non-covalent interaction. 
However, the evaluation of the covalent conjugation between the drug and cyclic 
peptide remained unexplored. 
Manuscript ІІ (published in Molecular Pharmaceutics 2013, 10(2), 488-499) 
embarked on taking advantage of both the cell-penetrating properties of the peptide 
and prodrug strategy. The hypothesis underlying this project is that cyclic CPP-drug 
conjugates can be used as potential prodrug to improve the cellular delivery of 
anticancer compounds. Doxorubicin (Dox), a potent anticancer drug, was covalently 
linked with the cyclic peptide containing alternate tryptophan and arginine 
([W(RW)4]) to afford their corresponding prodrug cyclic [W(RW)4]−Dox. To study 
the effect of the cyclic nature of the peptide, linear peptide attached to Dox (linear 
(RW)4−Dox) was also synthesized for comparative studies. The biological activities of 
cyclic [W(RW)4]−Dox and linear (RW)4−Dox prodrugs including their cellular uptake 
and anticancer potency were compared in cell-based assays. Comparative 
antiproliferative assays between covalent (cyclic [W(RW)4]−Dox and linear 
(RW)4−Dox) and the corresponding noncovalent physical mixtures of the peptides and 
 
 
Dox were performed. Cyclic [W(RW)4]−Dox inhibited the CCRF-CEM (62−73%), 
ovarian adenocarcinoma (SK-OV-3) (51−74%), colorectal carcinoma (HCT-116) 
(50−67%), and breast carcinoma (MDA-MB-468) (60−79%) cells at a concentration of 
1 μM after 72−120 h of incubation. Cyclic [W(RW)4]−Dox exhibited higher 
antiproliferative activity than linear (RW)4−Dox in all cancer cells after 72 h.. 
Furthermore, the cellular uptake of [W(RW)4]−Dox was observed to be higher than 
that of the linear prodrug after 24 h incubation in SK-OV-3 cells, suggesting that the 
cyclic nature offers major advantageous when compared with the corresponding linear 
ones. The result of this manuscript revealed that cyclic prodrug (cyclic 
[W(RW)4]−Dox) can be used as a potential prodrug candidate for enhancing the 
cellular retention of the drug in the treatment of ovarian cancer.  
In Manuscript Ш (published in Molecular Pharmaceutics, 2013, 10(2), 500-
511), we investigated the application of cyclic peptides in generating gold 
nanoparticles. We hypothesize that cyclic peptides containing specific amino acids 
can be used as reducing agents and generate peptide-capped gold nanoparticles (CP-
AuNPs) from gold ion (Au
3+
). Several cyclic peptides including [WR]4, [FK]4, [AK]4, 
[EL]4, [RFEF]2, [EK]4, and [FR]4 containing hydrophobic residues (W, F, L) and 
charged residues (K, R, E) where A = alanine, E = glutamic acid, F = phenylalanine, K 
= lysine, L = leucine, R = arginine, W= tryptophan were investigated for their ability 
to generate gold nanoparticles. Among all of them, only [WR]4 was discovered to be 
appropriate for the synthesis of CP-AuNPs. Flow cytometry studies showed that the 
cellular uptake of fluorescence-labeled anti-HIV drugs such as lamivudine, 
 
 
emtricitabine, and stavudine was significantly enhanced in human ovarian 
adenocarcinoma (SK-OV-3) cells in the presence of [WR]4-AuNPs. For instance, the 
cellular uptake of fluorescence labeled lamivudine-loaded [WR]4-AuNPs showed 12-
fold higher cellular uptake compared to fluorescence labeled lamivudine alone in 
CCRF-CEM cells after 2 h incubation. The morphology and size of nanoparticles were 
characterized using TEM.. TEM results showed [WR]4-AuNPs form nano-sized 
structures with approximate size 5-50 nm. [WR]4-AuNPs (100 μM) did not show 
significant toxicity in CCRF-CEM, SK-OV-3, and normal human colon myofibroblast 
(CCD-18Co) cells after 24-72 h incubation. To this point, we understand that the cell-
penetrating peptide-capped gold nanoparticles have potential to be used as prodrugs 
for delivery of antiviral and anticancer drugs through noncovalent conjugation. 
However, this strategy was required to be evaluated for non-cell penetrating peptides. 
Thus, we used a sequence of amino acids for designing a non-cell-penetrating peptide 
that generated peptide-capped gold nanoparticles with molecular transporting 
property.   
In Manuscript ІV, (published in Molecular Pharmaceutics, 
DOI: 10.1021/mp400199e), a green method for the synthesis of non-cell penetrating 
peptide-capped gold nanoparticles was reported. We hypothesize that a non-cell 
penetrating peptide containing lysine and tryptophan namely linear (KW)5 and cyclic 
[KW]5 can be converted to a cell-penetrating molecular transporter upon generation of 
cyclic peptide-capped gold nanoparticles (linear (KW)5-AuNPs and cyclic [KW]5-
AuNPs). A comparative flow cytometry results revealed that the cellular uptake of 
fluorescence-labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine (3TC)) in 
 
 
CCRF-CEM cells, and a negatively charged cell-impermeable phosphopeptide 
(GpYEEI) in SK-OV-3 cells was significantly higher in the presence of cyclic [KW]5-
AuNPs than that of linear (KW)5-AuNPs, parent cyclic [KW]5, and linear (KW)5 
peptides. For example, the cellular uptake of F-GpYEEI was enhanced 12.8-fold by 
cyclic[KW]5-AuNPs when compared with F-GpYEEI alone. Microscopy results 
showed that fluorescence-labeled-3TC-loaded cyclic[KW]5-AuNPs were localized in 
nucleus in SK-OV-3 cells after 1 h incubation. However, linear(KW)5-AuNPs 
delivered the majority of fluorescence-labeled-3TC into cell cytoplasm. The results 
from this work suggest that non-cell penetrating peptides can be converted to efficient 
drug carriers by forming peptide-capped gold nanoparticles. 
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Figure 1. General Application of [WR]4. 
 
 
 
In summary, the studies described in this dissertation provided insights about 
the application of a new generation of cyclic peptides for the delivery of a broad range 
of drugs and biomolecules. The cyclic peptide containing alternate tryptophan and 
arginine residues was found to be efficient molecular transporters and nuclear delivery 
agents (Figure 1). In addition, we have demonstrated that a non-cell penetrating cyclic 
peptide can be converted to an efficient intracellular drug transporter through 
generation and capping of the gold nanoparticles. A detailed investigation on the 
cyclic nature of the peptide compared to the linear one in terms of their chemical 
behavior and biological activity was provided. Overall, a concrete strategy has been 
established by developing non-toxic cyclic peptide molecular transporters that can be 
used in prodrug strategy or gold nanoparticle formation. The scientific knowledge was 
advanced in the area of application of cell-penetration peptides in prodrug strategy and 
designing nanocarriers. 
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MANUSCRIPT І: Efficient delivery of cell impermeable phosphopeptides by a 
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MANUSCRIPT ІІ: Design and biological evaluation of cell-penetrating peptide–
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MANUSCRIPT Ш: Cyclic peptide-capped gold nanoparticles as drug delivery 
systems 
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MANUSCRIPT ІV: Surface decorated gold nanoparticles by linear and cyclic 
peptides as molecular transporters 
This manuscript was published in “Molecular Pharmaceutics”, July 2013, DOI: 
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Abstract 
Phosphopeptides are valuable reagent probes for studying protein−protein and 
protein−ligand interactions. The cellular delivery of phosphopeptides is challenging 
because of the presence of the negatively charged phosphate group. The cellular 
uptake of a number of fluorescent-labeled phosphopeptides, including F′-GpYLPQTV, 
F′-NEpYTARQ, F′-AEEEIYGEFEAKKKK, F′-PEpYLGLD, F′-pYVNVQNNH2, and 
F′-GpYEEI (F′ = fluorescein), was evaluated in the presence or absence of a [WR]4, a 
cyclic peptide containing alternative arginine (R) and tryptophan (W) residues, in 
human leukemia cells (CCRF-CEM) after 2 h incubation using flow cytometry. [WR]4 
improved significantly the cellular uptake of all phosphopeptides. PEpYLGLD is a 
sequence that mimics the pTyr
1246
 of ErbB2 that is responsible for binding to the Chk 
SH2 domain. The cellular uptake of F′-PEpYLGLD was enhanced dramatically by 27-
fold in the presence of [WR]4 and was found to be time-dependent. Confocal 
microscopy of a mixture of F′-PEpYLGLD and [WR]4 in live cells exhibited 
intracellular localization and significantly higher cellular uptake compared to that of 
F′-PEpYLGLD alone. Transmission electron microscopy (TEM) and isothermal 
calorimetry (ITC) were used to study the interaction of PEpYLGLD and [WR]4. TEM 
results showed that the mixture of PEpYLGLD and [WR]4 formed noncircular 
nanosized structures with width and height of 125 and 60 nm, respectively. ITC 
binding studies confirmed the interaction between [WR]4 and PEpYLGLD. The 
binding isotherm curves, derived from sequential binding models, showed an 
exothermic interaction driven by entropy. These studies suggest that amphiphilic 
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peptide [WR]4 can be used as a cellular delivery tool of cell-impermeable negatively 
charged phosphopeptides. 
KEYWORDS: cellular uptake, cyclic peptides, nanoparticles, phosphopeptides, SH2 
domain 
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Introduction 
Peptide amphiphiles (PAs) are composed of a combination of amino acids 
carrying hydrophobic/hydrophilic and positively/ negatively charged residues.
1
 PAs 
have been found to be promising tools in drug and gene delivery due to their 
biocompatibility and bioactivity.
2−4 
These compounds are not toxic to cells at their 
experimental concentration and are able to cross the cell membrane because of their 
unique structural properties. 
Hydrophobic unit of PAs can contain long chain fatty acids or amino acids 
with hydrophobic side chain residues. This unit generates a pocket that could be 
responsible for the entrapment of drugs and facilitates the internalization into the cell 
membrane.
5
 At the same time, the presence of positively charged arginine facilitates 
the interaction between the peptide and the negatively charged phospholipids on the 
cell membrane. The application of positively charged linear cell-penetrating peptides 
(CPPs) as drug carriers for biologically active cargos has been reported previously.
6−9
 
Polyarginines, TAT (trans-acting activator of transcription), and Penetratin have been 
found to enhance the cellular uptake of a diverse range of drugs.
10−12
 Thus, the 
appropriate combination of amino acids in the structure of peptide determines the 
efficiency and function of the delivery system.  
Phosphopeptides are valuable reagent probes mimicking phosphoproteins for 
studying protein−protein and protein−ligand interactions 13,14 and determination of 
substrate specificity of the Src homology 2 (SH2) domain,
15
 phosphatases,
16,17
 and 
phosphotyrosine binding (PTB) domains.
18,19
 The use of phosphopeptides has been 
5 
 
challenging due to the fact that they have limited cellular uptake because of the 
presence of the negatively charged phosphate group. Several chemical modifications 
have been used to enhance the intracellular delivery of phosphopetides through 
covalent conjugation to other transporter peptides.
20−22
 These strategies suffer from 
several disadvantages including multistep synthesis of the fusion conjugates, low 
loading yields, and the requirement of cleavage through chemical or enzymatic 
reactions to release phosphopeptides.
23
  
Peptidomimetic prodrugs have been reported for intracellular delivery of aryl 
phosphoramidates
24
 and difluoromethyl phosphonates.
25
 Arrendale and co-workers 
developed a (difluoromethylene)phosphoserine prodrug to deliver negatively charged 
phosphoserine peptidomimetic intracellularly. FOXO3a is a transcription factor that is 
phosphorylated by Akt1 and binds to 14-3-3-adaptor protein. The released modified 
phosphopeptide was able to release FOXO3a from 14-3-3 protein, leading to cell death 
in leukemia cells.
26,27
 Other phosphoserine and phosphothreonine masked 
phosphopeptides have been evaluated in studying kinase regulation.
28,29
  
Considering the critical roles of the phosphopeptides in cellular signaling 
pathways, we have previously reported amphiphilic linear peptide analogs to improve 
the intracellular uptake of negatively charged phosphopeptides through noncovalent 
conjugation.
30
 The linear positively charged peptides were designed based on the Src 
SH2 domain phosphotyrosine (pTyr) binding pocket.  
We introduced a new class of homochiral cyclic peptides containing arginine 
(R) and tryptophan (W) such as [WR]4 that were appropriate carriers for a wide range 
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of drugs.
31
 This system showed that the optimized balance between positive charge 
and hydrophobicity was critical for the peptide to enhance the intracellular delivery of 
drugs through interaction with the cell membrane and penetration into the lipid 
bilayer. Cyclic [WR]4 provided major advantages compared to their linear 
counterparts, including higher enzymatic stability, bypassing endosomal uptake, 
improved cell permeability, and nuclear targeting.
31
  
In continuation of our efforts to introduce new applications of [WR]4 for the 
delivery of biomolecules, we report here using [WR]4 for improving the cellular 
delivery of negatively charge phosphopeptides. Addition of negatively charged 
phosphopeptides to the positively charged [WR]4 led to the formation of 
nanostructures through intermolecular interactions. To the best of our knowledge, this 
is the first report of using a cell-penetrating cyclic peptide for cellular delivery of 
impermeable phosphopeptides. 
 
EXPERIMENTAL SECTION 
General. All amino acids were purchased from Chem-Impex International, Inc. 
HBTU was purchased from Oakwood products, Inc. All other chemicals and reagents 
were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). The chemical 
structures of final products were confirmed by high resolution MALDI AXIMA 
performance TOF/TOF mass spectrometer (Shimadzu Biotech). Details of procedures 
and spectroscopic data of the respective compounds are presented below. Final 
compounds were purified on a Phenomenex Prodigy 10 μm ODS reversed-phase 
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column (2.1 cm × 25 cm) with a Hitachi HPLC system using a gradient system of 
acetonitrile (CH3CN) or methanol and water (CH3OH/H2O) (0−100%, pH 7.0, 60 
min). The purity of final products (≥95%) was confirmed by analytical HPLC. The 
analytical HPLC was performed on a Hitachi analytical HPLC system using a C18 
Shimadzu Premier 3 μm column (150 cm × 4.6 mm) and a gradient system 
(water/CH3CN), and a flow rate of 1 mL/min with detection at 220 nm. Cyclic peptide 
[WR]4 was synthesized according to our previously reported procedure.
31
 As 
representative examples, the synthesis of Ac-PEpYLGLD and F′-PEpYLGLD is 
outlined here.  
Synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD. Side chain protected peptide 
PE(pY)LGLD was assembled on Fmoc-Asp(OtBu)-Wang resin (740 mg, 0.54 
mmol/g, 0.4 mmol) by solid-phase peptide synthesis strategy using Fmoc-protected 
amino acids [Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Tyr(PO3tBu2)-OH, 
Fmoc-Glu(OtBu)-OH, and Fmoc- Pro-OH] on a PS3 automated peptide synthesizer at 
room temperature using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and N-methylmorpholine (NMM, 0.4 M) in N,N-
dimethylformamide (DMF) as coupling and activating agents, respectively (Scheme 
1). After the assembly of the side chain protected peptide sequence, the Fmoc 
protecting group at the N-terminal proline was removed using piperidine in DMF 
(20% v/v). The resin was washed with DCM (3 × 15 mL) and MeOH (3 × 15 mL) for 
further modification using either capping reagent (acetic anhydride) or fluorescein 
labeling reagent (5(6)-carboxyfluorescein isobutyrate). The resin was dried overnight 
under vacuum and divided into two parts. The capping reaction was carried out on the 
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first portion using acetic anhydride ((CH3CO)2O) (953 μL) and N,N-
diisopropylethylamine (DIPEA) (1,742 μL) (50/50 equiv) in DMF (10 mL). The 
mixture containing peptide-attached resin and reagents was shaken for 30 min, 
followed by washing with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH (3 × 15 
mL), respectively. The resin was dried under vacuum at room temperature for 24 h. 
The second portion of the resin was swelled in DMF (2 × 20 mL) for 2 h. The 
preactivation reaction was performed on the fluorescein reagent using a mixture of 
5(6)-carboxyfluorescein isobutyrate (5 equiv), 1-hydroxy-7-azabenzotriazole (HOAt, 
5 equiv)/7- azabenzotriazol-1-yloxy tripyrrolidinophosphonium hexafluorophosphate) 
(PyAOP, 5 equiv)/DIPEA, 10 equiv) in DMF:DCM (5:1 v/v, 12 mL) for 10 min. The 
activated fluorescein reagent was added to the peptide-attached resin and stirred at 
room temperature for 3 h. After the completion of the reaction, the resin was washed 
by DMF (5 × 15 mL), DCM (3× 15 mL), and MeOH (5 × 15 mL), respectively. The 
protecting group (isobutyrate) was removed from the carboxyfluorescein by treating 
the peptide-attached resin with 20% piperidine in DMF (5 × 15 mL, 25 min each). 
Finally, the resin was washed with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH 
(5 × 15 mL), respectively, followed by drying under a high vacuum at room 
temperature for 24 h. The cleavage reagent R cocktail containing trifluoroacetic acid 
(TFA)/thioanisole/ethandithiol (EDT)/anisole (90:5:3:2 v/v/v/v, 12 mL) was added to 
both portions of the resin, and the mixtures were stirred at room temperature for 2 h. 
The resins were filtered and washed with Reagent R (2 mL) again. The filtrates were 
evaporated to reduce the volume under dry nitrogen. The crude peptides were 
precipitated by adding cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm 
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for 5 min, followed by decantation to obtain the solid precipitates. The solid materials 
were further washed with cold ether (2 × 100 mL) for 2 times. The peptides were 
lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex 
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system 
to yield the linear capped Ac-PE(pY)LGLD and fluorescein-labeled F′-PE(pY)LGLD 
peptides, respectively. Similarly, other fluorescein-labeled peptides were synthesized 
according to this procedure.  
Ac-PE(pY)LGLD (Shown Here as PE(pY)LGLD). MALDITOF (m/z) 
[C39H58N7NaO17P]: calcd [M + Na]
+
, 950.3524; found, 950.3524.  
F′-PE(pY)LGLD. MALDI-TOF (m/z) [C58H67N7O22P]: calcd [M + H]
+
, 1244.4077; 
found, 1244.4080. [C58H66N7NaO22P]: calcd [M + Na]
+
, 1266.3896; found, 1266.3899.  
F′-G(pY)LPQTV. MALDI-TOF (m/z) [C57H67N8NaO20P]: calcd [M + Na]
+
, 
1237.4107; found, 1237.4108. [C57H67KN8O20P]: calcd [M + K]
+
, 1253.3846; found, 
1253.3846.  
F′-NE(pY)TARQ. MALDI-TOF (m/z) [C57H68N12O23P]: calcd [M + H]
+
, 1319.4258; 
found, 1319.4258.  
F ′-AEEEI(pY)GEFEAKKKK. MALDI-TOF (m/z) [C102H139N19O36P]: calcd [M + H]
+
, 
2236.9368; found, 2236.9370.  
F′-PS(pY)VNVQN-NH2. MALDI-TOF (m/z) [C61H74N12O22P]: calcd [M + H]
+
, 
1357.4778 ; found, 1357.4781.  
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F′-G(pY)EEI. MALDI-TOF (m/z) [C48H51N5O20P]: calcd [M+ H]
+
, 1048.2865; found, 
1048.2872.  
 
Cell Culture and Cytotoxicity Assay.  
Cell Culture. Human leukemia carcinoma cell line CCRF-CEM (ATCC No. CCL-
119), ovarian adenocarcinoma SK-OV-3 (ATCC No. HTB-77), colorectal carcinoma 
HCT-116 (ATCC No. CCL-247), and normal human colon myofibroblast (CCD-
18Co, ATCC No. CRL-1459) were obtained from American Type Culture Collection. 
Cells were grown in 75 cm
2
 cell culture flasks with EMEM (Eagle’s minimum 
essential medium), supplemented with 10% fetal bovine serum, and 1% 
penicillin/streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin 
in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 °C.  
Flow Cytometry Studies. Human leukemia adenocarcinoma (CCRF-CEM, 1 × 10
7
 
cells) or human ovarian adenocarcinoma cells (SK-OV-3, 3 × 10
5 
cells) were taken in 
6-well plates in opti-MEM or serum-free RPMI medium. Then the fluorescence- 
labeled phosphopeptides (F′-PE(pY)LGLD, F′-G(pY)-LPQTV, F′-NE(pY)TARQ, F′-
PS(pY)VNVQN-NH2, F′-AEEEI(pY)G EFEAKKKK, or F′-G(pY)EEI) (5−10 μM) 
were added to the different wells containing [WR]4 (25−50 μM) in media. The plates 
were incubated for 1−2 h at 37 °C. Cells and fluorescence-labeled phosphopeptides 
alone were used as negative controls. After 1−2 h incubation, the medium containing 
the peptide was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 
mM) for 5 min to remove any artificial surface binding. Then the cells were washed 
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twice with PBS. Finally, the cells were resuspended in flow cytometry buffer and 
analyzed by flow cytometry (FACSCalibur: Becton Dickinson) using FITC channel 
and CellQuest software. The data presented were based on the mean fluorescence 
signal for 10,000 cells collected. All assays were performed in triplicate. A similar 
procedure was used for linear (WR)4 and linear tripodal peptide LPA4 FACS studies.  
Cell Cytotoxicity Assay of [WR]4 + PEpYLGLD Mixture. SK-OV-3 (5,000 cells), 
CCRF-CEM (40,000 cells), HCT-116 (4,000), and CCD-18Co (3,000 cells) were 
seeded in 0.1 mL per well in 96-well plates 24 h prior to the experiment. The old 
medium (EMEM containing fetal bovine serum (FBS) (10%) for SK-OV-3, HCT-116, 
and CCD-18Co was removed. The stock solutions were prepared at high 
concentrations to generate maximum intermolecular interactions and then were diluted 
to desired concentrations for cellular studies. [WR]4 (25 μM) + PEpYLGLD (5 μM) or 
[WR]4 (50 μM) + PEpYLGLD (10 μM) in serum containing medium was added, and 
the cells were incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. In 
the case of CCRF-CEM (nonadherent cells), the final concentration was calculated 
after addition of the compounds. Cell viability was then determined by measuring the 
fluorescence intensity of the formazan product at 490 nm using a SpectraMax M2 
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD 
value of cells treated with the test mixture of compounds) − (OD value of culture 
medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.  
Cellular Uptake Studies in the Presence of Inhibitors. Human ovarian adenocarcinoma 
cells (SK OV-3) were seeded in 6-well plates (3 × 10
5
 cells/well) in opti-MEM. The 
cells were preincubated by various inhibitors including nystatin (50 μg/mL), 
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chloroquine (100 μM), chlorpromazine (30 μM), methyl-β-cyclodextrin (2.5 mM), and 
5-(N-ethyl-N-isopropyl) amiloride (EIA, 50 μM) for 30 min. The treatment was 
removed, and the cells were incubated with [WR]4 (25 μM), F′-PE(pY)LGLD (5 μM), 
and a similar concentration of inhibitors for 1 h. To induce ATP depletion, the cells 
were preicubated with 0.5% of 150 mM sodium azide in opti MEM prior to the 
addition of the compound followed by 1 h incubation. Consequently, a similar FACS 
protocol was performed as described above.  
Confocal Microscopy on Live Cells. Adherent SK-OV-3 cells were seeded with 
EMEM media overnight on coverslips in 6-well plates. Then the media were removed 
and washed with opti-MEM. The cells were treated with F′-PEpYLGLD (5 μM) in the 
presence or absence of [WR]4 (25 μM) for 1 h at 37 °C. The stock solutions were 
prepared at high concentrations to generate maximum intermolecular interactions and 
then were diluted to desired concentrations for cellular studies. After 1 h incubation, 
the media containing the treatments were removed followed by washing with PBS 
three times. Then the coverslips were mounted on a microscope slide with mounting 
media with the cell-attached side facing down. Laser scanning confocal microscopy 
was carried out using Carl Zeiss LSM 510 system. The cells were imaged using FITC 
and phase contrast channels.  
Transmission Electron Microscopy (TEM). TEM samples were prepared by drop 
casting of PEpYLGLD (1 mM in H2O), [WR]4 (1 mM in H2O), or mixture of 
PEpYLGLD and [WR]4 (1 mM in H2O) solution (incubated for one day) (10 μL) onto 
the Formvar coated carbon grid of mesh size 300, which was allowed to sit for 2 min. 
Excess solvent was carefully removed by capillary action (filter paper). Grids were 
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allowed to dry at room temperature overnight. All images were taken using a JEOL 
transmission electron microscope (Tokyo, Japan) maintained at 80 kV. After drop 
casting of peptide solutions, grids were then stained with uranyl acetate (20 μL) for 2 
min. Excess stain was removed, and the grids were allowed to dry overnight. 
Isothermal Titration Calorimetry (ITC). ITC was performed on a Microcal VP-ITC 
microcalorimeter (Microcal, Northampton, MA). Data acquisition and instrument 
control were carried out using a dedicated Origin software package. All the 
experiments were performed at 30 °C using cyclic peptide [WR]4 (500 μM) and 
PEpYLGLD (6 mM). Both PEpYLGLD and [WR]4 were dissolved in water. A 
solution containing [WR]4 (1.42 mL) was transferred into the sample cell. A solution 
of PEpYLGLD (6 mM, 10 μL) was injected from the syringe (280 μL) into the stirred 
sample cell (stirring speed 307 rpm). The reference cell was filled with deionized 
water. A 180 s time interval between injections was applied in order to allow the 
system to reach thermal equilibrium after each addition. Corrections were made for the 
dilution heat of the phosphopeptide, which was determined in control experiments 
under similar conditions. Analysis of the integrated heat data was performed using the 
Origin 7 package provided with the ITC instrument. Experimental data was fitted 
using a nonlinear least-squares minimization algorithm to a theoretical titration curve. 
Different binding models were assumed, involving a single set of identical sites, two 
sets of independent sites, or sequential binding events. The equations were included in 
the commercial ITC Data analysis software package of Origin 7.0. The chi-square 
parameter χ2 was used to establish the best fit.  
14 
 
Circular Dichroism. CD spectra were recorded on a JASCO J-810 spectropolarimeter 
using 1 mm path length cuvettes. The scan speed was 100 nm/min, and spectra were 
averaged over 8 scans. All experiments on the samples including [WR]4 (25 μM, H2O) 
and PEpYLGLD (25 μM, H2O) were tested at room temperature. The CD for 
background reference (water) was measured and subtracted from the sample.  
Molecular Modeling. Initial coordinates for [WR]5 were obtained using 
GAUSSVIEW.
32
 Ab initio Hartree−Fock molecular orbital calculations with complete 
geometry optimizations were performed with 6-31G33 basis set on monomer [WR]5 
utilizing GAUSSIAN’03 software. Geometry of monomers was completely optimized. 
All bond lengths, bond angles, and dihedral angles were allowed to relax without any 
constraint. 
 
RESULTS AND DISCUSSION 
Chemistry. A number of fluorescence labeled phosphopeptides, F′-GpYLPQTV, F′ 
NEpYTARQ, F′-AEEEIYGEFEAKKKK, F′-PEpYLGLD, F′-pYVNVQN-NH2, and 
F′-GpYEEI, where F′ is fluorescein (Figure 1), were synthesized according to the 
previously reported procedure.
34
 These phosphopeptides were selected based on the 
sequence of phosphoprotein binding motif of protein tyrosine kinases that binds to the 
SH2 domain of other protein tyrosine kinases and leads to enzyme activation.
35
  
As representative examples, the synthesis of Ac-PEpYLGLD (mentioned here 
as PEpYLGLD) and F′-PEpYLGLD is outlined here (Scheme 1). In general, the 
peptides were assembled on Wang resin using Fmoc solid-phase synthesis. Fmoc 
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protection group at the N-terminal was removed. Subsequent capping reaction by 
acetic anhydride or conjugation reaction with 5(6)-carboxyfluorescein isobutyrate was 
performed in the presence of HOAt, PyAOP, and N,N-diisopropylethylamine (DIPEA) 
in DMF:DCM (5:1 v/v) followed by deprotection, and cleavage from the resin in the 
presence of reagent R containing TFA/thioanisole/EDT/ anisole (90:5:3:2 v/v/v/v) 
afforded crude products, which were purified by preparative reversed-phase HPLC. 
The structures of the compounds were confirmed by high-resolution MALDI 
TOF/TOF and/or high-resolution electrospray mass spectrometry. We have previously 
reported the synthesis of [WR]4.
31
 A similar procedure was employed for the synthesis 
of other phosphopeptides by using appropriate resins and side chain protected amino 
acids.  
Cellular Uptake Studies. The cellular uptake of synthesized fluorescence-labeled 
phosphopeptides (10 μM) was examined in the presence and absence of [WR]4 (50 
μM) in human leukemia carcinoma (CCRF-CEM) cells after 2 h incubation at 37 °C 
using flow cytometry. After the incubation, cells were treated with trypsin to remove 
the cell surface-bound compound. [WR]4 enhanced the cellular uptake of all 
phosphopeptides, including F′-GpYLPQTV, F′-NEpYTARQ, F′-
AEEEIYGEFEAKKKK, F′-pYVNVQN-NH2, and F′-GpYEEI by 7-, 5-, 10-, 4-, and 
19-fold, respectively. Fluorescence activated cell sorting (FACS) analysis showed that 
the cellular uptake of F′-PEpYLGLD in the presence of [WR]4 was increased 
dramatically by 27-fold when compared to F′-PEpYLGLD alone (Figure 2). These 
data indicate that the cellular uptake of the phosphopeptides was improved in the 
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presence of [WR]4 in a sequence dependent manner possibly due to different binding 
affinity between the phosphopeptides and [WR]4.  
Because of dramatic effect of [WR]4 on improving the cellular delivery of F′-
PEpYLGLD, this phosphopeptide was selected for further studies. PEpYLGLD is a 
sequence that mimics the pTyr1246 of ErbB2 that is responsible binding to the Chk 
SH2 domain.
14
 The cellular uptake of F′-PEpYLGLD (10 μM) was also evaluated in 
the presence of the linear (WR)4 (50 μM) using FACS under similar conditions and 
compared with that of cyclic [WR]4 (Figure 3). The results showed that the linear 
(WR)4 enhanced the cellular uptake of F′-PEpYLGLD by 17-fold in CCRF-CEM cells 
after 1 h incubation. However, the cyclic [WR]4 was found to enhance the cellular 
uptake of F′-PEpYLGLD approximately 24-fold after 1 h incubation under similar 
conditions, suggesting the cyclic nature of the peptide is important for improving the 
cellular delivery of the phosphopeptide.  
We have previously reported that Lys-(CH2)11-Arg-(CH2)11-Arg, a linear 
tripodal amphipathic peptide containing two arginine and one lysine residues (LPA4), 
enhanced the cellular delivery of a phosphopeptide (F′-GpYEEI) in the human breast 
carcinoma cells BT-20 (ATCC No. HTB-19) cells by 10-fold.
30
 A comparative FACS 
study exhibited that the cellular uptake of F′-PEpYLGLD (10 μM) enhanced 
approximately 6 times in the presence of LP4 (50 μM) in CCRF-CEM cells after 1 h 
incubation. Thus, the transporting efficiency of LPA4 for F′-PEpYLGLD was 
significantly less than that of the cyclic [WR]4 that showed 24-fold higher cellular 
delivery of the same phosphopeptide after 1 h incubation (Figure 3). 
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To evaluate the cytotoxicity of PEpYLGLD and [WR]4, cell viability assay 
was employed in three different cancer cell lines, including CCRF-CEM, SK-OV-3, 
HCT-116 cells, and CCD-18Co cells at the experimental concentration of PEpYLGLD 
(5 μM) and [WR]4 (25 μM). We have previously shown that cyclic [WR]4 is not 
cytotoxic in HCT-116, CCRF-CEM, and SK-OV-3 cells at similar concentrations.
31
 
The mixture of [WR]4 (25 μM) and PEpYLGLD (5 μM) or [WR]4 (50 μM) and 
PEpYLGLD (10 μM) did not show any significant toxicity in normal cells and HCT-
116 carcinoma cells after 24 h incubation at 37 °C (Figure 4). While [WR]4 (25 μM) 
and PEpYLGLD (5 μM) did not exhibit any cytotoxicity in SK-OV-3 and CCRF-
CEM cells, the mixture showed 10−12% toxicity when higher concentrations of 
phosphopeptide (10 μM) and [WR]4 (50 μM) were used. Thus, a concentration of 
PEpYLGLD (5 μM) and [WR]4 (25 μM) was used in SKOV-3 and CCRF-CEM cells 
in all cellular uptake and confocal microscopy studies.  
To investigate whether the performance of [WR]4 is cell-type dependent, the 
intracellular uptake of a lower concentration of F′-PEpYLGLD (5 μM) was examined 
in human ovarian adenocarcinoma (SK-OV-3) cells in the presence or absence of 
[WR]4 (25 μM). After 1 h incubation at 37 °C, FACS showed 22-fold higher 
fluorescence signals in the cells treated with F′-PEpYLGLD-loaded [WR]4 compared 
to those treated with F′-PEpYLGLD alone, suggesting that the uptake of F′-
PEpYLGLD is also enhanced by [WR]4 in SK-OV-3 cells (Figure 5a).  
The cellular uptake and internalization of many CPPs along with the 
conjugated cargo occurs predominantly via an endocytic pathway that involves 
macropinocytosis, caveolae pathway, clathrin-mediated endocytosis, or lipid-raft 
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dependent endocytosis. The nature of the cell lines and the presence and type of the 
cargo could affect the specific mechanism employed by the CPP.
36
 We have 
previously shown that the cellular uptake of [WR]4 was independent of endocytosis.
31a
 
Thus, the mechanism of the cellular uptake of the complex mixture of [WR]4 and F′-
PEpYLGLD was evaluated in the presence of different inhibitors to determine whether 
the cargo changes the uptake mechanism  
To perform the ATP depletion, sodium azide was incubated with cells for 30 
min prior to the incubation with the complex followed by 1 h incubation. Significant 
intracellular uptake of F′-PEpYLGLD in the presence of [WR]4 in SK-OV-3 cells 
(Figure 5a) was still observed in the presence of sodium azide, suggesting that the 
cellular uptake is not significantly reduced by inducing ATP depletion.  
Furthermore, [WR]4 was still able to improve the cellular uptake of F′-
PEpYLGLD in SK-OV-3 cells in the presence of different endocytic inhibitors, such 
as nystatin, EIA, chlorpromazine, chloroquine, and methyl β-cyclodextrin, ruling out 
clathrin-mediated or caveolae-mediated endocytosis, and macropinocytosis as the 
major mechanism of uptake after 1 h incubation (Figure 5a). The cellular delivery of 
the phosphopeptide in the presence of [WR]4 and inhibitors was still higher than F′-
PEpYLGLD alone, suggesting the mechanism of cellular uptake is not exclusively 
endocytosis. This is a key advantage of [WR]4 compared to known CPPs, which are 
dependent on endocytotic entry. Another proposed mechanism for cellular uptake of 
CPPs is direct membrane transduction. The amphipathic nature of [WR]4 and 
interactions of arginine and tryptophan residues in [WR]4 with the corresponding 
negatively charged phospholipids and hydrophobic residues in lipid bilayer may have 
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contributed to the initial entry into the cell membrane. Hydrophobic interactions 
between tryptophan residues and the lipids could lead to possible distortion of the 
outer phospholipid monolayer, followed by peptide internalization and enhanced 
cellular uptake of the cargo. Model studies have suggested that the direct transduction 
occurs through carpet-like perturbations, pore formation, or inverted micelles formed 
in the bilayer membrane.
36
 Further mechanistic studies will provide insights for 
designing the next generation of cyclic peptides as molecular transporters of 
phosphopeptides.  
The cellular uptake of F′-PEpYLGLD was found to be rapid and time-
dependent. F′-PEpYLGLD (5 μM) was incubated with [WR]4 (25 μM) at different 
incubation times including 10 min, 30 min, and 1 h. FACS results showed that the 
cellular uptake of F′-PEpYLGLD was increased in a time-dependent pattern (Figure 
5b). On the other hand, the cellular uptake of F′-PEpYLGLD was not changed 
significantly in the absence of [WR]4.  
Confocal microscopy in live cells was used to monitor the cellular uptake of 
F′-PEpYLGLD in the presence and absence of the peptide. Incubation of a mixture of 
F′-PEpYLGLD [WR]4 showed significantly higher cellular uptake when compared to 
that of F′-PEpYLGLD alone as shown by intracellular fluorescence. Comparison of 
the intracellular localization of F′-PEpYLGLD-loaded [WR]4 to F′-PEpYLGLD alone 
after 1 h incubation at 37 °C confirmed that the presence of the cyclic peptide is 
critical for the enhanced cellular permeability (Figure 6).  
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Circular dichroism (CD), transmission electron microscopy (TEM), and 
isothermal titration calorimetry (ITC) were used to gain a better insight about the 
interaction of [WR]4 and PEpYLGLD. CD was used to get a better understanding of 
the secondary structure change in [WR]4 and PEpYLGLD upon mixing and 
intermolecular interactions. All spectra were corrected for background by subtraction 
of the blank. CD results showed that PEpYLGLD (25 μM) loaded with [WR]4 (25 
μM) showed a different CD pattern compared to those of parent analogs, [WR]4 (25 
μM) and PEpYLGLD (25 μM). While PEpYLGLD did not show any specific 
structure, both PEpYLGLD loaded [WR]4 and [WR]4 exhibited a maximum at 230 nm 
and a minimum at 203−205 nm, suggesting that [WR]4 maintain the secondary 
structure partially upon binding with in PEpYLGLD. These secondary structures are 
distinct from known α and β structures. However, the pattern of the spectra shows 
some major differences between PEpYLGLD loaded [WR]4 and [WR]4 at <190 nm 
and in intensity of ellipticity in maximum and minimum peaks (Figure 7).  
The interaction between PEpYLGLD and [WR]4 was visualized by using 
TEM. The stable mixture of [WR]4 and PEpYLGLD was prepared at a high 
concentration to achieve the maximum interaction. An optimized balance between the 
hydrophobic and electrostatic interactions generated by the drug and the carrier led to 
the formation of nanosized particles. [WR]4 generated self-assembled nanostructures 
after one day incubation at room temperature. Initial TEM imaging of negatively 
stained [WR]4 (1 mM aqueous solution) showed circular vesicle-like structures with 
approximate size of 25−60 nm. TEM images of PEpYLGLD (Figure 8a) exhibited 
amorphous structures with approximate size of 40 nm. When PEpYLGLD was added 
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to [WR]4 in solution, PEpYLGLD-loaded [WR]4 formed some larger noncircular 
nanosized structures with approximate width and height of 125 and 60 nm, 
respectively, possibly through electrostatic and/or hydrophobic intermolecular 
interactions between the positively charged cyclic peptide and negatively charged 
phosphopeptides (Figure 8b). TEM images further confirm that the structures of 
[WR]4 modify upon binding with PEpYLGLD, generating new nanostructures.  
ITC was used to measure the binding constants between PEpYLGLD and 
[WR]4 in complex formation. The ITC measurements were carried out at 30 °C by 
adding an aqueous solution PEpYLGLD (6 mM) to [WR]4 (500 μM) solution in water. 
The equation for three sequential binding events was found to be the best fit for the 
data as shown by the Origin software. The chi squared χ2 value was found to be 1.6 × 
10
2
 produced by three sequential models. The binding constant values for three 
sequential events were determined as K1 = 7.1 × 103 M
−1
, K2 = 4.9 × 103 M
−1
, and K3 
= 1.1 × 104 M
−1
 (Figure 9). The enthalpies (ΔH) for the binding were −0.17, 0.30, and 
−0.23 kcal/mol, and the entropies (TΔS) were 5.2, 5.4, and 5.3 kcal/mol, respectively. 
Therefore, the Gibbs free energies (ΔG) calculated from ΔH and TΔS were −5.4, −5.1, 
and −5.6 kcal/mol for each binding site. ITC data suggest that PEpYLGLD and [WR]4 
form a complex through multistep intermolecular interactions including hydrophobic 
interactions driven by entropy as shown previously.
37
 These data indicate that, in 
addition to the electrostatic interactions between positively charged cyclic peptide and 
negatively charged phosphopeptide, hydrophobic forces also contribute to the complex 
formation possibly due to the interactions of the hydrophobic tryptophan and leucine 
residues in [WR]4 and PEpYLGLD, respectively. ITC and TEM results are relevant to 
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cellular studies since the stock solutions were prepared at high concentrations to 
generate maximum intermolecular interactions and then were diluted further to obtain 
desired concentration for cell-based assays.  
Molecular modeling studies of [WR]5, a similar model cyclic peptide, were 
used to gain better insights of three-dimensional structure of this class of peptides. 
Initial coordinates for [WR]5 were obtained followed by ab initio Hartree−Fock 
molecular orbital calculations with complete geometry optimizations utilizing 
GAUSSIAN’03 software.32 Two different conformations were obtained (Figure 10). 
The lowest energy conformation did not allow any intramolecular H-bonding. Higher 
energy conformation (25 kcal/mol) showed intramolecular H-bonding between 
cationic and neutral side chains. Side chains have to reorganize for efficient 
intramolecular hydrogen bonding resulting in higher energy conformation. In the 
lowest energy conformation tryptophan side chains are disposed perpendicular to 
backbone. Higher energy conformation being more planar seems more suited for 
stacking.  
 
Conclusions 
In summary, a new carrier system for the delivery of cell impermeable 
phosphopeptides was discovered using cyclic octapeptide [WR]4 containing 
alternative tryptophan and arginine residues. The cellular uptake of F′-PEpYLGLD 
was enhanced by 27-fold in the presence of [WR]4, and was found to be time-
dependent. Positively charged cyclic peptide formed nanostructures in the presence of 
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negatively charged PEpYLGLD as shown by TEM. Binding affinity between [WR]4 
and PEpYLGLD was further confirmed by ITC studies. To the best of our knowledge, 
this is the first report of using cyclic peptides for noncovalent cellular delivery of cell 
impermeable phosphopeptides. These data provide insights about using cell-
penetrating cyclic peptides as PAs for delivery of negatively charged cell impermeable 
phophopeptides. 
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ABBREVIATIONS USED 
BT-20, human breast carcinoma cell line; CCRF-CEM, human leukemia carcinoma 
cell line; CD, circular dichroism; CCD-18Co, normal human colon myofibroblast; 
CPPs, cell-penetrating peptides; DCM, dichloromethane; DIPEA, N,N-
diisopropylethylamine; DMF, N,N-dimethylformamide; EIA, 5-(N-ethyl-N-
isopropyl)amiloride; F′, fluorescein; FACS, fluorescence activated cell sorter; FBS, 
fetal bovine serum; DCM, dichloromethane; EDT, ethandithiol; HBTU, 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexfluoro phosphate; HCT-116, 
human colorectal carcinoma; HOBt, hydroxybenzotriazole; HOAt, 1-hydroxy-7 
azabenzotriazole; ITC, isothermal calorimetry; NMM, N-methylmorpholine; PAs, 
peptide amphiphiles; PTB, phosphotyrosine binding; PyAOP, 7-azabenzotriazol- 1-
yloxy tripyrrolidinophosphonium hexafluorophosphate); SH2, Src homology 2; SK-
OV-3, human ovarian adenocarcinoma; TFA, trifluoroacetic acid; TEM, transmission 
electron microscopy. 
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Figure Legends: 
Figure 1: Chemical structure of [WR]4 and phosphopeptides synthesized by Fmoc-
based peptide chemistry 
Figure 2: Comparative cellular uptake of F′-phosphopeptides (10 μM) in the presence 
of [WR]4 (50 μM) in CCRF-CEM cells after 2 h 
Figure 3: Cellular uptake of F′-PEpYLGLD (10 μM) in the presence of cyclic [WR]4 
(50 μM), linear (WR)4 (50 μM), or a tripodal linear peptide (LP4) (50 μM) in CCRF-
CEM cells after 1 h incubation 
Figure 4: Cytotoxicity assay of the mixture of PEpYLGLD (5 and 10 μM) and [WR]4 
(25 and 50 μM) in CCRF-CEM, HCT-116, SK-OV-3, and CCD-18Co cells after 24 h. 
Figure 5: (a) Cellular uptake of F′-PEpYLGLD (5 μM) + [WR]4 (25 μM) in the 
absence or presence of different endocytic inhibitors and sodium azide in SK-OV-3 
cells after 1 h. (b) FACS analysis of cellular uptake assays of F′-PEpYLGLD (5 μM)-
loaded [WR]4 (25 μM) compared to F′-PEpYLGLD (5 μM) alone in CCRF-CEM 
Figure 6: Confocal microscope images of F′-PEpYLGLD (5 μM) uptake by SK-OV-3 
cells in the presence of [WR]4 (25 μM) 
Figure 7: CD pattern of PEpYLGLD and [WR]4 compared to the PEpYLGLD-loaded 
[WR]4 
Figure 8: (a) Negatively stained TEM images of [WR]4 (1 mM), PEpYLGLD (1 
mM), and PEpYLGLD-loaded [WR]4 (1 mM) in water after one day. (b) Proposed 
mechanism of interactions between PEpYLGLD and [WR]4 
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Figure 9: The binding isotherm obtained from titration of PEpYLGLD (6 mM) with 
[WR]4 (500 μM) using a three sequential-binding sites model 
Figure 10: Two different conformers of [WR]5 
 
Scheme Legends: 
Scheme 1: Solid-Phase synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD 
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Figure 6  
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Figure 8 
 
 
 
 
 
 
PEpYLGLD [WR]4 [WR]4 + PEpYLGLD
200 nm
200 nm
200 nm
200 nm
200 nm
200 nm
a
b
+
P
P P
P
P
P
P
P
P
-
-
- -
-
-
-
-
-
R
W
R
W
R
W
R
W
+
+
++
R
W
R
W
R
W
R
W
+
+
++
R
W
R
W
R
W
R
W
+
+
++
R
W
R
W
R
W
R
W
+
+
++
R
W
R
W
R
W
R
W
P
P
P
P
P
P
+
+
-
-
-
-
-
-
+
+ R
W
R
W
R
W
R
W
P
P
P
P
P
P
+
+
-
-
-
-
-
-
+
+
R
W
R
W
R
W
R
W
P
P
P
P
P
P
+
+
-
-
-
-
-
-
+
+ R
W
R
W
R
W
R
W
P
P
P
P
P
P
+
+
-
-
-
-
-
-
+
+
40 
 
Figure 9 
 
 
 
 
 
41 
 
Figure 10 
 
 
 
 
Relative energy= 0.0 kCal/mol
Relative energy= 25.33 kCal/mol
Top view Side view
42 
 
Scheme 1  
 
 
 
 
 
 
 
 
43 
 
Manuscript ІІ 
Published in Molecular Pharmaceutics, 2013, 10, 488-499 
 
Design and biological evaluation of cell-penetrating peptide−doxorubicin 
conjugates as prodrugs 
 
Amir Nasrolahi Shirazi, Rakesh Tiwari, Bhupender S. Chhikara, Dindyal Mandal, and 
Keykavous Parang* 
 
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, 
University of Rhode Island, Kingston, Rhode Island 02881, United States 
 
Corresponding Author 
*7 Greenhouse Road, Department of Biomedical and Pharmaceutical Sciences, 
College of Pharmacy, University of Rhode Island, Kingston, Rhode Island 02881, 
United States. Tel: +1-401-874-4471. Fax: +1-401-874-5787. E-mail: 
kparang@uri.edu. 
 
 
44 
 
Abstract 
Doxorubicin (Dox) is a hydrophilic anticancer drug that has short retention time due to 
the efficient efflux in some cancer cells (e.g., ovarian adenocarcinoma SK-OV-3). 
Cyclic [W(RW)4] and the corresponding linear peptide (RW)4 were conjugated with 
Dox through an appropriate linker to afford cyclic [W(RW)4]−Dox and linear 
(RW)4−Dox conjugates to enhance the cellular uptake and cellular retention of the 
parent drug for sustained anticancer activity. Comparative antiproliferative assays 
between covalent (cyclic[W(RW)4]−Dox and linear (RW)4−Dox) and the 
corresponding noncovalent physical mixtures of the peptides and Dox were 
performed. Cyclic [W(RW)4]−Dox inhibited the cell proliferation of human leukemia 
(CCRF-CEM) (62−73%), ovarian adenocarcinoma (SK-OV-3) (51−74%), colorectal 
carcinoma (HCT-116) (50−67%), and breast carcinoma (MDA-MB-468) (60−79%) 
cells at a concentration of 1 μM after 72−120 h of incubation. Cyclic [W(RW)4]−Dox 
exhibited higher antiproliferative activity than linear (RW)4−Dox in all cancer cells 
with the highest activity observed after 72 h. Flow cytometry analysis showed 3.6-fold 
higher cellular uptake of cyclic [W(RW)4]−Dox than Dox alone in SK-OV-3 cells 
after 24 h incubation. The cellular hydrolysis study showed that 99% of cyclic 
[W(RW)4]−Dox was hydrolyzed intracellularly within 72 h and released Dox. These 
data suggest that cyclic [W(RW)4]−Dox can be used as a potential prodrug for 
improving the cellular delivery and retention of Dox. 
KEYWORDS: anticancer, cellular uptake, doxorubicin, cyclic peptides, cell-
penetrating peptides 
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INTRODUCTION 
Doxorubicin (Dox) is a well-known anthracycline and widely used anticancer 
agent for the treatment of a wide variety of cancers, such as breast carcinoma, 
leukemia, and other solid tumors.
1
 The major mechanism of Dox activity is the 
inhibition of topoisomerase II (TOPO II)−DNA complex, causing DNA damage 
through intercalating with the DNA double helix.
2 
 
One of the major limitations of cancer chemotherapy treatment is the 
development of resistance to a certain dose of anticancer drugs, such as Dox. Several 
mechanisms of drug resistance have been introduced at different levels, including 
alteration of the target protein, decreased membrane permeability and drug 
metabolism, and/or efflux pumping.
3−5
 Dox is not being used widely for treating other 
tumors like ovarian carcinoma, liver cancer, and stomach cancer in the clinic,
6,7
 due to 
the development of resistance associated with Dox. Furthermore, the use of Dox for 
clinical application revealed undesired pharmacokinetics properties, such as rapid 
distribution, excretion, and low bioavailability of the drug, due to the hydrophilic 
nature, high volume of distribution, and short half-life.
8−10
 Thus, a high cumulative 
dose of Dox is required in cancer chemotherapy to achieve a sufficient therapeutic 
effect, which leads to dose-dependent side effects, such as such as cumulative 
cardiotoxicity, nephrotoxicity, and extravasation.
11,12
 
Moreover, intracellular Dox accumulation is dependent on a number of factors 
including cellular uptake, retention, relocalization, and efflux from the cell. Among 
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these factors, intracellular uptake of Dox suffers from efflux pumping in some cancer 
cells, such as ovarian carcinoma cells, leading to decreased intracellular Dox levels 
that could be related to the overexpression of energy-dependent drug efflux pump 
proteins such as P-glycoprotein (P-gp). This integral membrane protein removes drugs 
and thus reduces intracellular anticancer drug concentrations.
13
  
Efficacy and toxicity of an anticancer drug can be modified through using drug 
delivery systems and altering the physicochemical properties, such as lipophilicity, 
cellular uptake, and prolonging activity through chemical conjugation with various 
chemical moieties. One of the main applications of drug delivery systems is to avoid 
the P-gp and multidrug resistance proteins (MRPs) that are involved in drug efflux to 
overcome the resistance problem and P-gp-mediated drug efflux.
14−16
  
Prodrug strategy as one of the drug delivery systems through chemical 
conjugation with a parent drug
17,18 
has been widely used in Dox delivery.
6,19
 Several 
conjugation methods have been used to improve Dox delivery, including using gold 
nanoparticles,
20
 gold nanospheres,
21
 liposomes,
22
 peptides, 
23−27
 and dendrimers.
28
 
Conjugation of Dox with cellpenetrating peptides (CPPs) has been employed as one of 
the privileged methods to translocate a wide variety of cargo molecules into various 
cell lines.
16
 For instance, Dox has been conjugated with different linear CPPs 
including penetratin,
24
 tat,
29
 and polyarginine,
30
 and maurocalcine.
31
  
However, development of efficient and safe prodrug carriers to enhance 
delivery and retention of Dox into drug-resistant tumor cells and to reduce efflux 
remains less explored. We previously reported the application of a number of cyclic 
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peptides as noncovalent nuclear targeting molecular transporters
32
 of Dox. Cyclic 
peptides containing arginine and tryptophan [WR]n (n = 3−5) were found to be 
appropriate noncovalent carriers for Dox, however, the drug intracellular retention and 
toxicity behavior for cyclic peptide−Dox covalent conjugates remain unexplored. 
Herein, we report the synthesis of linear and cyclic peptides through the covalent 
conjugation with a 3-carbon chain linker at the 14-hydroxyl group, evaluation of their 
in vitro anticancer activities in multiple cancer cell lines, and cellular uptake and 
retention. The prodrug conjugates were designed to improve cellular uptake, to 
prolong biological activity, and to reduce intrinsic cellular efflux of Dox. 
 
EXPERIMENTAL SECTION 
Synthesis of Linear (RW)4 Peptide. The linear peptide was assembled on Fmoc-Rink 
amide resin (0.56 g, 0.54 mmol/ g, 0.3 mmol) by solid-phase peptide synthesis 
strategy using Fmoc-protected amino acids [Fmoc-Trp(Boc)-OH and Fmoc- Arg(Pbf)-
OH] on a PS3 automated peptide synthesizer at room temperature (Scheme 1). Linear 
peptide sequence was assembled on the resin after removing the Fmoc group at the 
end of the sequence (NH2-RWRWRWRW) (RW)4, using 20% piperidine in DMF. The 
resin was washed with DCM (3 × 15 mL) and MeOH (3 × 15 mL) for complete 
cleavage of peptide from the resin and side chain protecting groups. The resin was 
dried in vacuum for 24 h. A cleavage cocktail, namely, reagent R containing 
TFA/thioanisole/EDT/anisole (90:5:3:2 v/v/v/v, 12 mL), was added to the resin. The 
mixture was shaken at room temperature for 2 h. The resin was collected by filtration 
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and consequently washed with 2 mL of reagent R again. Collected filtrates were 
evaporated to reduce the volume under dry nitrogen. The crude peptide was 
precipitated by adding cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm 
for 5 min followed by decantation to obtain the solid precipitate. The solid material 
was further washed with cold ether (2 × 100 mL) for 2 times. The peptide was 
lyophilized and purified by reversed-phase Hitachi HPLC using a gradient system as 
described in the Supporting Information to yield linear (RW)4 peptide. 
(RW)4. MALDI-TOF (m/z) [C68H91N25O8]: calcd, 1385.7482; found, 1386.8219 [M + 
H]
+
. 
Synthesis of Cyclic Peptide [W(RW)4K]β-Ala. The linear-protected peptides 
sequence was assembled using a PS3 automated peptide synthesizer. The linear 
protected peptide (Dde-K(Boc-β-Ala)(WRWRWRWRW) was assembled on the H-
Trp(Boc)-2-chlorotrityl chloride resin (513 mg, 0.78 mmol/g, 0.40 mmol) in 0.40 
mmol scale (Scheme 2). After the final coupling with Boc-β-Ala-OH, the resin was 
washed with DMF (3 × 25 mL, each time 5 min). Then the Dde group at the lysine N-
terminal was deprotected by using hydrazine monohydrate (2% v/v) solution in DMF 
(3 × 25 mL, each time 5 min). The resin was washed with DMF (5 × 50 mL) followed 
by washing with DCM (3 × 50 mL). The side chain protected peptide was cleaved 
from trityl resin by using cleavage cocktail reagent, acetic acid/TFE/DCM (1:2:7 
v/v/v, 50 mL), by shaking for 1 h at room temperature to yield the side chain protected 
linear peptide. The resin was collected by filtration and washed with TFE/DCM (2:8 
v/v, 2 × 10 mL). The combined filtrates were evaporated under reduced pressure. 
Hexane (2 × 25 mL) and DCM (1 × 25 mL) were added to the residue to remove the 
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acetic acid from the cleaved crude peptide. The crude peptide was obtained as a white 
solid and was dried in vacuum overnight. The compound was directly used for the 
next cyclization reaction. The linear peptide was dissolved in DMF/DCM (5:1 v/v, 
250 mL). 1-Hydroxy-7-azabenzotriazole (HOAt, 223 mg, 1.64 mmol, 4 equiv) and 
1,3-diisopropylcarbodiimide (DIC, 290 μL, 1.86 mmol, 4.5 equiv) were added to the 
mixture, and the solution was stirred at room temperature for 6 h. The completion of 
the cyclization was checked by MALDI-TOF. After the reaction was completed, the 
solvents were removed under reduced pressure by using a rotary evaporator. The crude 
product was dried overnight in vacuum before the final cleavage reaction. The 
cleavage reaction was performed by using reagent R as previously described. The 
crude peptides were lyophilized and purified by reversed-phase Hitachi HPLC (L-
2455) as described in the Supporting Information to yield cyclic peptide 
[W(RW)4K(β-Ala)].  
MALDI-TOF (m/z) [C88H115N29O11]: calcd, 1753.9331; found, 1756.6570 [M + 3H]
+
. 
Synthesis of N-Fmoc-Dox-14-O-hemiglutarate. The synthesis of this N-Fmoc Dox 
derivative was carried out according to the previously reported procedure.33 In brief; 
Dox hydrochloride (100 mg, 0.17 mmol) was dissolved in anhydrous DMF (4 mL) in 
a round-bottom flask and stirred at room temperature under nitrogen atmosphere. 
Fmoc-OSu (60 mg, 0.18 mmol) was added to the reaction mixture followed by 
dropwise addition of anhydrous N,N-diisopropylethylamine (DIPEA, 60 μL, 0.34 
mmol). Aluminum foil was used to cover the reaction vessel from light, and stirring of 
the reaction mixture was continued at room temperature. The reaction was stopped, 
and the solvent was removed after 4 h. The remaining oily liquid was triturated with 
50 
 
0.1% TFA solution in water (v/v) to afford crystalline solid compound. The crystalline 
solid was collected through filtration and washed with cold diethyl ether to remove 
traces of excess of Fmoc-OSu. HPLC analysis showed that the crude product was pure 
(95%). The Fmoc-N-Dox (110 mg, 0.14 mmol) was reacted with glutaric anhydride 
(19.7 mg, 0.17 mmol) in the presence of anhydrous DIPEA (46 μL, 0.26 mmol) in 
anhydrous DMF (5 mL) for 16 h under nitrogen atmosphere. Analytical HPLC 
analysis showed that the reaction was completed after 16 h. The solvent was removed 
under reduced pressure, and the oily liquid was triturated with 0.1% TFA solution in 
water (v/v) to precipitate the crude solid material. The crude solid material was filtered 
and dried in high vacuum. The material was purified by HPLC to afford pure N-Fmoc-
Dox-14-O-hemiglutarate (95%). 
General Procedure for Coupling of the Peptides to Dox. N-Fmoc-Dox-14-O-
hemiglutarate (1 equiv), cyclic or linear peptide (1 equiv), benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.35 equiv), and 
hydroxybenzotriazole (HOBt, 2.70 equiv) were added to the glass vial under nitrogen 
atmosphere (Scheme 3). Anhydrous DMF (1−2 mL) was used as a solvent, and the 
reaction mixture was stirred to dissolve the compounds followed by the addition of 
DIPEA (8 equiv). Then, the reaction mixture was stirred for 1.5 h in the absence of 
light. The solvent was removed under reduced pressure, and cold diethyl ether was 
added to the residue. The crude peptide was precipitated and centrifuged to obtain the 
crude solid peptide conjugate. The peptide was dried under nitrogen gas. To remove 
the Fmoc group, a solution of piperidine in DMF was used (20% v/v, 2 mL for 5 min). 
The solution color turned to blue, and the reaction was terminated by adding drops of 
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TFA solution in DMF (20% v/v) until the solution color turned to light red. The 
solvent was removed under reduced pressure, and oily liquid was dissolved in 
acetonitrile/water (50% v/v). The HPLC purification afforded the final linear peptide 
or cyclic peptide−Dox conjugates. 
Cyclic [W(RW)4]−Dox Peptide. 
1
H NMR (DMSO-d6, 500 MHz, δ ppm): 0.80−0.97 
(m, 8H, CH2CH2CH2NH, Arg), 1.10−1.25 (m, 13H, CH2CH2CH2NH, Arg, Lys, 6′-
CH3), 1.89−2.25 (m, 4H, H-8 and H-2′), 2.40−2.67 (m, 14H, CH2CO and 
CH2CH2CH2NH), 2.90−3.20 (m, 12H, CH2, Trp, H-10), 3.55−3.52 (m, H-3′, H-4′ 
overlapped with DMSO peaks), 3.99 (s, 3H, OCH3), 4.20−4.40 (m, 6H, αCH, Arg, 
Lys, H-5′), 4.85−4.98 (m, 5H, αCH, Trp), 5.10−5.48 (m, 3H, H-7, OCH2CO), 
5.61−5.65 (m, 1H, H-1′), 6.27 (br s, 12 H, NH), 6.85−7.70 (m, aromatic, 25 H, Trp, 
aromatic CH), 7.75−8.00 (m, 4H, aromatic CH), 10.74 (br s, 5H, NH, Trp), 13.27 (s, 
2H, PhOH). MALDI-TOF (m/z) [C120H148N30O24]: calcd, 2393.1283; found, 
2393.5332 [M]
+
. 
Linear (RW)4−Dox. MALDI-TOF (m/z) [C100H124N26O21]: calcd, 2024.9434; found, 
2024.6139 [M]
+
. 
Cell Culture. Human leukemia carcinoma cell line CCRFCEM (ATCC no. CCL-
119), breast adenocarcinoma MDAMB-468 (ATCC no. HTB-132), ovarian 
adenocarcinoma SKOV-3 (ATCC no. HTB-77), and colorectal carcinoma HCT-116 
(ATCC no. CCL-247) were obtained from American Type Culture Collection. The 
cells were grown on 75 cm
2
 cell culture flasks with RPMI-16 medium for leukemia 
and EMEM medium for other cell lines and supplemented with 10% fetal bovine 
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serum (FBS) and 1% penicillin−streptomycin solution (10,000 units of penicillin and 
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air 
at 37 °C. 
Antiproliferation Assay. Antiproliferative activities of covalently synthesized cyclic 
[W(RW)4]−Dox, linear (RW)4−Dox derivatives, and noncovalent mixtures of cyclic 
[RW]4 + Dox and linear (RW)4 + Dox were evaluated in MDA-MB-468, CCRF-CEM, 
SK-OV-3, and HCT-116 cells, and the results were compared with that of Dox alone. 
The assay was carried out using CellTiter 96 AQueous One Solution Cell Proliferation 
Assay Kit (Promega, USA). As a representative example, SK-OV-3 cells were 
suspended in 5 × 10
3
/mL (CCRF-CEM, 4 × 10
4/mL), and 100 μL of the cell 
suspension was placed in each well of the 96 well culture plates. The cells were 
incubated with Dox (1 μM), cyclic [W(RW)4]−Dox (1 μM), linear (RW)4−Dox (1 
μM), cyclic [RW]4 (1 μM) + Dox (1 μM), and linear (RW)4 (1 μM) + Dox (1 μM) in 
2% DMSO and tested in triplicate. For the physical mixtures, an appropriate volume 
of Dox stock solution was mixed with an appropriate volume of an aqueous solution 
of cyclic and linear peptides physically to obtain a final concentration of Dox (1 μM) 
and the peptide (1 μM). The mixture was vigorously mixed and vortexed until the 
solution became homogeneous/ clear red color. Subsequently, the mixture was 
incubated for 30 min at 37 °C before addition to the cells. Incubation was carried out 
at 37 °C in an incubator supplied with 5% CO2 for 24−120 h. At the end of the sample 
exposure period (24−120 h), 20 μL of CellTiter 96 aqueous solution was added. The 
plate was returned to the incubator for 1 h in a humidified atmosphere at 37 °C. The 
absorbance of the formazan product was measured at 490 nm using a microplate 
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reader. The percentage of cell survival was calculated as [(OD value of cells treated 
with the test compound) − (OD value of culture medium)]/[(OD value of control cells) 
− (OD value of culture medium)] × 100%. 
Cell Cytotoxicity Assay. The cytotoxicity of Dox and cyclic [W(RW)4]−Dox against 
MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3 was determined by MTS assay 
using CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit (Promega, 
USA). All cells were plated overnight in 96 well plates with a density of 5000 cells per 
well in 0.1 mL of appropriate growth medium at 37 °C. Different concentrations of 
Dox or cyclic [W(RW)4]−Dox (up to a maximum of 10 μM) were incubated with the 
cells for 2 h. Compounds were removed from medium by replacing with fresh 
medium, and the cells were kept in an incubator for another 72 h. The cells without 
compounds were included in each experiment as controls. After 72 h of incubation, 20 
μL of MTS was added and incubated for 2 h. The absorbance of the formazan product 
was measured at 490 nm using microplate reader. The percentage of cytotoxicity was 
calculated as [(OD value of untreated cells) − (OD value of treated cells)]/(OD value 
of untreated cells) × 100%. 
Confocal Microscopy. SK-OV-3 cells were seeded with EMEM media overnight on 
coverslips in six well plates. Then the medium was removed and washed with opti-
MEM. The cells were treated with Dox or cyclic [W(RW)4]−Dox (5 μM) in opti-
MEM for 1 h at 37 °C. After 1 h incubation, the media containing the compound were 
removed followed by washing with PBS three times. Then coverslips were placed on a 
drop of mounting medium on a microscope slide with cell-attached side facing down. 
Laser scanning confocal microscopy was carried out using a Carl Zeiss LSM 510 
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system. The cells were imaged using rhodamine and phase contrast channels. In the 
case of drug efflux studies, after a 1 h incubation period, the medium containing drugs 
was removed and washed with opti-MEM. Then fresh medium with serum was added 
into the cells. After 24 h, the medium was removed and washed with PBS three times, 
and then the cells were visualized under confocal microscopy. 
Fluorescence Activated Cell Sorter (FACS) Analysis of Cellular Uptake 
Experiment. Ovarian carcinoma cells were plated overnight in six well plates (2 × 10
5
 
cells/well) in EMEM media. Then Dox (5 μM), cyclic [W(RW)4]−Dox (5 μM), linear 
(RW)4−Dox (5 μM), cyclic [RW]4 (5 μM) + Dox (5 μM), and (RW)4 (5 μM) + Dox (5 
μM) were added in serum-free RPMI to the cells. For the physical mixtures, an 
appropriate volume of Dox stock solution was mixed with an appropriate volume of an 
aqueous solution of cyclic and linear peptides physically to obtain a final 
concentration of Dox (5 μM) and CPPs (5 μM). The mixture was vigorously mixed 
and vortexed until the solution became homogeneous/clear red color. Subsequently, 
the mixture was incubated for 30 min at 37 °C before addition to the cells. The plates 
were incubated for 1 h at 37 °C. After 1 h incubation, the media containing drugs were 
removed. The cells were digested with 0.25% trypsin/0.53 mM EDTA for 5 min to 
detach from the plate. Then the cells were centrifuged and washed twice with PBS. 
Finally, the cells were resuspended in flow cytometry buffer and analyzed by flow 
cytometry (FACSCalibur: Becton Dickinson) using FL2 channel and CellQuest 
software. The data presented are based on the mean fluorescence signal for 10,000 
cells collected. All assays were performed in triplicate. 
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Fluorescence Activated Cell Sorter (FACS) Analysis of Cell Cycle Arrest. 
Colorectal carcinoma cells (2 × 10
5
 per well) were treated with cyclic [W(RW)4]−Dox 
at 1 μM for 1 h followed by 24 h incubation in drug-free medium. Cells were fixed in 
ice-cold ethanol:PBS (70:30, v/v) for 30 min at 4 °C, further resuspended in PBS with 
100 μg/mL RNase and 40 μg/ mL propidium iodide, and incubated at 37 °C for 30 
min. The DNA content (for 10,000 cells) was analyzed using a FACSCalibur 
instrument equipped with FACStation with FACSCalibur software (BD Biosciences, 
San Diego, CA, USA). The analyses of cell cycle distribution were performed in 
triplicate (n = 2 plates per experiment) for the sample treatment. The coefficient of 
variation, according to the ModFit LT Version 2 acquisition software package (Verity 
Software House, Topsham, ME, USA), was always less than 5%. 
Topo II Decatenation Assay. The topoisomearase II assay kit (Catalog No. 1001-1) 
was purchased from TopoGEN, Inc. (Port Orange, FL). Eukaryotic Topo II was 
assayed by decatenation of kDNA and monitoring the appearance of a smaller DNA 
(decatenated DNA circles). Reaction mixtures containing kDNA (0.1 μg) in a final 
volume of 20 μL and 1× reaction buffer containing Tris-HCl (50 mM, pH 8.0), NaCl 
(150 mM), MgCl2 (10 mM), dithiothreitol (0.5 mM), and ATP (2 mM) were incubated 
for 30 min at 37 °C without and with Dox, and cyclic [W(RW)4]−Dox at 10, 20, 30, 
40, and 50 μM final concentration. Reactions were terminated with the addition of 0.4 
volume of stop buffer (5% sarkosyl, 0.125% bromophenol blue, and 25% glycerol). 
One unit of Topo II is defined as the amount of enzyme required to fully decatenate 
0.1 μg of kDNA in 30 min at 37 °C. The decatenation products were analyzed on 1% 
agarose gels having 0.5 μg of ethidium bromide/mL. Eukaryotic Topo II products 
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were separated at 108 V, which allowed rapid resolution of catenated networks from 
the minicircles. Gels were photographed by ethidium bromide fluorescence on 
Typhoon Imager. 
Stability Studies. The stability of cyclic [W(RW)4]−Dox was evaluated using 
phosphate-buffered saline (PBS) and fetal bovine serum (FBS). PBS and FBS were 
purchased from Invitrogen and ATCC (Manassas, VA). FBS (1 mL, 100%) and PBS 
(1 mL, pH 7.0) were incubated with cyclic [W(RW)4]−Dox (75 μL, 1 mM in water) at 
37 °C followed by intermediate mixing. An aliquot of 75 μL of the mixture was taken 
out at different time intervals (10 min to 96 h) and diluted with water (75 μL). The 
mixture was analyzed by using analytical HPLC detecting the wavelength of 490 nm. 
The area under the curve (AUC) was calculated and used to find out the percentage of 
released Dox and remaining prodrug at a given time. Figure S1 (Supporting 
Information) was plotted between relative percentage of released Dox and cyclic 
[W(RW)4]−Dox based on HPLC analysis. 
Cellular Hydrolysis. Intracellular hydrolysis of cyclic [W(RW)4]−Dox and 
accumulation of Dox and the peptide−Dox conjugate were determined in CCRF-CEM 
cells by HPLC analysis. CCRF-CEM cells were grown in 75 cm
2
 culture flasks with 
serum-free RPMI medium to ∼70−80% confluence (1.37 × 107 cells/mL). The 
medium was replaced with fresh RPMI medium having cyclic [W(RW)4]−Dox (1 
μM), and the cells were incubated at 37 °C for 4 h. The medium containing cyclic 
[W(RW)4]−Dox was carefully removed by using centrifugation and replaced with 
fresh RPMI serum-free medium. The cells were partitioned/transferred to culture 
plates (six well) having 1.37 × 10
7
 cells per well in 5 mL of medium and incubated for 
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the indicated time. After incubation, the cells were collected by centrifugation. The 
medium was removed carefully by decantation, and cell pellets were washed with ice-
cold PBS to remove any medium. The cell pellets were thoroughly extracted with an 
equal volume of methanol, chloroform, and isopropanol mixture (4:3:1 v/v/v) and 
filtered through 0.2 μm filters. The relative Dox and cyclic [W(RW)4]−Dox 
concentrations in cell lysates were quantified by analytical HPLC analysis as 
described in the Supporting Information at 490 nm using the water/acetonitrile solvent 
method. 
 
RESULTS AND DISCUSSION 
Chemistry. Linear and cyclic peptides were synthesized by Fmoc/tBu solid-phase 
peptide synthesis. Scheme 1 depicts the synthesis of linear peptide (RW)4 on the Rink 
amide resin. The linear peptide sequence was assembled using a PS3 peptide 
synthesizer. The last Fmoc group on the N-terminal was deprotected by piperidine 
(20% v/v, DMF). The resin was dried, washed, and cleaved by cleavage cocktail 
(reagent R) to afford the linear (RW)4, which was purified by reversed-phase Hitachi 
HPLC. For the synthesis of the cyclic peptide, first the linear protected peptide (Dde-
K(Boc-β-Ala)(WRWRWRWRW) was assembled on the H-Trp(Boc)-2-chlorotrityl 
chloride resin. The Dde group of N-terminal lysine was removed in the presence of 
hydrazine (2% in DMF). The side chain protected peptide was cleaved from the resin 
using AcOH/TFE/DCM (1:2:7 v/v/v) cocktail. The cyclization of the side chain 
protected peptide was performed under pseudodilute conditions in the presence of 
HOAt and DIC (Scheme 2). The cyclic peptide was cleaved in the presence of reagent 
58 
 
R, purified using reversed-phase HPLC, and used for the conjugation with Dox. N-
Fmoc-Dox-14-O-hemiglutrate was prepared as described previously.
33
 In brief, the 
reaction of glutaric anhydride with Fmoc-protected Dox was carried out to produce the 
Dox hemiglutarate ester with a free COOH, which after HPLC purification and 
lyophilization was used for coupling with linear and cyclic peptides. The conjugation 
of the peptides with N-Fmoc-Dox-14-O-hemiglutrate was achieved in a similar pattern 
(Scheme 3). The equimolar amount of the peptide and Dox was coupled through 
formation of an amide bond between the amino group of peptides and carboxylic acid 
in the Fmoc-protected Dox. The carboxylic group in Fmoc-protected Dox was 
preactivated in the presence of HOAt/PyBOP/DIPEA in DMF for 15 min before 
reacting with the peptides. After conjugation, the Fmoc protecting group was removed 
using piperidine and was then acidified. The coupled peptide was purified using HPLC 
and lyophilized. The structures of all the final compounds were confirmed by a high-
resolution MALDI TOF/TOF mass spectrometer. The purity of the final product 
(≥95%) was confirmed by reversed-phase analytical HPLC using a gradient system 
with water (0.1% TFA) and acetonitrile as eluting solvents. 
 
Biological Activities. Cytotoxicity and Antiproliferative Activity of Peptide−Dox 
Derivatives. Cyclic [WR]4 and cyclic [W(RW)4K](β-Ala) did not show any significant 
toxicity in MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3 cells at a 
concentration of 10 μM (Figure 1) after different incubation times including 24 h, 72 
h, and 120 h. These data are consistent with previously reported data of cyclic 
[WR]4.
32
 Thus, a noncytotoxic concentration of 1 μM was selected for cell-based 
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studies of cyclic peptide conjugate cyclic [W(RW)4]−Dox and the physical mixture 
cyclic [RW]4 + Dox. 
We recently compared the toxicity of [WR]4 versus commonly used 
cellpenetrating peptides and transporters including polyArg CR7, TAT 
(YGRKKRRQRRRC) (100 μM), and oligofectamine 2000 (Invitrogen, a cationic lipid 
formulation).34 [WR]4 did not show any significant toxicity in human ovarian 
adenocarcinoma (SK-OV-3) and human leukemia (CCRFCEM) cancer cells and 
normal human colon myofibroblast (CCD-18Co) cells, while other cell-penetrating 
peptides polyArg CR7, TAT (YGRKKRRQRRRC), and oligofectamine 2000 
(Invitrogen, a cationic lipid formulation) reduced the viability by 21−55%. The 
activity of compounds on the cell proliferation of different cancer cells, CCRF-CEM, 
SK-OV-3, HCT-116, and MDA-MB-468, was investigated for up to 120 h at the 
concentration of 1 μM. The activity of synthesized compounds, linear (RW)4−Dox and 
cyclic [W(RW) 4]−Dox, was evaluated in a comparative study with the noncovalent 
physical mixtures of linear (RW)4 + Dox and cyclic [RW]4 + Dox, and Dox alone 
(Figure 2). Cyclic [W(RW)4]−Dox exhibited higher antiproliferative activity than 
linear (RW)4−Dox in all cancer cells, with the highest activity observed after 72 h.  
The effect of compounds was found to be time dependent. The cell 
proliferation inhibitory activity of compounds was enhanced at longer incubation 
period of compounds with cells presumably because of the hydrolysis of the conjugate 
to Dox. Cyclic [W(RW)4]−Dox inhibited the cell proliferation of CCRF-CEM 
(62−73%), SK-OV-3 (51−74%), HTC-116 (50−67%), and MDA-MB-468 (60−79%) 
cells at a concentration of 1 μM after 72−120 h of incubation, while linear (RW)4−Dox 
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exhibited antiproliferative activity against CCRF-CEM (46−69%), SK-OV-3 
(28−34%), HTC-116 (21−61%), and MDA-MB-468 (60−74%) under similar 
conditions.  
These data suggest that cyclization of peptide provided a more effective 
transporter for Dox. The antiproliferative activity of cyclic [W(RW)4]−Dox was in the 
order MDA-MB-468 > CCRF-CEM > SK-OV-3 > HTC-116. In general, the physical 
mixture of linear (RW)4 and cyclic [RW]4 with Dox derivative showed less 
antiproliferative activity in comparison to cyclic [W(RW)4]−Dox conjugate after 
72−120 h against CCRF-CEM (52−68%), SK-OV-3 (47−67%), and HTC-116 
(38−62%), and showed slightly better or comparable activity against MDA-MB-468 
(71−78%). Dox exhibited also similar antiproliferative activity in comparison to the 
physical mixture against CCRF-CEM (59−71%), SK-OV-3 (48−59%), HTC-116 
(37−64%), and MDA-MB-468 (71− 77%) after 72−120 h of incubation, indicating 
that conjugation of the cyclic peptide with Dox in cyclic [W(RW)4]−Dox improved 
the antiproliferative activity of Dox in some of the tested cancer cells. The cyclic 
peptide−Dox conjugate showed comparable antiproliferative activity against CCRF-
CEM and MDA-MB-468 when compared to Dox after 96 and 120 h incubation. 
However, the antiproliferative activities of cyclic [W(RW)4]−Dox conjugate in SK-
OV-3 and HCT-116 cells were higher than those of Dox at a concentration of 1 μM 
after 96 and 120 h incubation. For example, cyclic [W(RW)4]−Dox inhibited the cell 
proliferation of SK-OV-3 (67−74%) and HTC-116 (65−67%) cells at a concentration 
of 1 μM after 96−120 h of incubation, while Dox exhibited antiproliferative activity 
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against SK-OV-3 (57−59%) and HTC-116 (57−64%) under similar conditions. Cyclic 
[W(RW)4]−Dox showed higher cellular retention Than Dox and Linear (RW)4−Dox. 
Dox is easy to track by using fluorescence-based techniques, due to the 
inherent red fluorescence. Because of the higher antiproliferative activity of cyclic 
[W(RW)4]−Dox after 72 h compared to linear (RW)4−Dox and Dox, this compound 
was selected for further cellular uptake studies in comparison to other compounds to 
determine whether the higher activity of this compound is consistent with enhanced 
uptake of the compound. The cellular uptake of all derivatives was examined in Dox-
resistant SK-OV-3 cells using fluorescence-activated cell sorter (FACS) analysis 
(Figure 3). To obtain the primary influx, cells were allowed to be incubated with 
covalent cyclic [W(RW)4]−Dox and linear (RW)4−Dox peptides, noncovalent physical 
mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox, and Dox for 1 h. This 
process was followed by 24 h incubation with media to allow the cells to start the 
efflux process through pumping the compounds out. Then the amounts of Dox in cells 
were evaluated by using FACS in Dox-resistant SK-OV-3 cells. The data showed 
3.3−3.6-fold more cellular uptake of cyclic [W(RW)4]−Dox compared to Dox alone 
and noncovalent physical mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox, 
in SK-OV-3 (Figure 3). Between linear and cyclic peptide−Dox covalent conjugates, 
the retention of cyclic [W(RW)4]−Dox was found to be 2.6-fold higher compared to 
that of linear (RW)4−Dox. These data suggest that cyclic peptide−Dox, cyclic 
[W(RW)4]−Dox, enhanced the cellular uptake of the compound. The cyclic nature of 
the peptide was found to contribute in inhibition of the efflux. These data are 
consistent with higher antiproliferative activity of cyclic [W(RW)4]−Dox versus linear 
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(RW)4−Dox and Dox, suggesting that the presence of cyclic peptide in the conjugate 
reduces efflux, increases cellular uptake and retention of Dox, and enhances 
antiproliferative activity. 
 
Cyclic [W(RW)4]−Dox Nuclear Localization in SK-OV-3 Cells. The cellular 
localization of free Dox and conjugate cyclic [W(RW)4]−Dox was compared in SK-
OV-3 cells after 1 and 24 h incubation at 37 °C. A noncytotoxic concentration of 5 μM 
was chosen to ensure Dox fluorescence detection by confocal microscopy. Confocal 
microscopy images of SK-OV-3 cells are shown after 1 h incubation. Free Dox and 
cyclic [W(RW)4]−Dox were localized mainly in the nucleus (Figure 4a). The results 
showed that the covalent conjugation of Dox with cyclic [W(RW)4] did not prevent 
the nuclear accumulation of the drug. To compare the retention ability of cyclic 
[W(RW)4]−Dox versus Dox alone against efflux effects, SKOV-3 cells were 
incubated with both compounds for 1 h followed by incubation in drug-free media for 
24 h at 37 °C. The fluorescence intensity of Dox in cells treated with cyclic 
[W(RW)4]−Dox was found to be significantly higher than that in cells treated with 
Dox alone (Figure 4b), indicating that cyclic [W(RW)4]−Dox was retained in cells 
much longer than free Dox. Thus, this conjugate has a potential to be used as a tool for 
enhancing the nuclear retention of Dox. 
 
Stability of Cyclic [W(RW)4]−Dox. Cyclic [W(RW)4]−Dox was incubated with 
phosphate-buffered saline (PBS) and fetal bovine serum (FBS) solution at 37 °C at 
different time intervals. The results indicated that cyclic [W(RW)4]−Dox is relatively 
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stable in both systems with half-life values of 10.77 and 26.20 h in PBS and FBS, 
respectively. No interaction between serum proteins and cyclic [W(RW)4]−Dox was 
observed since the mixture was clear and no precipitation or turbidity was found 
during the assay. Cyclic [W(RW)4]−Dox was found to be stable in PBS (97%) and 
FBS (84%) after 1 h. For cellular uptake studies using FACS, the cells were incubated 
by cyclic [W(RW)4]−Dox for 1 h followed by 24 h incubation with drug-free media. 
During the 1 h period, the compound showed minimal hydrolysis in serum, suggesting 
that most of the compound is hydrolyzed intracellularly (Figures S5 and S6 in the 
Supporting Information). 
 
Intracellular Hydrolysis. Intracellular hydrolysis results for cyclic [W(RW)4]−Dox 
were monitored in CCRF-CEM cells. CCRF-CEM cells (1.37 × 10
7
) were incubated 
with the conjugate (1 μM) for 4 h followed by drug-free medium to determine the 
possibility of the intracellular hydrolysis to Dox. Drug-free medium was used to rule 
out the continuous cellular uptake of the conjugate, while the compound is hydrolyzed 
intracellularly. HPLC analysis with detection at 490 nm and at specific time intervals 
after cellular lysis was used to measure the ratio of the cyclic [W(RW)4]−Dox and 
released Dox. The cellular hydrolysis data exhibited that the cyclic peptide−Dox 
conjugate was hydrolyzed intracellularly and released Dox in a time-dependent 
manner. More than 46% of cyclic [W(RW)4]−Dox was hydrolyzed intracellularly 
within 12 h. Approximately 86% of cyclic [W(RW)4]−Dox was hydrolyzed 
intracellularly within 48 h (Figure 5). These data suggest that the enhanced uptake, 
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retention, and sustained intracellular hydrolysis of cyclic [W(RW)4]−Dox to Dox 
contribute to overall activity of the conjugate as a potential prodrug 
 
Cell Cycle Distribution Analysis. In addition to apoptosis,
35,36
 Dox treatment causes 
cell cycle arrest in cancer cells.
37
 The impact of cyclic [W(RW)4]−Dox on cell cycle 
distribution was investigated in colorectal carcinoma cells (HCT-116) compared to 
Dox. All experiments were performed under similar conditions, and appropriate 
controls were used to confirm the results. An hour incubation was selected followed 
by 24 h incubation in drug-free medium, due to the significant difference in the 
cellular uptake of cyclic [W(RW)4]−Dox and Dox. Control cells were found in G0/G1 
phase (46.8 ± 1.0%), S phase (36.5 ± 0.7%), and G2/M phase (16.5 ± 0.2%). The 
percentage of the pre-G0/G1 population indicates the apoptosis rate of cells. There 
was no significant pre-G0-G1 population as shown in the histograms because the cells 
were incubated with Dox and the prodrug only for 1 h. Cells treated with compounds 
(Dox and cyclic [W(RW)4]−Dox) showed different patterns than control cells for 
G0/G1 phase (53.0 ± 1.0% and 42.2 ± 1.4%), S phase (21.8 ± 3.0% and 23.5 ± 0.2%), 
and G2/M phase (25.1 ± 2.0% and 34.1 ± 1.2%), respectively (Figure 6). The data 
showed that, in cells treated with cyclic [W(RW)4]−Dox, the proportion of cells in 
G0/G1 phase was decreased nearly 10% compared to values for Dox. On the other 
hand, the proportion of cells in G2/M phase increased nearly 10% compared to values 
for Dox. These data suggest that cyclic [W(RW)4]−Dox led to a significant reduction 
of cells in G0/G1 phase, and caused more accumulation in G2/M phase in HCT-116 
cells. This pattern is slightly different when compared to Dox. This could be due to the 
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requirement for cyclic [W(RW)4]−Dox to get hydrolyzed to Dox. Based on the 
population of cells at different phases, prodrug follows a different pattern when 
compared with Dox. Some of the antiproliferative activity by cyclic [W(RW)4]−Dox 
could be due to the differential pattern of cell cycle distribution by the conjugate, in 
addition to intracellular hydrolysis to Dox. The histograms were also provided in the 
Supporting Information (Figure S4).  
 
Topo II Inhibitory Activity. One of the major anticancer mechanisms of Dox is the 
inhibition of topoisomerase II.
2
 Thus, a comparative study was performed between 
cyclic [W(RW)4]−Dox and Dox to determine whether the conjugate has Topo II 
inhibitory activity similar to that of the parent drug. Topo II is responsible for 
catalyzing the DNA double-stranded cleavage process by isolating catenated DNA 
duplexes. Kinetoplast DNA (kDNA) is used as a DNA substrate in the in vitro 
decatenation assay. The potency of Dox and cyclic [W(RW)4]−Dox to inhibit Topo II 
enzyme for the decatenation of kDNA was used to analyze the comparative inhibitory 
activity of the compounds. Topo II decatenation assay exhibited that Dox inhibited 
Topo II at concentrations between 10 and 20 μM; however cyclic [W(RW)4]−Dox 
inhibited the Topo II activity at concentrations between 20 and 30 μM (Figure 7) 
under similar reaction conditions. As expected, the conjugate acts at higher 
concentration compared to Dox since the conjugate is required to get hydrolyzed to 
Dox to be able to inhibit Topo II more efficiently. Under the in vitro conditions used 
here, the conjugate is not hydrolyzed and the reduced Topo II inhibitory activity is 
possibly due to the conjugation to the peptide and associated steric hindrance. 
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Hydrolysis to Dox is required to generate maximum Topo II inhibitory activity 
associated with Dox. The conjugate does not undergo hydrolysis under in vitro 
conditions in this assay. 
 
CONCLUSIONS 
In summary, linear and cyclic peptide−Dox conjugates were synthesized as 
prodrugs, were evaluated for their activities against various cancer cell lines, and were 
compared with the corresponding physical mixtures. The conjugation of Dox with a 
specific cyclic peptide, cyclic [W(RW)4]−Dox, improved the antiproliferative activity 
compared to the corresponding physical mixtures in all tested cell lines. Cyclic 
peptide−Dox conjugate showed comparable antiproliferative activity against CCRF-
CEM and MDA-MB-468 when compared to Dox. However, the antiproliferative 
activities of cyclic [W(RW)4]− Dox conjugate in SK-OV-3 and HCT-116 cells were 
higher than those of Dox and linear (RW)4−Dox at a concentration of 1 μM after 96 
and 120 h incubation. Dox has short retention time in some cancer cells (e.g., ovarian 
adenocarcinoma SKOV-3) due to the efficient efflux effect. Thus, the differential 
cytotoxicity of cyclic [W(RW)4]−Dox with Dox in SK-OV-3 could be due to the 
retention of Dox in the presence of the cyclic peptide. Since the system was designed 
as a prodrug, we did not expect to detect a huge difference between Dox and cyclic 
[W(RW)4]−Dox in cytotoxicity. Furthermore, we demonstrated that the prodrug 
approach for Dox using a cyclic peptide conjugate significantly improved the cellular 
uptake and retention time of Dox in SK-OV-3 cancer cells. Flow cytometry analysis 
showed 3.3−3.6-fold higher cellular uptake of cyclic [W(RW)4]−Dox than Dox alone 
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and the physical mixtures, cyclic [W(RW)4] + Dox and linear (RW)4 + Dox, in SK-
OV-3 cells after 24 h incubation. The conjugate exhibited nuclear localization and 
retention after 24 h, and underwent intracellular hydrolysis to Dox in CCRF-CEM 
cells, suggesting to be a potential prodrug for delivery of the drug. The cellular 
hydrolysis study showed that 99% of cyclic [W(RW)4]−Dox was hydrolyzed 
intracellularly within 72 h and released Dox. These data suggest that cyclic 
[W(RW)4]−Dox can be used as a potential prodrug for improving the biological 
profile, cellular delivery, and retention of Dox. 
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ABBREVIATIONS USED 
CCRF-CEM, human leukemia carcinoma cell line; CPPs, cellpenetrating peptides; 
DCM, dichloromethane; Dox, doxorubicin; DIPEA, N,N-diisopropylethylamine; 
HBTU, DDS, drug delivery systems; FACS, fluorescence activated cell sorter; FBS, 
fetal bovine serum; DCM, dichloromethane; HCT-116, human colorectal carcinoma; 
HOBt, hydroxybenzotriazole; HBTU, 1,1,3,3-tetramethyluronium 
hexafluorophosphate; MDA-MB- 468, human breast adenocarcinoma; MRPs, 
multidrug resistance proteins; NMM (N-methylmorpholine); P-gp, P-glycoprotein; 
PBS, phosphate buffered saline solution; PyBOP, benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate; SK-OV-3, human ovarian 
adenocarcinoma, 1,1,3,3-tetramethyluronium hexafluorophosphate; TOPO II, 
topoisomerase II 
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Figure Legends: 
Figure 1: Cytotoxicity assay of cyclic [WR]4 and cyclic [W(RW)4K]-(β-Ala) in 
MDA-MB-468, HCT-116, CCRF-CEM, and SK-OV-3 
Figure 2: Inhibition of (a) CCRF-CEM, (b) SK-OV-3, (c) HCT-116, and (d) MDA-
MB-468 cells by compounds (1 μM) after 24−120 h incubation. The results are shown 
as the percentage of the control DMSO that has no compound (set at 100%). All the 
experiments were performed in triplicate (±SD) 
Figure 3: FACS analysis of cellular uptake assays of cyclic [W(RW)4]−Dox (5 μM) in 
SK-OV-3 cells compared with linear (RW)4−Dox (5 μM) and the physical mixtures, 
cyclic [RW)4] (5 μM) + Dox (5 μM) and linear (RW)4 (5 μM) + Dox (5 μM) 
Figure 4: (a) Confocal microscopy images of Dox and cyclic [W(RW)4]−Dox (5 μM) 
uptake in SK-OV-03 cells after 1 h. Red represents the fluorescence of Dox. (b) 
Confocal microscopy images of Dox and cyclic [W(RW)4]−Dox (5 μM) uptake in SK-
OV-03 cells. SK-OV-3 cells were treated with the compound for 1 h. The compound 
was removed, and the cells were incubated with complete media for 24 h. Red 
represents the fluorescence of Dox) 
Figure 5: HPLC chromatograms for the cellular uptake studies of cyclic 
[W(RW)4]−Dox using CCRF-CEM cells after incubation for 1−72 h 
Figure 6: Comparison of cell cycle arrest by Dox and cyclic [W(RW)4]-Dox 
Figure 7: Topo II assay for Dox (middle) and cyclic [W(RW)4]−Dox (right). The lines 
A1 and A2 were linear markers and decatenated DNA markers, respectively. Line A3 
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represents the blank kDNA in the absence of any compound. kDNA was incubated 
with compound Dox (10−50 μM, lanes B1−B5) and cyclic [W(RW)4]−Dox (10−50 
μM, lanes C1−C5) and decatenated using topoisomerase II for 30 min at 37 °C. The 
decatenation was monitored by gel electrophoresis and imaged by ethidium bromide 
fluorescence 
 
Scheme Legends: 
 
Scheme 1: Synthesis of Linear (RW)4 Peptide 
Scheme 2: Synthesis of Cyclic [W(RW)4K](β-Ala) Peptide 
Scheme 3: Synthesis of Dox−Peptide (Linear or Cyclic) Conjugates 
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ABSTRACT 
 
A number of cyclic peptides were synthesized and evaluated as simultaneous reducing 
and capping agents for generation of cyclic peptide-capped gold nanoparticles 
(CPAuNPs). Among them, direct dissolution of cyclic peptides containing alternate 
arginine and tryptophan [WR]n (n = 3−5) into an aqueous solution of AuCl4
−
 led to the 
formation of CPAuNPs, through the reducing activity of tryptophan residues and 
attraction of positively charged arginine residues toward chloroaurate anions in the 
reaction environment. Differential interference contrast microscopy of fluorescence-
labeled lamivudine in the presence of [WR]4-capped AuNPs showed significantly 
higher cellular delivery of antiviral drug versus that of parent drug alone. Flow 
cytometry studies also showed that the cellular uptake of fluorescence-labeled 
lamivudine, emtricitabine, and stavudine was significantly enhanced in human ovarian 
adenocarcinoma (SK-OV-3) cells in the presence of [WR]4-AuNPs. For example, 
fluorescence labeled lamivudine loaded [WR]4-AuNPs exhibited approximately 12- 
and 15-times higher cellular uptake than that of fluorescence labeled lamivudine alone 
in CCRF-CEM cells and SK-OV-3 cells, respectively. Confocal microscopy revealed 
that the presence of the [WR]4-AuNPs enhanced the retention and nuclear localization 
of doxorubicin in SK-OV-3 cells after 24 h. These data suggest that these complexes 
can be used as potential noncovalent prodrugs for delivery of antiviral and anticancer 
agents. 
 
KEYWORDS: arginine, cellular delivery, cyclic peptide, gold nanoparticle, 
tryptophan 
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INTRODUCTION 
Gold nanoparticles (AuNPs) have become subjects of major interest because of 
their broad applications in biosensing,
1
 imaging,
2
 drug delivery,
3
 and cancer 
therapy.
4−6
 AuNP-based drug delivery systems (DDS) have become attractive due to 
their low toxicity, nonimmunogenicity, and biocompatibility.
7
 To date, most current 
prodrug strategies for cellular delivery of compounds with limited cell permeability 
have taken advantage of covalent conjugation with carriers. These strategies require 
cleavage and release of the cargo compounds from the conjugate. The covalent 
conjugation of gold and drugs through functionalization of AuNPs by −SH and −NH 
moieties has been also investigated as an efficient strategy for drug delivery.
8
 
We have previously reported the application of a number of cyclic peptides as nuclear 
targeting molecular transporters.
9
 Herein, we report evaluation of L-cyclic peptides as 
simultaneous reducing and capping agents for generation of cyclic peptide-capped 
gold nanoparticles (CP AuNPs). We used cellpenetrating properties of both cyclic 
peptides and capped AuNPs for in situ generation of a DDS. To the best of our 
knowledge, this is the first report of using cyclic peptides in generation of cell-
penetrating CP-AuNPs and as drug delivery tools. 
Multifunctional CP-AuNPs with Au
3+
 reducing, capping, and cell-penetrating 
properties are distinct from the previously reported AuNPs for the following reasons: 
(1) Cell-penetrating properties of both cyclic peptides and capped AuNPs are used for 
cellular drug delivery applications. Positively charged and hydrophobic residues in the 
peptides can be designed to perturb and/or permeate membranes by interacting with 
the corresponding negatively charged and hydrophobic residues, respectively, in the 
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phospholipid bilayer and to promote a higher uptake of molecular cargo than 
conventional delivery routes. (2) No chemical modification or functionalization is 
required on the surface of the generated AuNPs by the cyclic peptides. Furthermore, 
no covalent conjugation is needed between biologically active compounds and CP-
AuNPs. Hydrophobic amino acids of the peptide generate a pocket for noncovalent 
entrapment of drugs. (3) Amino acid residues in the structure of the cyclic peptide 
work as simultaneous reducing and capping agents. Amino acids and linear peptides 
have been studied as reducing agents.
10−13
 Linear peptides incorporating amino acids 
containing nitrogen heteroaromatics are strong metal binders. Tryptophan (W) has 
been shown as the most efficient reducing agent among 20 amino acids.
13
 
Furthermore, positively charged linear peptides found to enhance the reduction 
because of the favorable charge interactions can bring the chloroaurate anions in 
proximity for reaction.
13
 The application of cell-penetrating cyclic peptides as 
simultaneous reducing and capping agents in AuNP formation remains unexplored. (4) 
The enhancement of intracellular delivery of biologically active cargos by employing 
linear cationic cell-penetrating peptides (CPPs) has been previously reported.
14,15
 
Compared to linear peptides that are susceptible to hydrolysis by endogenous 
peptidases, cyclic peptide counterparts are chemically and enzymatically more 
stable.
16
 (5) CP-AuNPs in combination with antiviral and anticancer drugs can be used 
as potential scaffold for generation of noncovalent prodrugs. 
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EXPERIMENTAL SECTION 
Materials and Methods. The synthesis of cyclic peptides was carried out according to 
the previously reported procedure.
7
 All reactions were carried out in Bio-Rad 
polypropylene columns by shaking and mixing using a Glass-Col small tube rotator in 
dry conditions at room temperature unless otherwise stated. Chlorotrityl chloride resin, 
trityl chloride resins, coupling reagents, and Fmoc-amino acid building blocks were 
purchased from Chempep (Miami, FL). 
Other chemicals and reagents were purchased from Sigma-Aldrich Chemical Co. 
(Milwaukee, WI). All peptides were synthesized using a solid-phase synthesis method 
employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-L-
amino acid building blocks. In the solid-phase synthesis 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluoro phosphate (HBTU) and N,N-
diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as 
coupling and activating reagents, respectively. Piperidine in DMF (20% v/v) was used 
for Fmoc deprotection at each step. Side chain protected peptides were cleaved from 
the resins by shaking the resins with a mixture of trifluoroethanol (TFE)/acetic acid/ 
dichloromethane (DCM) (2:2:6, v/v/v, 15 mL) for 2 h. The resins were filtered off, 
and the liquid was evaporated to dryness to obtain side-chain protected linear peptide. 
In general, the cyclization of the peptides was carried out in the presence of a mixture 
of 1-hydroxy-7-azabenzotriazole (HOAt, 163.3 mg, 1.2 mmol) and N,N′-
diisopropylcarbodiimide (DIC, 187.0 μL, 1.2 mmol) in dry DMF (100 mL) and dry 
DCM (40 mL) for 24 h. DMF and DCM were evaporated. The side chain deprotection 
was carried with trifluoroacetic acid (TFA)/thioanisole/anisole/1,2-ethanedithiol 
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(EDT) (90:5:2:3 v/v/v/v) for 2 h. The crude peptides were precipitated by the addition 
of cold diethyl ether (Et2O) and purified by reversed-phase Hitachi HPLC (L-2455) on 
a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) with 
using a gradient system on a Phenomenex Prodigy 10 μm ODS reversed-phase column 
(2.1 cm × 25 cm). The peptides were purified by eluting the crude peptides at 10.0 
mL/min using a gradient of 0−100% acetonitrile (0.1% TFA) and water (0.1% TFA) 
over 60 min, and then, they were lyophilized to yield cyclic. The chemical structure of 
[WR]4 was characterized by nuclear magnetic resonance spectra (
1
H NMR) 
determined on a Varian NMR spectrometer (500 MHz). The chemical structures of all 
final products were confirmed by a high-resolution Biosystems QStar Elite time-of-
flight electrospray mass spectrometer as described previously
7
 or MALDI AXIMA 
Performance TOF/ TOF mass spectrometer (Shimadzu Biotech.). The purity of final 
products (>95%) was confirmed by analytical HPLC. The analytical HPLC was 
performed on the Hitachi analytical HPLC system on a C18 Shimadzu Premier 3 μm 
column (150 cm × 4.6 mm). As representative examples, the synthesis of cyclic [WE]4 
and linear (WR)4 is outlined in Scheme S1 in the Supporting Information. A similar 
procedure was employed for the synthesis of other cyclic peptides by using 
appropriate resins and protected amino acids as described previously.
7
 
 
Linear (WR)4. H-Trp(Boc)-2-chlorotrityl chloride resin (385 mg, 0.30 mmol, 0.78 
mmol/g) was swelled in anhydrous DMF for about 15 min under dry nitrogen. The 
excess of the solvent was filtered off. The swelling and filtration steps were repeated 
for 2 more times before the coupling reactions. Fmoc-Arg(Pbf)-OH (584 mg, 0.9 
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mmol) was coupled to the N-terminal of tryptophan trityl resin in the presence of 
HBTU (340 mg, 0.894 mmol) and DIPEA (313.4 μL, 1.8 mmol) in DMF (6 mL) by 
mixing for 1.5 h. After the coupling was completed (confirmed by Kaiser test), the 
reaction solution was filtered off, and the resin was collected by filtration and washed 
with DMF (7 × 15 mL), followed by N-terminal Fmoc deprotection using piperidine in 
DMF (20% v/v, 10 mL, 2 times, 5 and 10 min). The resin was washed with DMF (7 × 
15 mL). The subsequent amino acids, Fmoc-Trp(Boc)-OH (474 mg, 0.9 mmol) and 
Fmoc-Arg(Pbf)-OH (584 mg, 0.9 mmol), were coupled alternatively three times, 
respectively, in a similar manner. Fmoc-deprotection at the N-terminal was carried out 
in the presence of piperidine in DMF (20% v/v, 10 mL, 2 × 10 min) to afford the 
linear peptide on solid phase. The resin was washed with DMF, DCM, DMF-MeOH, 
and MeOH, respectively (each 2 × 25 mL). The resins were dried in vacuum for 24 h. 
Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/EDT/anisole (90:5:3:2 
v/v/v/v, 10 mL), was added to the resins. The mixture was shaken at room temperature 
for 2 h. The resin was collected by filtration and washed with another 2 mL of 
cleavage cocktail. Combined filtrates were evaporated to a minimum volume under 
dry nitrogen. The crude peptide was precipitated by the addition of cold diethyl ether 
(75 mL, Et2O), lyophilized, and purified by reversed-phase Hitachi HPLC (L-2455) on 
a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a 
gradient system to yield linear (WR)4. MALDI-TOF (m/z) [C68H90N24O9]: calcd, 
1386.7323; found, 1387.5351 [M + H]
+
, 1409.5862 [M + Na]
+
. 
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Synthesis of Cyclic Peptides. The synthesis of cyclic peptides was carried out 
according to the previously reported procedure.
9
 As a representative example, the 
synthesis of [WE]4 is described here. 
 
Cyclic [WE]4. The linear peptide was assembled on the H-Trp(Boc)-2-chlorotrityl 
chloride resin (513 mg, 0.40 mmol, 0.78 mmol/g) in 0.40 mmol scale as described 
above except with the use of Fmoc-Glu(OtBu)-OH in place of arginine. After the final 
deprotection of the N-terminal Fmoc group by piperidine in DMF (20% v/v), the side 
chain protected peptide was cleaved from trityl resin in the presence of the cleavage 
cocktail acetic acid/TFE/DCM (1:2:7 v/v/v, 50 mL) by shaking for 1 h at room 
temperature to yield the side chain protected linear peptide. The resin was collected by 
filtration and washed with TFE/DCM (2:8 v/v, 2 × 10 mL). The combined filtrates 
were evaporated to dryness under reduced pressure. To the residue were added hexane 
(2 × 25 mL) and DCM (1 × 25 mL) to remove the acetic acid from the mixture and to 
solidify the crude material as white solid. The crude protected peptide was dried in 
vacuum overnight. Examining a small portion of the crude showed a main peak by 
HPLC analysis. Thus, the crude was used directly for the cyclization reaction. The 
dried crude linear protected peptide was dissolved in DMF/DCM (5:1 v/v, 250 mL). 
HOAt (223 mg, 1.64 mmol, 4 equiv) and DIC (290 μL, 1.86 mmol, 4.5 equiv) were 
added to the mixture, and the solution was stirred for 4 h. After completion of the 
cyclization, as shown by the MALDI-TOF, the solvents were removed under reduced 
pressure on a rotary evaporator. The crude product was dried overnight in vacuum 
before the final cleavage. Freshly prepared cleavage cocktail, reagent R, 
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TFA/thioanisole/EDT/ anisole (90:5:3:2 v/v/v/v, 20 mL) was added to the crude 
product. The mixture was stirred at room temperature for 2 h. The cleavage cocktail 
was concentrated to a minimum volume under reduced pressure by a rotary 
evaporator. After precipitation of crude peptide in cold diethyl ether (75 mL, Et2O) 
and centrifugation, the crude peptide was lyophilized and purified by reversed-phase 
Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase 
column (2.1 cm × 25 cm) using a gradient system to yield [WE]4. MALDI-TOF (m/z) 
[C64H68N12O16]: calcd, 1260.4876; found, 1261.3163 [M]
+
, 1283.3769 [M + Na]
+
, 
1299.3489 [M + K]
+
. 
 
Synthesis of AuNPs. The formation of AuNPs was studied in the presence of the 
peptides. In general, a peptide stock solution (1−2 mM) was mixed with an aqueous 
solution of HAuCl4 (1−2 mM) at room temperature, and the absorbance was read 
using SpectraMax M2 spectrophotometer (Molecular Devices, CA). The color of the 
solution turned red after 4−8 h due to the formation of peptide capped AuNPs. 
Furthermore, UV−vis spectroscopy study was carried out using HAuCl4 (1 mM) and 
[WR]4 (100 μM to 2 mM) on a 96-well plate, and the absorbance was read after 4 h 
incubation using a SpectraMax M2 spectrophotometer to determine the optimized 
concentration ratio for the reduction. The visible range was chosen because of the 
characteristic surface plasmon peak of AuNPs appearing around 520−550 nm. All 
experiments were performed in triplicate. 
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 Fluorescence Study of [WR]5 in the Presence of HAuCl4. A fluorescence study was 
carried out in the presence of HAuCl4 (1 mM) solution in deionized water and various 
concentrations of [WR]5 (1 μM to 2 mM) in deionized water. After mixing, the 
solutions were transferred into a 96-well plate and fluorescence intensity was read 
using a SpectraMax M2 fluorescence spectrophotometer (Molecular Devices, CA). At 
lower concentrations of the peptide, the fluorescent intensity remained constant. At 
peptide concentrations of 250 μM and higher the intensity proportionally increased, 
demonstrating maximum binding at 1 mM concentration of the peptide. These data 
were consistent with visible spectroscopy data described above. Thus, 1:1 equivalent 
([WR]5/HAuCl4) and 1 mM optimal concentration were selected for further studies. 
 
Transmission Electron Microscopy (TEM), Selected Area Electron Diffraction 
(SAED), Energy Dispersive Xray Spectroscopy (TEM-EDS), and Scanning 
Electron Microscopy (SEM). To prepare a sample for TEM or SEM microscopy, 
[WR]4-AuNPs (5 μL of 0.5 mM solution in H2O) solution was spotted onto a carbon-
coated copper grid (300 mesh). The liquid drop was then allowed to stay on the carbon 
film for 10 min. The excess of the solution was removed from the surface of the grid, 
and the sample was kept overnight to get dried. TEM analyses were conducted in a 
JEOL transmission electron microscope (Tokyo, Japan) at an accelerating voltage 80 
keV as described in the Supporting Information. SEM analyses of [WR]5-AuNPs were 
conducted in an FEI Nova NanoSEM using the directional backscatter (DBS) electron 
detector. 
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Cell Culture. Human ovarian adenocarcinoma cell line (SKOV-3, ATCC No. HTB-
77), human leukemia cell line (CCRFCEM, ATCC No. CCL-119), and normal human 
colon myofibroblast (CCD-18Co, ATCC No. CRL-1459) cell lines were obtained 
from American Type Culture Collection. The cells were grown on 75 cm
2
 cell culture 
flasks with RPMI-16 medium for CCRF-CEM cells and with EMEM (Eagle’s 
minimum essential medium) for SK-OV-3 and CCD-18Co cells, supplemented with 
10% fetal bovine serum (FBS), and 1% penicillin−streptomycin solution (10,000 units 
of penicillin and 10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 
5% CO2, 95% air at 37 °C. Cytotoxicity Assay of [WR]4 and [WR]4-AuNP 
Complexes. SK-OV-3 (5,000 cells), CCRF-CEM (40,000 cells), and CCD 18Co 
(3,000 cells) were seeded in 0.1 mL per well in 96-well plates 24 h prior to the 
experiment. The old medium (EMEM containing FBS (10%) for SK-OV-3 and CCD-
18Co) was replaced by different concentrations of [WR]4 or [WR]4-AuNPs (100 μM) 
in serum containing medium and incubated for 24 or 72 h at 37 °C in a humidified 
atmosphere of 5% CO2. For CCRF-CEM the concentration was calculated after 
addition of the compounds. Cell viability was then determined by measuring the 
fluorescence intensity of the formazan product at 490 nm using a SpectraMax M2 
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD 
value of cells treated with the test mixture of compounds) − (OD value of culture 
medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%. 
Other cell-penetrating peptides polyArg CR7, TAT (YGRKKRRQRRRC) (100 μM), 
and oligofectamine 2000 (Invitrogen, a cationic lipid formulation) were used as 
controls.  
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Cytotoxicity of Dox in the Presence or Absence of [WR]4-AuNPs. The cell viability 
in the presence of Dox and [WR]4-AuNPs and Dox alone against ovarian carcinoma 
cells SK-OV-3 was determined by MTT assay. All cells were plated overnight in 96-
well plates with a density of 5000 cells per well in 0.1 mL of appropriate growth 
medium at 37 °C. Dox alone (5 μM) or a combination of Dox (5 μM) and [WR]4- 
AuNPs (25 μM) were incubated with the cells for 8 h. Excess of compounds were 
removed and washed by fresh media. The cells were kept in an incubator for 24−120 
h. The cells without compounds were included in each experiment as controls. After 
24 h, 48 h, 72 h, 96 h, and 120 h incubation, 20 μL of MTT was added and incubated 
for 2 h. The absorbance of the formazan product was measured at 490 nm using 
microplate reader. The percentage of cell viability was calculated as (OD value of 
untreated cells - OD value of treated cells)/OD value of untreated cells × 100%. 
 
Loading of Doxorubicin. Aqueous Dox solution (10 μL, 10−3 M) was mixed with 
aqueous [WR]4-AuNP solution (100 μL, 10−4 M) to obtain 1:1 molar ratio. Dox in 
H2O was mixed with water as a negative control. Mixed solution was incubated in a 
96-well plate at room temperature for 2 h. Fluorescence of the solution was measured 
using SpectraMax M2 fluorescence spectrophotometer (Molecular Devices, CA) with 
excitation at 480 nm and emission at 550 nm. 
 
Fluorescence Microscopy. Fluorescence-Labeled Peptide-AuNP Uptake. The cellular 
uptake studies of carboxyfluorescein- labeled peptide-AuNP were imaged using a 
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ZEISS Axioplan 2 light microscope equipped with transmitted light microscopy with a 
differential-interference contrast method and an Achroplan 40X objective. Human 
leukemia cells (CCRF-CEM) were taken in 6-well plates (2 × 10
6
 cells/well) in serum-
free media. Then F′-[W5R4K]-AuNPs (10 μM) was added. After 1 h incubation at 37 
°C, the media containing peptide were removed. The cells were digested with 0.25% 
trypsin/EDTA (0.53 mM) for 5 min to remove any artificial cell surface association 
and to detect only intracellular uptake. Then the cells were washed twice with PBS, 
resuspended in media, and were observed under a fluorescent microscope under bright 
field and FITC channels (480/520 nm). 
 
Differential Interference Contrast Microscopy. The cellular uptake studies of 
fluorescence labeled beta alanine-3TC (F′-3TC) were imaged using a ZEISS Axioplan 
2 light microscope equipped with transmitted light microscopy with a differential 
interference contrast method and an Achroplan 40X objective. In the case of SK-OV-3 
cell line, ovarian carcinoma cells (SKOV- 3) were grown on a coverslip in a 6-well 
plate. The cells were incubated with F′-3TC (5 μM) and [WR]4-AuNPs (25 μM), F′-
3TC alone (5 μM), and [WR]4-AuNPs alone (25 μM, SK-OV-3 and CCRF-CEM cells) 
in opti-MEM for 1 h at 37 °C. Then the cells were washed with PBS three times, fixed 
with 3.5% paraformaldehyde followed by washing with PBS three times, and observed 
under a fluorescence microscope as described above.  
 
Flow Cytometry. Human leukemia cells (CCRF-CEM) were taken in 6-well plates (1 
× 107 cells/well) in serum-free medium. Then F′-3TC, F′-GpYEEI, fluorescence-
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labeled FTC (F′-FTC), or fluorescence-labeled d4T (F′-d4T) (5 μM) was added to the 
different wells containing [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) in serum-free 
medium. [WR]4-AuNPs (25 μM) were used as a control. The plates were incubated for 
1 h at 37 °C. DMSO and 5(6)-carboxyfluorescein (FAM) were used as negative 
controls. After 1 h incubation at 37 °C, the medium containing the peptide was 
removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min to 
remove any artificial surface association and to detect only intracellular uptake. Then 
the cells were washed twice with PBS. Finally, the cells were resuspended in flow 
cytometry buffer and analyzed by flow cytometry (FACSCalibur:Becton Dickinson) 
using FITC channel and CellQuest software. The data presented were based on the 
mean fluorescence signal for 10,000 cells collected. All assays were performed in 
triplicate. In the case of Dox, SK-OV-3 cells were seeded in 6-well plates (3 × 105 
cells/well) in opti-MEM. The drugs (Dox, F′- 3TC, F′-GpYEEI, F′-FTC, and F′-d4T) 
(5 μM) were added to the various wells containing [WR]4 (25 μM) or [WR]4-AuNPs 
(25 μM) in opti-MEM. The plates were incubated for 1 h at 37 °C. A well containing 
cells and drug alone was used as negative control. After 1 h incubation, the medium 
was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min 
to remove any artificial surface association and to detect only intracellular uptake. 
Then the cells were washed twice with PBS. Finally, the cells were resuspended in 
flow cytometry buffer and analyzed by flow cytometry (FACSCalibur: Becton 
Dickinson) using FL2 channel and CellQuest software. The data presented are based 
on the mean fluorescence signal for 10,000 cells collected. All assays were performed 
in triplicate. Doxorubicin Retention Assay. Human ovarian cancer cells (SK-OV-3) 
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were seeded in 6-well plates (3 × 105 cells/ well) in EMEM including 10% FBS. The 
cells were incubated overnight. The medium was removed, and Dox (5 μM) was 
added to the various wells containing [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) in 
opti-MEM (reduced serum). The plates were incubated for 1 h at 37 °C. Two wells 
containing cells and Dox and cells and [WR]4-AuNPs alone were used as negative 
controls. The medium was removed after 1 h incubation, and complete medium 
including 10% FBS (EMEM) was added to the cells and incubated for 48 h. The 
medium was removed after 48 h, and the cells were digested with 0.25% trypsin/0.53 
mM EDTA for 5 min to remove any artificial surface association and to detect only 
intracellular uptake. Then the cells were washed twice with PBS. Finally, the cells 
were resuspended in flow cytometry buffer and analyzed by flow cytometry 
(FACSCalibur: Becton Dickinson) using FL2 channel and CellQuest software. The 
data presented are based on the mean fluorescence signal for 10,000 cells collected. 
All assays were performed in triplicate.  
 
Confocal Microscopy of [WR]4-AuNPs and Dox or F′- d4T in Live Cells. Adherent 
SK-OV-3 cells were seeded with EMEM media overnight on coverslips in 6-well 
plates. Then the medium was removed and washed with opti-MEM (reduced serum). 
The cells were treated with Dox or F′-d4T (5 μM), the mixture of Dox (5 μM) and 
[WR]4 (25 μM), and the mixture of Dox or d4T (5 μM) and [WR]4-AuNPs (25 μM) in 
opti-MEM for 1 h at 37 °C. After 1 h incubation, the medium containing the peptide 
was removed followed by washing with PBS three times, and treated with complete 
EMEM including 10% of FBS. Then, the coverslips were mounted on a microscope 
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slide with mounting medium with cell-attached side facing down. Laser scanning 
confocal microscopy was carried out using Carl Zeiss LSM 510 system. The cells 
were imaged using rhodamine and phase contrast channels. In the case of drug efflux 
studies, after a 1 h incubation period, the medium containing drugs was removed and 
washed with opti-MEM. Then fresh medium with serum was added into the cells. 
After 24 h, the medium was removed and washed with PBS three times, and then the 
cells were visualized under confocal microscopy. 
 
RESULTS 
 
Chemistry. Synthesis of Cyclic Peptides. Cyclic octapeptides, [WR]4, [FK]4, [AK]4, 
[EL]4, [RFEF]2, [EK]4, and [FR]4, containing hydrophobic residues (W, F, L) and 
charged residues (K, R, E) (Figure 1) were synthesized by using 9-
fluorenylmethyoxycarbonyl (Fmoc)-based chemistry.
9
 
 
Evaluation of Cyclic Peptides for Generation of CP-AuNPs. The generation of 
AuNPs was studied in the presence of the synthesized cyclic peptides. The formation 
of AuNPs using peptides includes two key steps: reduction reaction of Au3+ solution 
(HAuCl4) and capping the newly nanosized gold particles. The surface plasmon 
maximum band for generated AuNPs was observed in the range of 520−550 nm by 
using UV−vis spectroscopy. Among all cyclic peptides, direct dissolution of [WR]4 
into an aqueous solution of AuCl4
−
 led to the formation of AuNPs showing maximum 
absorption at 539 nm (Figure 1B) and change in the color of the solution to red. The 
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broad absorption peak at >954 nm represents the surface plasmon resonance (SPR) 
peak associated with the excitation of surface plasmons in AuNPs. [WR]4-AuNP 
formation is a controlled process by the balance between reduction, nucleation, and 
growth steps. In general, anisotropy in the nanoparticle product is caused by the 
asymmetric adsorption of capping peptides on different crystallographic planes of the 
nuclei. 
Because peptides were also used here as the reducing agent, the reduction 
kinetics affected both the size and the shape of the nanoparticles. The presence of 
extremely smaller particles indicated that the growth of the AuNP nanoparticles to 
spherical forms occurs via an initial nucleation step. Triangular and hexagonal shapes 
exhibit SPR bands in the near-infrared region 800−1100 nm,16 suggesting the 
formation of anisotropic Au particles. Generally, synthesis of AuNPs is a kinetically 
controlled process where a slow growth environment favors the selective adsorption of 
the capping molecules on the nuclei and the development of anisotropy.
13
 Cyclic 
peptides were used as the reducing agent. Thus, the reduction process affected both the 
size and the shape of the nanoparticles. [WR]4-AuNP formation is a controlled process 
by the balance between reduction, nucleation, and growth steps. The presence of 
spherical AuNPs is consistent with a single localized surface plasmon resonance 
(LSPR) in visible spectroscopy around 539 nm. UV−vis spectroscopy demonstrated 
that the formation of [WR]4-AuNPs from [WR]4 and HAuCl4 was concentration 
dependent. The main experiment was performed by mixing a fixed concentration of an 
aqueous solution of HAuCl4 with the same volume of different concentrations of 
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aqueous solutions of peptides. The intensity of the SPR band was altered as the 
concentration of peptides changed (Figure S3, Supporting Information). 
Because of the capability of [WR]4 in generating AuNPs, other cyclic peptides 
with similar amino acids, [WR]3 and [WR]5 (Figure 1A), were investigated under 
similar conditions to determine whether the ring size has any effect in the AuNP 
formation. UV−vis spectroscopy suggested that all the peptides in the [WR]n (n = 3−5) 
series were able to generate AuNPs from Au
3+
, but [WR]5 and [WR]4 generated higher 
intensity of SPR band at 537−539 nm (Figure 1B). These data suggest that the number 
of tryptophan residues has an impact on the SPR band intensity. The intensity of the 
SPR band of [WR]4-AuNPs is less than that of [WR]5-AuNPs. The intensity difference 
in the SPR band showed more efficient generation of AuNPs in the presence of [WR]5 
compared to [WR]4. Tryptophan works as reducing agent for generating AuNPs. Thus, 
the number of tryptophan residues is critical in reducing efficiency of the peptide. 
[WMeR]4, a cyclic peptide containing N-methyl-L-tryptophan showed no color 
change in the presence of HAuCl4 even after 1 week. These data suggest that the 
presence of a free amino group in the indole of tryptophan for reduction is critical in 
generating AuNPs. Furthermore, [WE]4 as a cyclic peptide containing tryptophan and 
glutamic acid was synthesized to determine whether the presence of arginine residues 
was required for AuNP formation. This peptide was not capable of generating AuNPs. 
The presence of glutamic acid was detrimental (Figure 1B), possibly because the 
negatively charged amino acid has unfavorable electrostatic interaction with 
negatively charge AuCl4
−
, reducing the accessibility of reducing tryptophan residue 
with Au
3+
. The [WR]n series (n =3−5) generated AuNPs with higher intensity in SPR 
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band at 537−539 nm, possibly because tryptophan acted as a reducing agent and 
positively charged arginine residues attracted and absorbed AuCl4
−
 anions. 
[WR]4-AuNPs were characterized using transmission electron microscopy 
(TEM), selected area electron diffraction (SAED), scanning electron microscopy 
(SEM), and energy dispersive X-ray spectroscopy (TEM-EDS) (Supporting 
Information). As described in the Supporting Information, TEM images (Figures 
S3−S5 in the Supporting Information) exhibited nanosized structures with 
approximate size of 5−50 nm after 4 days incubation. AuNPs were obtained in a 
mixture of spherical and triangular shapes (Figures S3−S5 in the Supporting 
Information). [WR]4-AuNP formation is a controlled process by the balance between 
reduction, nucleation, and growth steps. In general, anisotropy in nanoparticle product 
is caused by the asymmetric adsorption of capping peptides on different 
crystallographic planes of the nuclei. AuNP formation includes nucleation from 
spherical forms to triangular. Hexagonal shapes, growth, and aggregation were 
obtained at higher concentration and incubation times. Because peptides were also 
used here as the reducing agent, the reduction kinetics affected both the size and the 
shape of the nanoparticles. Some of the [WR]4-AuNPs form aggregates as seen in 
some parts of the TEM grid perhaps because of hydrophobic interactions between 
oxidized tryptophan residues in CP-AuNPs. In summary, these data showed, there is a 
formation of spherical and trigonal platelets and particles with diameters of 5−50 nm. 
Longer incubation times and higher concentrations led to the hexagonal shapes 
(100−200 nm) and aggregation of the particles. 
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 Two methods were used for preparing the samples for TEM analysis. The 
samples (1 mM of peptide and HAuCl4 each) were prepared by depositing a droplet of 
a mixture of gold and peptide on a carbon-coated Cu support grid of mesh size 300 
and drying at room temperature overnight. Alternatively, another method for the 
preparation of peptide-capped AuNPs was the direct addition of peptide powder to the 
aqueous Au solution. When the peptide was added to HAuCl4 as a powder, TEM 
showed a layer of peptide surrounding AuNPs, suggesting the capping of the formed 
AuNPs by the peptide (Figure S4C in the Supporting Information). Some of the CP-
AuNPs form aggregates as seen in some parts of TEM grid perhaps because of 
hydrophobic interactions between oxidized tryptophan residues in CP-AuNPs. This 
observation is consistent with earlier investigation with tryptophan-reduced AuNPs 
that showed a membrane surrounding the synthesized AuNPs.
11
 
Cyclic [WR]4 and linear (WR)4, which have the same number and sequence of 
amino acids, were compared using visible spectroscopy under similar conditions. Both 
peptides generated AuNPs (Figure 1B), but a weaker SPR band was observed for 
linear (WR)4 in the region higher than 600 nm. We have previously reported 
significantly higher cellular uptake of a cyclic peptide compared to that of the 
corresponding linear peptide.
9
 Thus, [WR]4-AuNPs were selected for further cellular 
studies. 
It is important to emphasize that UV−vis and TEM studies were carried out at 
high concentration peptides (500 μM to 2 mM) and long incubation times that may not 
correlate with significantly lower concentrations (10−25 μM) of peptides prepared in 
short incubation time and used for the cell-based and cellular delivery studies. At this 
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low concentration, only spherical AuNPs were observed for cyclic peptides because of 
nucleation steps and the number of AuNPs decreased dramatically. Herein, we have 
provided some details about the characterization of [WR]4-AuNPs under high 
concentration that is beyond the scope of this work for cellular studies. We focused on 
using generated cyclic peptide-capped nanoparticles formed under mild conditions as 
molecular transporters. In all comparative experiments, [WR]4 and [WR]4-AuNPs 
were used under similar conditions. In general, the stock solution of [WR]4-AuNPs 
was generated by mixing the same volume of aqueous solution of [WR]4 and HAuCl4. 
The concentration of [WR]4-AuNPs was based on the concentration of peptide 
solutions. All the particles are in the form of [WR]4-AuNPs instead of AuNPs + 
[WR]4. The solution was filtered by using 0.2 μm and diluted with water for further 
cell-based assays. The inductively coupled plasma mass spectrometry (ICP-MS) data 
for the [WR]4-AuNPs showed that the conversion of [WR]4 and HAuCl4 to [WR]4-
AuNPs was in high yield. 
 
Cytotoxicity of [WR]4-AuNPs. [WR]4-AuNPs did not show any significant toxicity in 
human ovarian adenocarcinoma (SK-OV-3) and human leukemia (CCRF-CEM) 
cancer cells and normal human colon myofibroblast (CCD-18Co) cells at a 
concentration of ≤25 μM (Figure S5 in the Supporting Information) while other cell-
penetrating peptides polyArg CR7, TAT (YGRKKRRQRRRC), and oligofectamine 
2000 (Invitrogen, a cationic lipid formulation) reduced the viability by 21−55% 
(Figure S6 in the Supporting Information). After formation of [WR]4-AuNPs at higher 
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concentrations (>1 mM), the solution was diluted and a noncytotoxic concentration of 
≤25 μM was selected for cell-based studies. 
 
Cellular Uptake of CP-AuNPs. A 5(6)-carboxyfluorescein (FAM)-labeled conjugate 
of [WR]5 as F′-[K-W-R-W-R-W-RW-R-W] (F′-[W5R4K]) was synthesized as 
described previously, where F′ = fluorescein.9 F′-[W5R4K] was reacted with HAuCl4 
solution to generate CP-AuNPs. Incubation of F′-[W5R4K]-capped AuNPs with 
CCRF-CEM cells showed significantly higher cellular uptake when compared with 
that of FAM (Figure 2A). Flow cytometry studies exhibited the cellular uptake of F′-
[W5R4K]-capped AuNPs to be rapid even after 10 min (Figure 2B). The cellular 
uptake of cyclic F′-[W5R4K]-capped AuNP was approximately 1.5-, 1.7-, and 3.2- fold 
higher than that of linear F′-(W5R4K)-capped AuNP, cyclic F′-[W5R4K], and linear F′-
(W5R4K), respectively, after 1 h incubation (Figure S7 in the Supporting Information). 
Further evidence of the accumulation of AuNPs in SK-OV-3 cells was 
obtained by inductively coupled plasma mass spectrometry (ICP-MS) for quantifying 
the cellular uptake of gold. [WR]4-AuNPs (25 μM) were incubated with SK-OV-3 
cells for 3 and 24 h. The cell lysate was subjected to digestion and analysis by ICP-
MS. The data showed the 163 ng (3 h) and 233 ng (24 h) corresponding to 33−47% 
cellular uptake (Figure S8 in the Supporting Information), suggesting the intracellular 
accumulation of AuNPs in cells. 
The cellular membrane integrity in SK-OV-3 cells was examined in the 
presence of [WR]4-AuNPs and using propidium iodide and showed no significant 
modification (Figure S9 in the Supporting Information), ruling out the damage of the 
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plasma membrane by [WR]4-AuNPs (50 μM) and confirming that the highly efficient 
transport of the complex was not a result of decreased cellular membrane integrity. 
 
Entrapment of Drugs by CP-AuNPs. To study the potential of [WR]4-AuNPs as 
molecular transporters, doxorubicin (Dox) were selected as a model drug for loading 
studies using fluorescence spectroscopy. Incubation of Dox with [WR]4-AuNPs 
demonstrated significant decreased in emission intensity (Figure S10 in the Supporting 
Information), possibly due to the self-quenching of bound drug and/or the result of the 
partitioning and entrapment in the hydrophobic pocket generated by the CP-AuNPs. 
 
Evaluation of CP-AuNPs as Molecular Transporters. Cellular Delivery of 
Lamivudine. To evaluate [WR]4-AuNPs as DDS, lamivudine ((−)-2′,3′ dideoxy-3′-
thiacytidine, 3TC), an anti-HIV and anti-HBV nucleoside reverse transcriptase 
inhibitor,
17
 was selected as a cargo drug. To monitor the molecular transport ability of 
the CP AuNPs, a carboxyfluorescein derivative of 3TC (F′-3TC, Figure 3A) was 
synthesized. 18 SK-OV-3 cells were incubated with F′-3TC in the presence or absence 
of carrier [WR]4-AuNPs for 1 h at 37 °C and then treated with trypsin to remove cell 
surface-bound drugs. F′-3TC uptake was monitored by fluorescence microscopy, 
showing significantly higher fluorescence signals in cells treated with F′-3TC-loaded 
[WR]4-AuNPs (Figure 3A) as compared to those treated with controls F′-3TC alone 
(Figure S11 in the Supporting Information). Furthermore, nuclear localization of F′-
3TC was observed as shown by overlapping of green (FITC) and blue (4′,6 diamidino-
2-phenylindole, DAPI) colors as the result of fluorescence of F′-3TC and stained 
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nuclei, respectively (Figure 3A). In a control experiment, the incubation of [WR]4-
AuNPs alone with CCRFCEM cells and SK-OV-3 cells showed no fluorescence or the 
cellular autofluorescence (Figure S12 in the Supporting Information), suggesting that 
the enhanced fluorescence signal in the presence of F′-3TC is related to the increased 
cellular drug uptake. 
Cellular uptake of F′-3TC (5 μM) was examined in CCRF-CEM cells using 
fluorescence activated cell sorter (FACS) in the presence or absence of [WR]4 and 
[WR]4-AuNPs (25 μM) with trypsin treatment (Figure 3B). FACS showed 
significantly higher fluorescence signals in cells treated with F′-3TC-loaded [WR]4-
AuNPs compared to those treated with F′-3TC alone and F′-3TC-loaded with [WR]4, 
suggesting that the uptake of F′-3TC is facilitated by [WR]4 AuNPs. F′-3TC-loaded 
[WR]4-AuNPs exhibited approximately 12- and 15-times higher cellular uptake than 
that of F′-3TC alone in CCRF-CEM cells (Figure 3B) and SK-OV-3 cells (Figure S13 
in the Supporting Information), respectively. F′-3TC-loaded [WR]4-AuNPs (25 μM) 
exhibited approximately 2.0-, 2.50-, and 7.5-fold higher cellular uptake than F-3TC-
loaded linear (WR)4-AuNPs, cyclic [WR]5, and linear (WR)5, respectively (Figure 
S14 in the Supporting Information). [WR]4-AuNPs showed minimal fluorescence 
intensity in the absence of the fluorescence-labeled compounds as shown with FACS, 
suggesting that the increased fluorescence is due to the cellular drug uptake. 
 
Cellular Delivery of Emtricitabine and Stavudine. Furthermore, anti-HIV drugs 
2′,3′-dideoxy-5-fluoro-3′-thiacytidine (emtricitabine, FTC) and 2′,3′-didehydro-2′,3′-
dideoxythymidine (stavudine, d4T) were attached to 5(6)-carboxyfluorescein (FAM) 
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through β-alanine to afford fluorescently labeled conjugates F′-FTC and F′-d4T, 
respectively.
18,19
 F′- FTC and F′-d4T showed 12- and 15-times higher cellular uptake 
in CCRF-CEM cells, respectively, in the presence of [WR]4-AuNPs, while control 
peptide-capped AuNPs did not show significant fluorescence intensity (Figure 4A). 
Significantly higher cellular uptake for F′-FTC and F′-d4T in the presence of [WR]4-
AuNPs than the parent analogs alone was also observed in SK-OV-3 cells (Figure 4B). 
Confocal microscopy of F′-d4T in the presence of [WR]4-AuNPs in SK-OV-3 live 
cells demonstrated significant cellular delivery, while F′-d4T alone showed minimal 
uptake (Figure 4C). 
 
Cellular Delivery of Doxorubicin. Cellular uptake studies of Dox in the presence of 
[WR]4 and [WR]4-AuNPs also exhibited slightly higher cellular uptake than Dox after 
1 h, but the enhancement was modest since Dox itself has a high inherent cellular 
uptake (Figure S15 in the Supporting Information). Confocal microscopy was 
employed in order to study the application of [WR]4-AuNPs on the intracellular 
retention of Dox in SK-OV-3 cells. Dox is effluxed efficiently within 1 h in ovarian 
cancer SK-OV-3 cells. The cells were treated with free Dox (5 μM) and Dox-loaded 
[WR]4-AuNPs alone (Figure 6A). The data showed higher Dox retention in the 
presence of CP-AuNPs.  
These data show that more Dox is retained in cells even after 48 h. Cellular viability 
studies showed that when Dox is used in the presence of [WR]4-AuNPs, cyctoxicity 
increases in a time-dependent manner. The cytotoxicity of Dox in the presence of 
[WR]4-AuNPs is approximately 13% and 15% more than Dox alone after 96 and 120 
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h, respectively (Figure 6B). Time-dependent cell proliferation data showed that there 
is a time-dependent inhibitory effect on the cell proliferation of SK-OV-3 cells, 
suggesting sustained release of Dox. Binding between [WR]4-AuNPs and Dox has a 
noncovalent nature, and the release will not be in the same nature of the conversion of 
prodrug to the parent drug. These data indicate that [WR]4-AuNPs may have a 
prolonged effect possibly due to the sustained intracellular release of Dox. Dox is 
possibly trapped between AuNPs and the cyclic peptide and is released in a sustained 
pattern. We have been previously shown the binding affinity of Dox with [WR]4 using 
isothermal calorimetry.
9
 Dox (free or encapsulated with [WR]4) was placed inside a 
dialysis membrane (molecular weight cut off 250) immersed in PBS (pH 7.4) or HCl 
(0.02 N). The dialysis membrane was sampled at predetermined time increments, and 
the amount of Dox was determined by UV. Monitoring of in vitro drug release 
revealed sustained release for over 10 days. These data indicate that [WR]4 may have 
a prolonged effect possibly due to the sustained intracellular release of Dox. 
Thus, acute cytotoxicity is not observed immediately even when higher 
concentration of Dox is retained intracellularly. [WR]4-AuNPs are composed of 
charged (R) and hydrophobic (W) residues and are able to noncovalently entrap or 
bind therapeutic molecules for delivery. The peptide portion of the [WR]4-AuNPs is 
responsible for binding with the drug. 
 
DISCUSSION 
 AuNPs are usually synthesized under sometimes harsh conditions in the 
presence of Au(III) ions and inorganic (e.g., sodium borohydride, hydrazine) or 
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organic (e.g., sodium citrate, ascorbic acid) reducing agents to control the size and 
shape of particles. It has been previously reported that AuNPs generated by peptides 
exhibited less toxicity compared to chemical methods.
13
 As described above, [WR]4-
AuNPs did not show any significant toxicity in SK-OV-3 and CCRF-CEM cancer 
cells, and normal human colon myofibroblast (CCD-18Co) cells at a concentration of 
≤25 μM. Formed AuNPs are usually stabilized by peptides, proteins, DNA, 
surfactants, or carbohydrates.
20−23
 Traces of remaining reagents are unsuitable for use 
in biomedical and cellular uptake studies.
24−26
 CPAuNPs were generated under mild 
reaction conditions using cyclic peptides as reducing and capping agents. The 
formation of capped structures was confirmed by TEM showing tryptophan-reduced 
AuNPs with a membrane surrounding the synthesized nanostructures. 
[WR]4-AuNPs did not exhibit any significant toxicity against normal human 
colon myofibroblast (CCD-18Co) cells, human ovarian adenocarcinoma (SK-OV-3), 
and human leukemia (CCRF-CEM) cancer cells at a concentration of of ≤25 μM. 
Thus, the [WR]n series (n = 3−5) could provide alternative potential noncytotoxic 
simultaneous reducing and capping reagents. 
Flow cytometry studies showed the cellular uptake of the corresponding 
fluorescence-labeled CP-AuNPs to be rapid even after 10 min in CCRF-CEM cells. 
Inductively coupled plasma mass spectrometry further confirmed the intracellular 
presence of gold after incubation of [WR]4-AuNPs in SK-OV-3 cells. The mechanism 
of cellular uptake is under investigation, but it is presumably through cellular uptake 
of AuNPs and the interactions of positively charged and hydrophobic residues of the 
cell-penetrating peptide
9
 with the corresponding negatively charged and hydrophobic 
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moieties in the phospholipid bilayer. Both the peptide and AuNPs have cell-
penetrating properties. We previously reported that the cyclic peptides can act as 
nuclear targeting molecular transporters.
9
 Cyclic peptide-capped AuNPs presented a 
new complex system including both AuNPs and the cyclic peptide. 
[WR]4-capped AuNPs showed significantly higher cellular delivery of antiviral 
drugs versus that of parent drug alone. Flow cytometry studies showed that the cellular 
uptake of fluorescence-labeled 3TC, FTC, and d4T was significantly enhanced in 
CCRF-CEM and SK-OV-3 cells in the presence of [WR]4-AuNPs. F′-3TC-loaded 
[WR]4-AuNPs exhibited approximately 12- and 15-times higher cellular uptake than 
that of F′-3TC alone in CCRF-CEM cells and SK-OV-3 cells, respectively. Similarly 
F′-FTC and F′-d4T showed 12- and 15-times higher cellular uptake in CCRF-CEM 
cells, respectively, in the presence of [WR]4-AuNPs. Thus, biologically active 
compounds can be loaded onto AuNPs through noncovalent interactions without any 
structural modification to the drug for release. The presence of tryptophan makes an 
appropriate hydrophobic cavity for loading different drugs. The interactions between 
drugs and [WR]4 and AuNPs containing hydrophobic pockets have been previously 
reported.
9,27,28
 
Confocal microscopy revealed that the presence of the [WR]4-AuNPs enhances 
the retention of Dox in SK-OV-3 cells after 24 h. Our previous report showed that 
there are intermolecular interactions between the cyclic peptide and drugs, including 
Dox as shown by isothermal titration calorimetry.
9
 The peptide portion of the [WR]4-
AuNPs is responsible for binding with the drug. UV titration analysis of [WR]4 and 
Dox also confirmed the complex formation. The cyclic peptide forms a complex with 
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Dox possibly through intermolecular noncovalent interactions. We assume that there is 
interaction through entrapment of the drug in the hydrophobic pocket part of this 
complex due to the available tryptophan. 
 
CONCLUSIONS 
 In summary, CP-AuNPs containing tryptophan and arginine residues were 
generated under a mild reaction condition without any surface functionalization of 
gold. To the best of our knowledge this is the first study for designing AuNPs using 
cyclic peptides as both reducing and capping agents. CP-AuNPs offered several 
advantages including low cytotoxicity, hydrophobic drug entrapment through 
noncovalent interactions, and improving cellular uptake by both cell-penetrating cyclic 
peptide and AuNPs. CP-AuNPs were able to act as molecular transporters of 
fluorescence-labeled lamivudine, emtricitabine, and stavudine intracellularly and to 
improve the Dox intracellular retention. High cellular internalization of the labeled 
drugs and retention of Dox by [WR]4-AuNP suggest the potential application of CP-
AuNPs as molecular transporters and for generation of noncovalent prodrugs. The 
peptide nature of CP-AuNPs should make this system highly amenable to targeting 
strategies. 
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Figure Legends: 
 
Figure 1: (A) Chemical structures of synthesized peptides. A = alanine, E = glutamic 
acid, F = phenylalanine, K = lysine, L = leucine, R = arginine, W = tryptophan. (B) 
UV– Vis absorption spectra of HAuCl4 and/or AuNP formation in the presence of 
cyclic peptides (1 mM), [WR]n (n = 3−5), linear (WR)4, and [WE]4 (1 mM) 
Figure 2: (A) Cellular uptake of F′-[W5R4K]-capped AuNP compared with FAM (10 
μM) in CCRF-CEM cells. (B) Rapid uptake of F′-[W5R4K]-AuNPs versus FAM (10 
μM) in CCRF-CEM cells (FACS) (mean ± SD) 
Figure 3: (A) Differential interference contrast microscopy of fluorescence-labeled 
lamivudine (F′-3TC) (5 μM) in the presence of [WR]4-AuNP (25 μM) in SK-OV-3 
cells. (B) Flow cytometry studies for F′-3TC (5 μM) in the presence or absence of 
[WR]4 or [WR]4-AuNPs (25 μM) in CCRF-CEM cells (mean ± SD, n = 3) 
Figure 4: Flow cytometry studies in (A) CCRF-CEM and (B) SK-OV-3 cells for 
fluorescence-labeled FTC and fluorescence-labeled d4T alone (5 μM) and in the 
presence or absence of [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) after 1 h (mean ± 
SD). (C) Confocal microscopy of F′-d4T (5 μM) uptake in the presence of [WR]4-
AuNPs (25 μM) in SK-OV-3 cells (live cells) 
Figure 5: Confocal microscopy images of Dox (5 μM) and [WR]4-AuNPs (25 μM) 
uptake in SK-OV-3 cells. SK-OV-3 cells treated with drug for 1 h. The compound was 
removed, and the cells were incubated with complete medium for 24 h. Red represents 
fluorescence of Dox 
120 
 
Figure 6: (A) Flow cytometry studies in SK-OV-3 cells for Dox alone (5 μM) and in 
the presence of [WR]4 (25 μM) or [WR]4-AuNPs (25 μM) for 1 h (mean ± SD). The 
compound was removed, and the cells were incubated with complete medium for 48 h. 
(B) Cytotoxicity assay of Dox (5 μM) in the absence and presence of [WR]4-AuNP 
(25 μM) in SK-OV-3 cells (24−120 h) (mean ± SD) 
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Figure 2 
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Figure 4 
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Figure 5 
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Figure 6 
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ABSTRACT 
Gold nanoparticles (AuNPs) were synthesized in situ in a green and rapid method 
from the reaction of reducing linear and cyclic peptides containing tryptophan and 
lysine residues, (KW)5 and cyclic [KW]5, with an aqueous solution of HAuCl4 and 
were evaluated as cellular nanodrug delivery systems. The cyclic or linear nature of 
the peptide was found to determine the morphology and size of the formed peptide-
AuNPs and their in vitro molecular transporting efficiency. While cyclic [KW]5-
AuNPs formed sponge-like agglomerates, linear (KW)5-AuNPs demonstrated ball-
shaped structures. A comparative flow cytometry study showed that the cellular 
uptake of fluorescence-labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine 
(3TC)) in human Leukemia (CCRF-CEM) cells, and a negatively charged cell-
impermeable phosphopeptide (GpYEEI) in human ovarian adecarcinoma (SK-OV-3) 
cells was significantly higher in the presence of cyclic [KW]5-AuNPs than that of 
linear (KW)5-AuNPs, parent cyclic [KW]5, and linear (KW)5 peptides. For example, 
the cellular uptake of F-GpYEEI was enhanced 12.8-fold by c[KW]5-AuNPs. 
Confocal microscopy revealed the localization of fluorescence-labeled-3TC in the 
presence of c[KW]5-AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other 
hand, l(KW)5-AuNPs delivered fluorescence-labeled-3TC in cytoplasm. These data 
suggest that non-cell penetrating peptides can be converted to efficient molecular 
transporters through peptide-capped AuNPs formation. 
 
Keywords: cellular uptake, cyclic peptide, drug delivery, gold nanoparticles, lysine, 
nuclear targeting, tryptophan 
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INTRODUCTION 
The cellular delivery of hydrophobic and poorly water-soluble compounds to 
enhance the efficacy using Drug delivery systems (DDS) is a subject of major 
interest.
1 
Among all delivery systems, nuclear targeting nanodrug delivery systems 
(nano-DDS) have attracted significant attention. Common approaches in gene therapy 
involve using DNA as a pharmaceutical agent to replace or correct a mutated gene.
2
 
Moreover, the nucleus is a target for a diverse number of anticancer and antiviral 
drugs,
3
 due to the presence of the genetic information and transcription systems.  
The nuclear membrane (envelope) is composed of a double lipid bilayer that 
works as a physical barrier between cell nucleus content and the cytoplasm. The 
nuclear membrane contains many nuclear pore complexes (NPCs) that facilitate and 
regulate the exchange of proteins and RNA between the cell nucleus and the 
cytoplasm. Depending on the cell line, NPCs have different sizes from 20 to 60 nm.
4 
Although NPCs operate as available passages for all exchange between the 
nucleoplasm and cytoplasm, they can be exploited as pathways for nanoparticle 
delivery.
5,6
 Therefore, the delivery of the therapeutic agents to the nucleus by using 
nano-DDS offers several advantages compared to other systems.  
The application of prodrug strategy among researchers is now well established. 
Prodrugs are chemically modified analogs of the active metabolite that can improve 
pharmacokinetics and pharmacodynamic (PK/PD) properties of the active drug. 
However, intracellular chemical transformation needed to be occurred in the presence 
of different enzymes to convert prodrugs to their corresponding pharmacologically 
potent compounds in in vivo systems. Prodrug approach offers several advantageous, 
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such as enhancing water solubility, improved chemical stability, decreased toxicity, 
and insufficient brain penetration.
7
 
Gold nanoparticles (AuNPs) have received an increased attention due to their 
unique potential use as nano-DDS.
8 
Most of the known AuNPs as nano-DDS lead to 
the intracellular localization of nanoparticles mainly in the cytoplasm.
9
 However, 
appropriate functionalization of AuNPs with other compounds can be used for their 
optimization as nano-DDS for a specific application.  
Peptide-mediated drug delivery has been widely used for a broad range of 
cargo molecules including drugs, siRNA, and genes due to their versatility and the 
presence of a wide range of amino acids.
10 
Thus, the peptides have the potential to be 
used for decoration of the surface of metal nanoparticles. Recently, AuNPs 
functionalized by peptides have been used as biocompatible systems in drug 
delivery.
11
 For example, AuNPs capped by linear Tat was reported to be able to get 
internalized into the cytoplasm of 3T3 and HepG2 cells.
11c 
 
After the localization of DDS in the destination, it should release the cargo. 
Thus, drug loading and release issues are critical for optimized DDS function. Two 
major strategies for drug loading include covalent and non-covalent binding between 
AuNPs and drugs.
12
 Non-covalent loading offers two main advantages, including ease 
of the drug loading and facilitating drug release in intact form over covalent loading.
13
 
Thus, the entrapment of unmodified drugs into functionalized AuNPs through non-
covalent interaction is introduced as one of the prodrug strategies for the delivery of a 
broad range of drugs. Employing appropriate surface functionalization provides a 
hydrophobic pocket for the loading of drugs. 
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We have previously reported cyclic peptides containing alternative arginine 
(R) and tryptophan (W) as efficient molecular transporters that showed improving the 
cellular uptake of different cargos.
14
 Subsequently, it was found that a physical 
mixture of the cell-penetrating cyclic peptide [WR]4 and HAuCl4 led to the formation 
of peptide-capped gold nanoparticles (P-AuNPs) and enhanced the cellular uptake of 
drugs significantly.
15 
It remains to be determined whether non-cell penetrating 
peptides can be converted to a nuclear targeting DDS through generation of peptide-
AuNPs. 
Herein, we report the generation of a novel nuclear-targeting nano-DDS 
containing AuNPs and a non-cell penetrating peptide containing alternative lysine and 
tryptophan residues. The presence of these amino acids was found to be appropriate to 
generate in situ biocompatible AuNPs. To the best of our knowledge, this is the first 
report of converting a non-cell penetrating peptide to an efficient nuclear targeting 
nano-DDS through cyclic peptide-capped AuNPs formation. 
 
EXPERIMENTAL SECTION 
General 
All reactions were carried out in Bio-Rad polypropylene columns by shaking 
and mixing using either a Glass-Col small tube rotator or PS3 automated peptide 
synthesizer in dry conditions at room temperature unless otherwise stated. In general, 
all cyclic and linear peptides were synthesized by the solid-phase synthesis strategy 
employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-L-
amino acid building blocks. 2-(1HBenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
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hexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIPEA) in N,N-
dimethylformamide (DMF) were used as coupling and activating reagents, 
respectively. 2-Chlorotrityl chloride resin, Fmoc-amino acid trityl chloride resins, 
coupling reagents, and Fmoc-amino acid building blocks were purchased from 
Chempep (Miami, FL). Other chemicals and reagents were purchased from Sigma-
Aldrich Chemical Co. (Milwaukee, WI). Fmoc deprotection at each step was carried 
out using piperidine in DMF (20%). Side chain protected peptides were cleaved from 
the resins by shaking the resins with a mixture of trifluoroethanol (TFE)/acetic 
acid/dichloromethane (DCM) (1:2:7 v/v/v, 15 ml) for 2 h. The resins were filtered off, 
and the liquid was evaporated to dryness to get side-chain protected linear peptide. 
Generally, the cyclization of the peptides was carried out in the presence of a mixture 
of 1-hydroxy-7-azabenzotriazole (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in 
dry DMF and dry dichloromethane (DCM) for 24 h. DMF and DCM were evaporated. 
The side chain deprotection was carried with TFA/thioanisole/anisole/1,2-
ethanedithiol (EDT) (90:5:2:3 v/v/v/v) for 2 h. The crude peptides were precipitated 
by the addition of cold diethyl ether (Et2O) and were purified by using a reversed-
phase Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase 
column (2.1 cm × 25 cm) and a gradient system. The peptides were separated by 
eluting the crude peptides at 10.0 mL/min using a gradient of 0-100% acetonitrile 
(0.1% TFA) and water (0.1% TFA) over 60 min, and then were lyophilized to yield 
cyclic peptides (Figure 1). The purity of final products (95%) was confirmed by 
analytical HPLC. The analytical HPLC was performed on a Hitachi analytical HPLC 
system using a C18 Shimadzu Premier 3 μm column (150 cm × 4.6 mm) and a 
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gradient system (water/CH3CN), and a flow rate of 1 mL/min with detection at 220 
nm. The chemical structures of final products were confirmed by high-resolution 
MALDI AXIMA performance TOF/TOF mass spectrometer (Shimadzu Biotech) or a 
high-resolution Biosystems QStar Elite time-of-flight electrospray mass spectrometer. 
As a representative example, the synthesis of linear (KW)4 is outlined here. 
 
Synthesis of Linear (KW)4 and Linear (KW)5. Fmoc-Trp(Boc)-Wang resin (555 mg, 
0.54 mmol/g, 0.3 mmol) was swelled in anhydrous DMF for about 15 min under dry 
nitrogen. The excess of the solvent was filtered off. The swelling and filtration steps 
were repeated for 2 more times before the coupling reactions. Fmoc-Lys(Boc)-OH 
(325 mg, 0.75 mmol) was coupled to the N-terminal of tryptophan Wang resin in the 
presence of HBTU (285 mg, 0.75 mmol) and DIPEA (262 μL, 1.50 mmol) in DMF (7 
mL) by mixing for 1.5 h. After the coupling was completed, the reaction solution was 
filtered off, and the resin was collected by filtration and washed with DMF (7 × 15 
mL), followed by N-terminal Fmoc deprotection using piperidine in DMF (20% v/v, 
10 mL, 2 times, 5 and 10 min). The resin was washed with DMF (7 × 15 mL). The 
subsequent amino acids, Fmoc-Trp(Boc)-OH (395 mg, 0.75 mmol) and Fmoc-
Lys(Boc)-OH (325 mg, 0.75 mmol), were coupled alternatively three times, 
respectively, in a similar manner (Scheme S2). Fmoc-deprotection at the N-terminal 
was carried out in the presence of piperidine in DMF (20% v/v, 10 mL, 2 × 10 min) to 
afford the linear peptide on solid phase. The resin was washed with DMF and DCM 
respectively (each 2 × 25 mL). The resins were dried under vacuum for 24 h. Fresh 
cleavage cocktail, reagent R, TFA/thioanisole/ EDT/anisole (90:5:3:2 v/v/v/v, 10 mL), 
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was added to the resins. The mixture was shaken at room temperature for 2 h. The 
resin was collected by filtration and washed with another 2 mL of cleavage cocktail. 
Combined filtrates were evaporated to a minimum volume under dry nitrogen. The 
crude peptide was precipitated by the addition of cold diethyl ether (75 mL, Et2O), 
lyophilized, and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex 
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system 
as described above to yield linear (KW)4. MALDI-TOF (m/z) [C68H90N16O9]: calcd, 
1274.7077; found, 1275.1780 [M + H]
+
, 1297.1747 [M + Na]
+
. A simliar procedure 
was performed for the synthesis of the linear (KW)5. l(KW)5: MALDI-TOF (m/z) 
[C85H112N20O11]: calcd, 1588.8819; found, 1589.7442 [M + H]
+
, 1611.7890 [M + 
Na]
+
, 1627.7601 [M + K]
+
. 
 
Synthesis of Cyclic Peptides. The synthesis of cyclic peptides was carried out 
according to the previously reported procedure.
14,16
 As a representative example, the 
synthesis of cyclic [KW]4 is described here. 
 
Cyclic [KW]4. The linear protected peptide (KWKWKWKW) was assembled on the 
H-Trp(Boc)-2-chlorotrityl chloride resin (975 mg, 0.41 mmol/g) in 0.40 mmol scale as 
described above. After the final deprotection of the N-terminal Fmoc group by 
piperidine in DMF (20% v/v, 15 mL, 2 times, 5 and 10 min), the side chain protected 
peptide was cleaved from assembled trityl resin in the presence of the cleavage 
cocktail TFE/acetic acid/DCM (1:2:7 v/v/v, 50 mL) by shaking for 1 h at room 
temperature to yield the side chain protected linear peptide. The filtrates were 
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evaporated to dryness under reduced pressure. To the residue was added hexane (2 × 
25 mL) and DCM (1 × 25 mL) to remove the acetic acid from the mixture and to 
solidify the crude material as white solid. The crude protected peptide was dried under 
vacuum overnight. Examining a small portion of the crude by MALDI analysis 
confirmed the formation of the linear protected peptide. Thus, the crude was used 
directly for the cyclization reaction. The dried crude linear protected peptide was 
dissolved in DMF/DCM (2:1 v/v, 150 mL). HOAt (135 mg, 1 mmol) and DIC (137 
μL, 0.88 mmol) were added to the mixture, and the solution was stirred for 12 h under 
the nitrogen atmosphere. After completion of the cyclization as confirmed by the 
MALDI-TOF, the solvents were removed under reduced pressure on a rotary 
evaporator. The crude product was dried overnight in vacuum before the final 
cleavage. Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/EDT/anisole 
(90:5:3:2 v/v/v/v, 15 mL) was added to the crude product. The mixture was stirred at 
room temperature for 2 h. The cleavage cocktail was concentrated to a minimum 
volume under reduced pressure by a rotary evaporator. After precipitation of crude 
peptide in cold diethyl ether (75 mL, Et2O) and centrifugation, the crude peptide was 
lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex 
Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system 
to yield cyclic [KW]4. A similar procedure was employed for the synthesis of other 
cyclic peptides by using appropriate resins and protected amino acids. The mass 
spectra data for c[KW]5, c[KF]4, c[KA]4, c[RFEF]2, and c[KE]4 have been previously 
reported by us.
16
 
 
136 
 
c[KW]4: MALDI-TOF (m/z) [C68H88N16O8]: calcd, 1256.6971; found, 1257.2083 [M 
+ H]
+
, 1281.2555 [M + H + Na]
+
, 1295.2420 [M + K]
+
; C[EL]4: HR-MS (ESI-TOF) 
(m/z): C44H72N8O16 calcd, 968.5066 ; found, 969.4220 [M + H]
+
, 485.2551 [M + 
2H]
2+
; C[RF]4: HR-MS (ESI-TOF) (m/z): C60H84N20O8: calcd, 1212.6781; found, 
1212.6052 [M + H]
+
, 607.3026 [M + 2H]
2+
, 405.5428 [M+ 3H]
3+
, 304.1588 [M + 
4H]
4+
; C[RC]4: HR-MS (ESI-TOF) (m/z): C36H68N20O8S4 calcd, 1036.4412; found, 
1037.4096 [M + H]
+
, 345.1323 [M + 3H]
3+
, 259.1024 [M + 4H]
4+
. 
 
Synthesis of Fluorescence Labeled-A-Cyclic[KWKWKWKWKW] (F-[KW]5). 
The linear peptide (Dde-K(Fmoc)-WKWKWKWKW) was assembled on solid phase 
using Fmoc/tBu solid phase methodology. Appropriately protected amino acids were 
assembled on H-Trp(Boc)-2 chlorotrityl resin (513 mg, 0.40 mmol, 0.78 mmol/g) 
according to the solid-phase synthesis strategy described above. Dde-Lys(Fmoc)-OH 
was used at the N-terminal of the peptide. The Fmoc protecting group was removed 
from the side chain of lysine using piperidine in DMF (20%, 10 mL, 2 times, 5 and 10 
min) and a short linker Fmoc-β-alanine (312 mg, 1 mmol) was coupled with the 
unprotected side chain amine group of lysine using HBTU/DIPEA (380 mg, 1 
mmol/349 uL, 2 mmol) in DMF (8 mL). Fmoc of β-alanine was removed in the 
presence of piperidine in DMF (20%, 10 mL, 2 times, 5 and 10 min) to attach 
carboxyfluorescein. 5(6)-Carboxyfluorescein diisobutyrate (CFDI, US Biological) 
(516 mg, 1 mmol) was used for labeling the peptide. This was achieved by adding 
resin-bound linear peptide (0.4 mmol) into a solution of CFDI (516 mg, 1 mmol), 
azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 
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520 mg, 1 mmol), HOAT (135 mg, 1 mmol), and DIPEA (350 μL, 2 mmol) in dry 
DMF (12.0 mL). The mixture was shaken for 3 h at room temperature and then the 
solvents were filtered off. The resin was washed with DMF (3  10 mL). The ester 
group of carboxyfluorescein was deprotected with 20% piperidine (20 mL) for 30 min. 
The N-terminal Dde protection was deprotected by treating the resin-bound peptide 
with hydrazine hydrate in DMF (2% v/v, 20 mL, 2 × 5 min). Finally, the side chain 
protected peptide was cleaved from the resin by shaking the resins with a mixture of 
TFE/acetic acid/DCM (15 mL, 1:2:7 v/v/v) for 1 h. The resin was filtered off, and the 
solution was evaporated to dryness under reduced pressure to yield side-chain 
protected linear peptide. The cyclization and purification was carried out according the 
described general method above used for other cyclic peptides to yield fluorescence-
labeled cyclic [KW]5. MALDI-TOF (m/z) [C109H127N21O17]: calcd, 2001.9719; found, 
2000.9316 [M]
+
, 2023.0032 [M + Na]
+
, 2038.9458[M + K]
+
. 
 
Synthesis of Fluorescence Labeled-A-Linear(KWKWKWKWKW) (F-(KW)5). 
The labeled linear sequence was assembled on H-Trp(Boc)-2 chlorotrityl resin (513 
mg, 0.40 mmol, 0.78 mmol/g). The synthesis of the fluorescence-labeled side chain-
protected linear peptide was carried out according to the similar procedure that 
described above. The peptide was assembled on resin using Dde-Lys(Fmoc)-OH at N-
terminal. The Fmoc was removed in the presence of piperidine (20%, DMF). After the 
coupling of -alanine and carboxyfluorscein in the side chain, the Dde protection at 
the N-terminal was removed by reacting with 2% hydrazine hydrate in DMF followed 
by washing with DMF. Then, the linear peptide was removed from the resin by using 
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TFA/thioanisole/anisole/EDT (15 mL, 90:5:2:3 v/v/v/v) for 2 h to obtain the crude 
product. The crude peptide was precipitated by the addition of cold diethyl ether (75 
mL, Et2O). Reversed-phase Hitachi HPLC (L-2455) and the gradient system described 
above were used for the purification of the peptide. MALDI-TOF (m/z) 
[C109H129N21O18]: calcd, 2019.9824; found, 2019.8717 [M]
+
, 2042.8717 [M + Na]
+
, 
2058.8717 [M + K]
+
. 
 
HAuCl4 Reduction by Peptides Dissolved in DMSO/Water Mixtures. The peptides 
were dissolved in 1 mL of deionized water in order to prepare a stock solution of 1 
mM. The stock solution (1 mL, 1 mM) was physically mixed with HAuCl4 solution (1 
mL, 1 mM) in deionized water to obtain AuNPs. The final concentrations of gold and 
peptides were 500 μM. The formation of purple AuNPs was observed by the apparent 
change in the color of solution and confirmed by UV-Vis spectroscopy.  
 
UV-Vis Spectroscopy Studies. The formation of P-AuNPs was studied in the 
presence of different peptides. In general, a peptide stock solution (1 mM) was mixed 
with an aqueous solution of HAuCl4 (1 mM) at room temperature. The color of 
solution turned red after 1 h due to the formation of peptide capped-AuNPs. UV-Vis 
spectroscopy study was carried out using HAuCl4 (1 mM) and different cyclic peptides 
(1 mM) using 96-well plate, and the absorbance was read using SpectraMax M2 
spectrophotometer (Molecular Devices, CA) (Figure S16). The visible range was 
chosen because of the characteristic maxima peak of AuNPs appeared around 520-560 
nm. All experiments were performed in triplicate. 
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Encapsulation of Camptothecin (CPT). CPT was dissolved in DMSO, and 10 µL of 
10
-3
 M camptothecin solution was mixed with 100 µL of 10
-4 
M aqueous peptide 
solution in a 1:1 molar ratio. CPT in DMSO was mixed with water as a negative 
control. Mixed solution was incubated in a 96 well plate at room temperature for 4 h. 
Fluorescence of the solution was measured using SpectraMax M2 fluorescence 
spectrophotometer (Molecular Devices, CA) with excitation at 290 nm and emission at 
360 nm. 
 
Drug Loading. Doxorubicin (Dox) aqueous solution (100 μL, 100 μM) was added 
into [KW]5-AuNPs solution (900 μL, 500 μM) with the concentration ratio of 1:5 for 
Dox to peptide-capped AuNPs. The mixture was transferred into a 1 mL dialysis 
membrane (with the cutoff molecular weight 1000 D; Float-A-Lyzer G2, Spectrum 
Labs). The membrane was sealed and submerged into water (500 mL) as a medium. 
After stirring in dark for 24 h, unloaded Dox in the mixture was collected and 
evaporated to reduce the volume. The concentration of Dox was measured using a 
reverse phase HPLC system installed with Hitachi premier C18 column (3 m, 4.6 x 
150 mm) at UV/Vis 490 nm wavelength. Mobile phases were water (0.1% 
trifluoroacetic acid) and acetronitrile (0.1% trifluoroacetic acid). The gradient of 10% 
to 90% acetonitrile was applied to separate the Dox peak from other impurities. The 
calibration standard solutions were injected to quantify Dox in the sample solution.   
The loading efficiency was calculated using the following equation:   
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To measure the loading capacity, the amount of the AuNPs in the dialysis membrane 
was measured after 24 h by using ICP-MS. The ICP-MS results showed the amount of 
AuNPs were responsible for the encapsulation of Dox. Thus, the loading capacity was 
calculated based on the following equation. 
                           
                     
                     
     
 
Transmission Electron Microscopy (TEM). TEM analyses were conducted in JEOL 
Transmission Electron Microscope (Tokyo, Japan) at an accelerating voltage 80 keV. 
The stock solution (1 mL, 1 mM) was physically mixed with HAuCl4 solution (1 mL, 
1 mM) in deionized water to obtain AuNPs. The final concentrations of gold and 
peptides were 500 μM. The mixture was incubated for 12 days. TEM samples of 
c[KW]5-AuNPs and l(KW)5-AuNPs were prepared by depositing a droplet of 5 μL of 
0.5 mM solution in H2O on a carbon-coated Cu support grid of mesh size 300 that 
were dried in air overnight.  
 
Cell Culture. Human leukemia cell line CCRF-CEM (ATCC no. CCL-119), ovarian 
carcinoma SK-OV-3 (ATCC no HTB-77), and colon myofibroblasts CCD-18Co 
(ATCC no. CRL-1459) were obtained from American Type Culture Collection. Cells 
were grown on 75 cm
2 
cell culture flasks with RPMI-16 medium (for leukemia cells) 
and EMEM medium (for SK-OV-3 and CCD-18Co cells), supplemented with 10% 
fetal bovine serum (FBS), and 1% penicillin-streptomycin solution (10,000 units of 
penicillin and 10 mg of streptomycin in 0.9 % NaCl) in a humidified atmosphere of 
5% CO2, 95% air at 37 ºC.  
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Cytotoxicity Assay. SK-OV-3, CCRF-CEM, and CCD-18Co cells were seeded at 
5,000 cells, 30,000 cells, and 3,000 cells, respectively, in 0.1 ml per well in 96-well 
plates 24 h prior to the experiment. The old medium (EMEM containing FBS (10%)) 
was replaced (not in case of CCRF-CEM) by different concentrations of c[KW]5, 
l(KW)5, c[KW]5-AuNPs or l(KW)5-AuNPs in serum containing medium and 
incubated for 24 h (or 72 h) at 37 °C in a humidified atmosphere of 5% CO2. Cell 
viability was then determined by measuring the fluorescence intensity at 490 nm using 
a SpectraMax M2 microplate spectrophotometer. The percentage of cell survival was 
calculated as [(OD value of cells treated with the test mixture of compounds) − (OD 
value of culture medium)]/[(OD value of control cells) − (OD value of culture 
medium)] × 100% (Figure S17). 
 
Flow Cytometry Studies. Human leukemia  and ovarian carcinoma cells (CCRF-
CEM and SK-OV-3) were taken in 6-well plates (1 × 10
7
 cells/well (CCERF-CEM) 
and 3 × 10
5
 cells/well (SK-OV-3)) in opti-MEM. Then the fluorescence-labeled 
compound (F′-3TC, F′-FTC, or F′-GpYEEI) (5 µM) was added to the different wells 
containing c[KW]5-AuNPs (25 M), l(KW)5-AuNPs (25 M), l(KW)5 (25 M), or 
c[KW]5 (25 M) in serum-free media. The plates were incubated for 1 h at 37 C. 
Cells, P-AuNPs, and the fluorescence-labeled compound alone were used as negative 
controls. After 1 h incubation, the media containing the peptide was removed. The 
cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min to remove any 
artificial surface binding. Then the cells were washed twice with PBS. Finally, the 
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cells were resuspended in flow cytometry buffer and analyzed by flow cytometry 
(FACSCalibur™:Becton Dickinson) using FITC channel and CellQuest software. The 
data presented were based on the mean fluorescence signal for 10,000 cells collected. 
All assays were performed in triplicate.  
In the case of fluorescence-labeled peptide gold nanoparticles (F′-Peptide-AuNPs) and 
their corresponding peptides (F′-Peptide), SK-OV-3 cells were seeded in 6-well plates 
(3 × 10
5
 cells/well) in opti-MEM. The F′-labeled compound (F′-c[KW]5, F′-l(KW)5, 
F′-c[KW]5-AuNPs, or F′-l(KW)5-AuNPs (5 μM) was added to the various wells. The 
plates were incubated for 1 h at 37 °C. Wells containing no treatment and 5-(6) 
carboxyfluorescein (FAM) were used as negative controls. After 1 h incubation, the 
medium was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) 
for 5 min to remove any artificial surface association and to detect only intracellular 
uptake. Then the cells were washed twice with PBS. Finally, the cells were 
resuspended in flow cytometry buffer and analyzed by flow cytometry (FACSCalibur: 
Becton Dickinson) using FL2 channel and CellQuest software. The data presented are 
based on the mean fluorescence signal for 10,000 cells collected. All assays were 
performed in triplicate. 
 
Cellular Uptake Studies in the Presence of Inhibitors. Human ovarian 
adenocarcinoma cells (SK-OV-3) were seeded in six well plates (3 × 10
5
 cells/well) in 
opti-MEM. The cells were pre-incubated by various inhibitors including, nystatin (50 
µg/ml), chloroquine (100 µM), chlorpromazine (30 µM), methyl-β-cyclodextrin (2.5 
mM), and 5-(N-ethyl-N-isopropyl)amiloride (EIA, 50 µM) for 30 min. The treatment 
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was removed, and the cells were incubated with F-l(KW)5-AuNPs or F-c[KW]5-
AuNPs (5 μM) a similar concentration of inhibitors for 1 h. Consequently, similar 
FACS protocol was performed as described above.  
 
Membrane Integrity Test. Ovarian carcinoma cells SK-OV-3 were grown in six well 
plates (1 × 10
5 
 cells/ well). Cells were treated with [KW]5-AuNPs (50 μM) and 
(KW)5-AuNPs (50 μM) in serum-free media for 1 h at 37 ⁰C. After 1 h incubation, the 
cells were detached with trypsinization for 5 min followed by washing twice with 
PBS. Then they were resuspended in serum-free media. Trypan blue (2 μL) was added 
into the cell suspension (18 μL) and incubated for 5 min. Finally, trypan blue-stained 
cells were counted using cellometer vision (Nexcelom Bioscience, Lawrence, MA, 
USA) (Figure S18). 
 
Confocal Microscopy on Live Cells. Adherent SK-OV-3 cells were seeded with 
EMEM media overnight on coverslips in six well plates (1×10
5
 cells per well). Then, 
the media were removed and washed with opti-MEM. The cells were treated with the 
mixture of F′-3TC (5 µM) and c[KW]5-AuNPs (25 M), and the mixture of F′-3TC (5 
µM) and l(KW)5-AuNPs (25 M) in opti-MEM for 1 h at 37 ºC. After 1 h incubation, 
the media containing the treatments were removed followed by washing with PBS 
three times. To stain the nuclei, cells were incubated with 4,6-diamidino-2-
phenylindole (DAPI, 0.5 mL) solution in PBS for 5 min. After the incubation, the cells 
were softly washed twice with PBS to remove the excessive DAPI. The coverslips 
were mounted on a microscope slide with mounting media with cells-attached side 
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facing down. Laser scanning confocal microscopy was carried out using Carl Zeiss 
LSM 700 system. The cells were imaged using FITC and phase contrast channels. The 
fluorescence images were taken under 20 × objective. Blue and green luminescent 
emissions from DAPI and FITC were excited at the wavelength of 405 nm and 488 
nm, respectively. The emission wavelengths were ranged from 425 nm to 475 nm for 
DAPI and 500 nm to 550 nm for FITC. There was no interference between these two 
channels. The scanning mode was in sequential frame. 
 
Time-Dependent Antiproliferative Assay. The antiproliferative activity of CPT 
alone and in the presence of c[KW]5-AuNPs against SK-OV-3 cells was determined 
by MTS assay. All cells were plated overnight in 96-well plates with a density of 5000 
cells per well in 0.1 mL of appropriate growth medium at 37 °C. CPT alone (5 μM) or 
a combination of CPT (5 μM) and c[KW]5-AuNPs (25 μM) were incubated with the 
cells for 4 h. Excess of compounds was removed and washed by fresh media. The cells 
were kept in an incubator for 24−72 h. The cells without compounds were included in 
each experiment as controls. After 24 h, 48 h, and 72 h incubation, 20 μL of MTS 
solution was added and incubated for 2 h. The absorbance of the formazan product 
was measured at 490 nm using microplate reader. The percentage of cell viability was 
calculated as (OD value of untreated cells - OD value of treated cells)/OD value of 
untreated cells × 100%. 
 
Intracellular Release of Dox. Intracellular release and accumulation of Dox were 
determined in CCRF-CEM cells by HPLC analysis. CCRF-CEM cells were grown in 
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75 cm
2
 culture flasks with RPMI medium (containing 10% FBS and 1% penicillin-
streptomycin) to achieve ∼70−80% confluence (1.2 × 107 cells/mL). The cells were 
partitioned/transferred to culture plates (six well) having 1.2 × 10
7
 cells per well in 2 
mL of medium. The treatment in fresh RPMI medium containing Dox-loaded c[KW]5-
AuNPs (7.5/37.5 μM) was added to cells, and they were incubated at 37 °C for 
different incubation times including 2, 12, 24, and 48 h. After the incubation time, the 
cells were collected by centrifugation. The medium was removed and cell pellets were 
washed with ice-cold PBS (5 mL) twice to remove any medium. The cell pellets were 
thoroughly extracted with an equal volume of methanol, chloroform, and isopropanol 
mixture (4:3:1 v/v/v) and filtered through 0.2 μm filters. The solvents were evaporated 
under N2 gas. The released Dox was quantified by reverse phase HPLC system with 
UV/Vis detector (490 nm) (Figures S4-S9, Supporting Information). The HPLC 
condition was using mobile phase water (0.1% trifluoroacetic acid) and acetronitrile 
(0.1% trifluoroacetic acid) and the gradient of 10% to 90% acetonitrile as described 
above in drug loading section.  
 
RESULTS AND DISCUSSION 
Chemistry 
A number of cyclic octapeptides containing diverse combination of amino 
acids including c[KW]4, c[KF]4, c[KA]4, c[EL]4, c[RFEF]2, c[EK]4, c[RF]4, and 
c[RC]4 (Figure S16) were synthesized by employing 9-fluorenylmethyoxycarbonyl 
(Fmoc)-based chemistry according to the previously reported procedure.
14,16
 Synthesis 
of c[KW]4 and l[KW]4 is described in Supporting Information (Schemes S1 and S2). 
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Fluorescently-labeled conjugates of linear (KW)5 and cyclic [KW]5 were synthesized 
as described previously.
14
 For example, F-l(KW)5 was synthesized by the Fmoc 
protection group at the N-terminal was removed. Subsequent conjugation reaction with 
5(6)-carboxyfluorescein isobutyrate was performed in the presence of HOAt, PyAOP, 
and N,N-diisopropylethylamine (DIPEA) in DMF:DCM followed by deprotection and 
cleavage from the resin in the presence of reagent R afforded the crude product that 
was purified by preparative reversed-phase HPLC (Scheme S2). The structures of all 
the final compounds were confirmed by high-resolution MALDI TOF/TOF and/or 
high-resolution electrospray mass spectrometry. 
 
Evaluation of Cyclic and Linear Peptides for Generation of Peptide-AuNPs and 
Characterization 
All peptides were examined for their ability to generate AuNPs by direct 
addition of the peptide solution (1 mM) into an aqueous solution of HAuCl4 (1 mM) at 
room temperature. UV-Vis spectra and monitoring of surface plasmon resonance peak 
at ~550 nm showed that among all peptides, c[KW]4 and the corresponding linear 
peptide l(KW)4 were able to produce peptide capped AuNPs (P-AuNPs) (Figure S16). 
Mechanistically, c[KW]4 acts as reducing and capping agent, making this method a 
one-step (one-pot) reaction without any need for chemical modification on the surface 
of AuNPs.
 
Amino acids have been used as reducing agents. Among them, tryptophan 
(W) has been shown to be the most efficient reducing agents among 20 amino acids.
17 
Addition of positively charged residues, such as lysine (K) in the structure of the 
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peptide enhances the reduction through the favorable charge interactions with the 
chloroaurate anions.
18
  
To optimize the yield of P-AuNPs by increasing the reducing and capping efficiency 
of the peptide, cyclic c[KW]5 containing ten alternative tryptophan and lysine (Figure 
1) was synthesized. The corresponding linear peptide l(KW)5 (Figure 1) was also 
designed and synthesized to determine the effect of the peptide cyclic nature of the 
peptide on the shape and size of P-AuNPs. UV-Vis spectra of both c[KW]5-AuNPs 
and l(KW)5-AuNPs showed also a SPR peak at approximately 550 nm. 
Further studies were conducted by Transmission electron microscopy (TEM) to 
characterize the size and shape of P-AuNPs. TEM images of c[KW]5-AuNPs and 
l(KW)5-AuNPs showed that these two systems formed entirely different nanosized 
structure. c[KW]5-AuNPs formed sponge-like agglomerates containing peptide and 
AuNPs containing peptide and AuNPs with an approximate diameter size of 250-450 
nm (Figure 2) along with some isolated AuNPs in mostly spherical and triangular 
shapes (6-60 nm). Compared to cyclic peptide-capped AuNPs, TEM images of 
l(KW)5-AuNPs demonstrated ball-shaped structures with the approximate diameter 
size of 900-1000 nm composed of a large number of AuNPs (Figure 3). The majority 
of individual l(KW)5-AuNPs were found to be spherical and approximately in the size 
range of 4-35 nm. The distribution pattern of AuNPs in the ball-shape structure of 
l(KW)5-AuNPs showed an organized arrangement (Figure 3). No visible peptide 
agglomerates were observed. Cavities between AuNPs were found to be tailored in a 
similar range size (approximately 45 ± 2 nm). The presence of the tryptophan in the 
structure of the linear peptide induces presumably hydrophobic interactions that could 
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be an efficient driving force for the formation of this specific structure. c[KW]5 and 
l(KW)5 alone did not form any specific nanostructures under similar conditions, 
suggesting that the binding between AuNPs and peptides contributes to different 
morphology in P-AuNPs.   
cyclic nature and rigidity of the peptide in c[KW]5-AuNPs and different 
orientation of amino acids in the skeleton of peptide generated a different environment 
surrounding the complex that led to aggregation or agglomeration of the peptides. This 
orientation altered the number of available tryptophan and/or lysine residues in 
reduction of Au
3+
 reaction.
18
 However, l(KW)5 has more flexible conformation 
compared to the corresponding conformationally constrained cyclic counterpart 
c[KW]5 during the AuNPs formation. The presence of additional positively charge 
amino group and negatively charge carboxylate at N-terminal lysine and C-terminal 
tryptophan, respectively, could also contribute in intermolecular interactions of the 
peptide. Thus, the cyclic and linear nature of the peptide and the orientation of amino 
acids were found to be responsible for the different morphology and size of formed P-
AuNPs.  
Circular dichroism (CD) was used to obtain a better understanding about the 
effect of AuNPs formation on the secondary structure of these peptides. CD 
experiment of aqueous solution of peptides and their corresponding P-AuNPs (100 
μM) was performed at room temperature. CD spectra of c[KW]5 (Figure 4) revealed a 
negative band at approximately 216 nm and a positive band around 230 nm. 
Compared to c[KW]5, the linear counterpart l(KW)5 showed a different CD spectra 
pattern with a negative band at 201 nm and a positive band at 227 nm. However, the 
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CD spectra of both c[KW]5-AuNPs and l(KW)5-AuNPs exhibited relatively similar 
pattern with a minima at 204 ± 2 nm and a maxima at maxima at 229 ± 1 nm. 
Although two P-AuNPs showed approximately similar pattern and intensity, l(KW)5-
AuNPs (206 nm) minima was shifted compared to that of c[KW]5-AuNPs (203 nm). 
The CD spectra demonstrated a significant decrease in spectral elipticity of both P-
AuNPs compared to their corresponding parent peptides, suggesting significant 
modification of secondary structures upon reducing Au
3+
 and/or binding to AuNPs. 
These data show the binding between peptides and AuNPs leads to the formation of 
c[KW]5-AuNPs and l(KW)5-AuNPs with differential CD spectra pattern compared to 
the parent peptides. 
 
 
Encapsulation of Camptothecin by Peptide-AuNPs 
To evaluate the potential of c[KW]5-AuNPs and l(KW)5-AuNPs to encapsulate 
drugs, camptothecin (CPT), a hydrophobic potent anticancer drug targeting 
topoisomerase I
19 
was selected as a model drug for evaluation of loading using 
fluorescence spectroscopy. Incubation of CPT with c[KW]5-AuNPs and l(KW)5-
AuNPs demonstrated significant shift in emission maxima of CPT. A characteristic 
maxima band of CPT alone at 458 nm was shifted to 433 nm and 430 nm in the 
presence of c[KW]5-AuNPs and l(KW)5-AuNPs, respectively (Figure S19). The 
spectral blue shift in the presence of c[KW]5-AuNPs and l(KW)5-AuNPs was possibly 
due to partitioning of CPT into a hydrophobic core and hydrophobic interactions. 
Moreover, the intensity of the maxima band was decreased that could be due to the 
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self-quenching of bound-drug and/or the result of the partitioning and entrapment in 
the hydrophobic pocket generated by the P-AuNPs.
20
 These data exhibited that the P-
AuNPs were able to encapsulate CPT due to the generated hydrophobic pocket 
possibly by tryptophan in the structure of the peptide. 
 
Drug Loading. To get a better understanding of the quantitative drug loading 
efficiency of the system, Dox was selected as a model drug because of its stability and 
fluorescence property. The loading measurement was performed based on the 
previously reported method.
27
 Aqueous Dox solution (100 μL, 100 μM) was mixed 
with aqueous c[KW]5-AuNPs solution (900 μL, 500 μM) to obtain 1:5 molar ratio. 
The unloaded Dox was separated by using dialysis to analyze the Dox loading 
efficiency and loading capacity in the c[KW]5-AuNPs. After 24 h stirring, the loading 
efficiency was found to be 72 ± 1% when the weight ratio of Dox to c[KW]5-AuNPs 
in feed is 1:5. The loading capacity was calculated to be 16 ± 1 % based on the weight 
ratio of Dox to c[WK]5-AuNPs (1:5) when the amount of AuNPs was determined 
using inductively coupled plasma mass spectrometry (ICP-MS). 
 
Cytotoxicity of Peptide-AuNPs. Generated c[KW]5-AuNPs and  l(KW)5-AuNPs did 
not show any significant toxicity in human ovarian adecarcinoma (SK-OV-3), human 
leukemia (CCRF-CEM) cancer cells, and normal human colon myofibroblast (CCD-
18Co) cells at a concentration of 100 μM after 24 and 72 h incubation times (Figure 
S17). Thus, concentration of ˂100 μM was selected for further cell-based studies. It is 
important to emphasize that the cytotoxicity of c[KW]5 and l(KW)5 (100 μM) was 
151 
 
decreased through P-AuNPs formation dramatically. For example, c[KW]5 was found 
to be toxic in normal colon CCD-18Co cells (61.3% cell viability) compared to 
c[KW]5-AuNPs (99.3% cell viability) after 24 h at a concentration of 100 M. These 
data indicate that the cytotoxicity of the parent peptide significantly reduces upon 
generation of P-AuNPs.  
 
Cellular Uptake of Peptide-AuNPs. To confirm the internalization of P-AuNPs 
alone, F-l(KW)5-AuNPs and F-c[KW]5-AuNPs were prepared as described above by 
incubating of fluorescently-labeled conjugates of linear (KW)5 and cyclic [KW]5, F-
l(KW)5 and F-c[KW]5, with HAuCl4 solution according to the previously reported 
procedure.
15
 Incubation of F-l(KW)5-AuNPs and F-c[KW]5-AuNPs with SK-OV-3 
cells showed 3.3- and 4.3-fold higher cellular uptake compared to the corresponding 
fluorescently-labeled peptides F-l(KW)5 and F-c[KW]5, respectively, thus suggesting 
the formation of P-AuNPs is crucial for the enhanced cellular permeability (Figure 5). 
FACS results confirmed that F-c[KW]5-AuNPs showed approximately 1.6-fold higher 
cellular uptake than F-l(KW)5-AuNPs, suggesting that the cyclic nature of the peptide 
in P-AuNPs contributes to improving the cellular uptake. 
 To investigate whether c[KW]5-AuNPs and l(KW)5-AuNPs localize in 
different locations in the cell, F-l(KW)5-AuNPs (5 μM) and F-c[KW]5-AuNPs (5 
μM) were incubated with SK-OV-3 for 1 h. 4',6-Diamidino-2-phenylindole (DAPI) 
was employed as a marker of nucleus. Confocal microscopy showed significantly 
higher nuclear localization of the cyclic peptide-capped AuNPs (F-c[KW]5-AuNPs) 
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versus the corresponding linear system (F-l(KW)5-AuNPs) as shown by overlayed 
picture with DAPI (Figure 6).  
 Cells use different mechanisms to internalize macromolecules and particles, 
such as phagocytosis, micropinocytosis, and receptor-mediated endocytosis (RME) 
pathways including clathrin-mediated, caveolae-mediated, and caveolae/clathrin 
independent endocytosis.
21
 To get a better understanding of the mechanism of peptide-
capped gold nanoparticles uptake by cells, the cellular uptake of fluorescein-labeled 
peptide capped gold nanoparticles, F-l(KW)5-AuNPs and F-c[KW]5-AuNPs (5 μM), 
were tested quantitatively in the presence of several inhibitors by using FACS 
including, nystatin, chloroquine, chlorpromazine, methyl-β-cyclodextrin, and 5-(N-
ethyl-N-isopropyl)- amiloride (EIA).  
As it is shown in Figure 7, the intracellular uptake of F-l(KW)5-AuNPs and F-
c[KW]5-AuNPs did not significantly change in SK-OV-3 cells in the presence of 
different endocytic inhibitors after 1 h incubation, suggesting that the mechanism of 
cellular uptake is not exclusively clathrin-mediated or caveolae-mediated endocytosis, 
and macropinocytosis. These peptide-AuNPs provide an advantage to known gold 
nanoparticles and cell-penetrating peptides that their uptake is dependent mainly on 
endocytotic entry.
22
 
The surface decoration of AuNPs by amphipathic c[KW]5 and l(KW)5 peptides 
could improve the interactions of lysine and tryptophan residues with the 
corresponding negatively charged phospholipids and hydrophobic residues in lipid 
bilayer. This interaction could be a strong driving force for the initial entry into the 
cell membrane. Hydrophobic interactions generated by tryptophan residues and the 
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lipids can potentially distort the outer phospholipid monolayer. This process will be 
followed by peptide internalization and enhanced cellular uptake of the cargo. The 
nature of the peptide in surface of AuNPs is an important parameter that can alter the 
mechanism of nanoparticle uptake by cells. Further investigation is required to 
pinpoint the detailed mechanism of cell entry by these P-AuNPs.  
 The cellular membrane integrity in SK-OV-3 cells was examined in the 
presence of c[KW]5-AuNPs and l(KW)5-AuNPs and using trypan blue and showed no 
significant difference to the control cells (Figure S18), ruling out the damage of the 
plasma membrane by P-AuNPs at 50 μM and confirming that the highly efficient 
transport of the complex was not a result of decreased cellular membrane integrity.  
 
Evaluation of Peptide-AuNPs as Molecular Transporters. To evaluate P-AuNPs as 
molecular transporters, model experiments with anti-HIV drugs 2',3'-dideoxy-5-
fluoro-3'-thiacytidine (emtricitabine, FTC) and 2',3'-didehydro-2',3'-dideoxythymidine 
(lamivudine, 3TC) as cargo drugs were performed. FTC and 3TC are nucleoside 
reverse transcriptase inhibitors those blocks HIV-1 and hepatitis B virus replication.
22
 
The efficient cellular uptake of FTC and 3TC are critical for anti-HIV activity. To 
monitor the molecular transporter ability of P-AuNPs, carboxyfluorescein derivatives 
of FTC (F-FTC) and 3TC (F-3TC) were synthesized as described previously, where 
F= fluorescein.24,25  
CCRF-CEM cells were incubated with F-FTC and F-3TC (5 μM) in the 
presence or absence of diluted carriers c[KW]5-AuNPs and l(KW)5-AuNPs (25 μM) 
and their parent peptides for 1 h at 37 ºC and then treated with trypsin to remove cell 
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surface-bound drugs. Intracellular uptake of F-FTC and F-3TC (5 μM) was measured 
in cells using fluorescence activated cell sorter (FACS). FACS showed significantly 
higher fluorescence signals in cells treated with F-Drug-loaded P-AuNPs compared to 
those with drug alone. The cellular uptake of F-drug-loaded c[KW]5-AuNPs and F-
drug–loaded l(KW)5-AuNPs were found to be 5.2–5.3- and 2.5–2.9-fold higher for F-
FTC and F-3TC, respectively, than those of drug alone respectively (Figure 8), 
suggesting that the uptake of drugs is facilitated by P-AuNPs. The results showed that 
parent cyclic or linear parent peptides did not improve the cellular uptake of drugs. 
However, after the formation of P-AuNPs, the cellular uptake of drugs was increased 
significantly. c[KW]5-AuNPs were found to be more efficient transporter than l(KW)5-
AuNPs, while c[KW]5 and l(KW)5 exhibited similar results. These data suggest that a 
non-cell penetrating cyclic peptide can be converted to cell-penetrating P-AuNPs, 
presumably due to the new orientation of amino acids and the secondary structure in 
peptides as shown with CD in the presence of generated AuNPs for drug entrapment.  
To visualize the enhancement of the cellular uptake of drugs, F-3TC was used 
as a model for confocal microscopy in SK-OV-3 cells. Confocal microscopy showed 
nuclear localization of F-3TC–loaded c[KW]5-AuNPs compared to the corresponding 
linear system and drug alone. F-3TC-loaded l(KW)5-AuNPs exhibited a modest 
fluorescence mostly in the cytoplasm of the cells. However, incubation of cells with 
F-3TC alone did not show any fluorescence intensity in cells. These data confirm that 
the cyclic nature of the peptide is critical for the enhanced cellular permeability 
(Figure 9) and the nuclear targeting delivery of cargos.  
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 Thus, differential application of linear and cyclic [KW]5-AuNPs was 
discovered for localization of fluorescence-labeled-3TC. Confocal microscopy 
revealed the localization of fluorescence-labeled-3TC in the presence of c[KW]5-
AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other hand, l(KW)5-
AuNPs delivered fluorescence-labeled-3TC in cytoplasm. Furthermore, c[KW]4-
AuNPs offered two major advantages over c[RW]4-AuNPs that we previously 
reported.
15 
First, the reaction time for the formation of c[KW]4-AuNPs (1 h) was 
significantly shorter compared to that of c[RW]4-AuNPs (4-8 h). The Surface Plasmon 
Resonance peak for both c[KW]4-AuNPs and c[RW]4-AuNPs
15
 was compared by 
using UV-Vis spectroscopy (Figure S20) after 1 h. The results showed that c[KW]4-
AuNPs formed faster than c[RW]4-AuNPs. Second, the size and morphology of 
nanoparticles can be used to control the amount of intracellular uptake of AuNPs by 
cells. Intracellular accumulation of 233 ng and 288 ng of c[RW]4-AuNPs and c[KW]4-
AuNPs was detected, respectively, in SK-OV-3 cells after 24 h incubation
15
 as 
measured by ICP-MS.  
The molecular transporting efficiency of P-AuNPs for cell-impermeable 
negatively charges phosphopeptides was also evaluated using flow cytometry. The 
phosphopeptide do not cross the cell-membrane readily because of the presence of the 
negatively charged phosphate group. The pTyr-Glu-Glu-Ile (GpYEEI) peptide 
template has been reported to be an optimal binding sequence for the Src SH2 domain 
of Src kinase.
25
 The cellular uptake of F-GpYEEI was monitored in the presence of P-
AuNPs in SK-OV-3 cells. FACS analysis showed that the cellular uptake of F-
GpYEEI was enhanced 3.5- and 12.8-fold by l(KW)5-AuNPs and c[KW]5-AuNPs, 
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respectively (Figure 10), suggesting that these systems may function as a delivery 
tools for F-GpYEEI. c[KW]5-AuNPs improved the cellular uptake of F-GpYEEI 4.2-
fold higher when compared to l(KW)5-AuNPs, suggesting the critical role of the cyclic 
peptide in improving the cellular uptake. These results are consistent with cellular 
uptake studies of lamivudine and emtricitabine.  
 Considering the significant enhancement of F-GpYEEI in the presence of P-
AuNPs (Figure 10), confocal microscopy was used to confirm the cellular uptake of 
this negatively charged phosphopeptide in the presence and absence of P-AuNPs. 
Thus, confocal microscopy was conducted by measuring the fluorescence intensity of 
F-GpYEEI-loaded P-AuNPs compared to F-GpYEEI alone in SK-OV-3 cells. 4',6-
Diamidino-2-phenylindole (DAPI) was employed as a marker of nucleus. The cells 
were incubated with F-GpYEEI-loaded c[KW]5-AuNPs, F-GpYEEI-loaded L[KW]5-
AuNPs, and F-GpYEEI alone. No green fluorescence was observed for the parent 
fluorescence-labeled phosphopeptide, suggesting that F-GpYEEI alone did not cross 
the membrane because of the presence of negative charge phosphate. As shown in 
Figure 11, the cell nuclei stained by DAPI (blue) were circumvented by the green 
fluorescence showing the fluorescent-labeled phosphopeptide localized in the 
cytoplasm in the presence of L[KW]5-AuNPs (Figure 11b). However, the presence of 
c[KW]5-AuNPs led an overlay of green and blue fluorescence signals revealing the 
localization of the phosphopeptide mostly in the nuclei of SK-OV-3 cells (Figure 11c). 
These results indicated that the presence of P-AuNPs is critical to improve the cellular 
uptake of cell-impermeable phosphopeptide. Furthermore, the linear or cyclic nature 
of the peptide determines the final destination of the cargo.  
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Time-Dependent Antiproliferative Assay. To determine whether c[KW]5-AuNPs 
can be exploited for the delivery of biologically relevant doses of CPT to cells, the 
antiproliferative activity of CPT was evaluated in SK-OV-3 cells in the presence and 
absence of peptide-capped AuNPs in a time-dependent manner. The antiproliferative 
activity of CPT (5 M) in the presence of the c[KW]5-AuNPs was improved by 
approximately 9%, 32%, and 33% compared to that of CPT alone after 24, 48, and 72 
h incubation, respectively (Figure 12). Time-dependent inhibitory effect on the cell 
proliferation of SK-OV-3 cells suggests that the sustained intracellular release of CPT 
and improved efficacy of the compound. c[KW]5-AuNPs alone did not show any 
toxicity in SK-OV-3 cells under similar condition, suggesting that the higher 
antiproliferative is possibly related to the enhanced uptake of the drug in the presence 
of the peptide-capped AuNPs and intracellular release of CPT.  
 
Intracellular Release of Dox. To investigate the kinetics of drug release in cells, Dox 
was selected as a model drug. The intracellular release of Dox in the presence of the 
c[KW]5-AuNPs in CCRF-CEM cells was monitored by HPLC. The CCRF-CEM cells 
(1.2 × 10
7) were incubated with Dox (7.5 μM)-loaded c[KW]5-AuNPs (37.5 μM) for 
different times including 2, 12, 24, and 48 h. HPLC analysis at 490 nm and a specific 
time intervals after cellular lysis was used to measure the quantity of the released Dox. 
The data exhibited that the intracellular release of Dox occurred in a time-dependent 
manner. Dox was observed at 15.8-15.9 min in the HPLC profile (Figures S4-S9, 
Supporting Information). HPLC data showed that approximately 30, 35, 55, and 88% 
158 
 
of Dox was released intracellularly within 2, 12, 24, and 48 h, respectively. These data 
suggest the sustained release of Dox contributes to overall activity of the Dox–loaded 
c[KW]5-AuNPs as a potential prodrug.  
 
Conclusions 
In conclusion, a new class of DDS containing AuNPs and peptides with 
tryptophan and lysine residues were generated under a mild reaction condition. Cyclic 
and linear peptide capped-AuNPs (l(KW)5-AuNPs and c[KW]5-AuNPs) exhibited 
entirely different morphology and sizes. Both l(KW)5-AuNPs and c[KW]5-AuNPs 
showed minimal cytotoxicity at 100 M. P-AuNPs were able to entrap hydrophobic 
CPT through non-covalent interactions, and act as molecular transporters of 
fluorescence-labeled lamivudine, emtricitabine, and a phosphopeptide (GpYEEI) 
intracellularly. High cellular internalization of the labeled drugs by P-AuNPs suggests 
the potential application of P-AuNPs as molecular transporters. Confocal microscopy 
showed that l(KW)5-AuNPs and c[KW]5-AuNPs delivered cargos to different 
destinations in cells e.g. cytoplasm and nucleus, respectively. The present results 
provide insights for generation of a new class of peptide-capped metal nanoparticles as 
cellular delivery transporters.  
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Figure Legends: 
Figure 1: Chemical structures of synthesized cyclic peptides 
Figure 2: TEM images of c[KW]5-AuNPs 
Figure 3: TEM images of l(KW)5-AuNPs 
Figure 4: Comparative CD of cyclic c[KW]5, linear l(KW)5, and compared to c[KW]5-
AuNPs and l(KW)5-AuNPs 
Figure 5: Cellular uptake of F-l(KW)5-AuNPs and F-c[KW]5-AuNPs (5 M) versus 
the corresponding fluorescently-labeled peptides F-l(KW)5 and F-c[KW]5 (5 M) 
after 1 h incubation 
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Figure 6: Confocal microscope images of F-l(KW)5-AuNPs (5 μM) and F-c[KW]5-
AuNPs (5 μM) uptake by SK-OV-3 cells after 1 h incubation 
Figure 7: Cellular uptake of (a) F-l(KW)5-AuNPs (5 μM) and (b) F-c[KW]5-AuNPs 
(5 μM) in the absence or presence of different endocytic inhibitors in SK-OV-3 cells 
after 1 h 
Figure 8: Cellular uptake studies for F-FTC and F-3TC alone (5 M) in the presence 
of cyclic and linear peptides and their corresponding P-AuNPs (25 µM) after 1 h 
incubation 
Figure 9: Confocal microscope images of F-3TC (5 M) uptake by SK-OV-3 cells in 
the presence of l(KW)5-AuNPs and c[KW]5-AuNPs (25 M) after 1 h incubation 
Figure 10: Cellular uptake of F-GpYEEI (5 M) in the presence of l(KW)5-AuNPs, 
c[KW]5-AuNPs, l(KW)5 and c[KW]5 (25 M) after 1 h incubation 
Figure 11: Confocal microscope images of F-GpYEEI (5 M) uptake by SK-OV-3 
cells in the presence of l(KW)5-AuNPs and c[KW]5-AuNPs (25 M) after 1 h 
incubation  
Figure 12. Time-dependent antiproliferative assay of CPT in the absence and presence 
of c[KW]5-AuNPs. 
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Figure 9 
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Figure 10 
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Figure 11 
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SUPPORTING FIGURES AND SCHEMES 
Figure S1. Stability of cyclic [W(RW)4]-Dox after incubation with (a) PBS and (b) 
FBS. 
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Figure S2. Comparison of cell cycle arrest by Dox and cyclic [W(RW)4]-Dox. 
 
 
 
Figure S3. Detection of AuNP formation by UV-Vis absorption spectroscopy by 
HAuCl4 (1 mM) with different concentrations of [WR]4 (100 M-2 mM).  
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Figure S4. TEM images of [WR]4-AuNPs generated from incubation of [WR]4 with 
HAuCL4. 
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Figure S5. Cytotoxicity assay of [WR]4-AuNP and [WR]4 in SK-OV-3 cells (24 h and 
72 h), CCRF-CEM (24 h), and CCD-18Co (24 h) (mean ± SD). 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140 CCRF-CEM (24 h)
SK-OV-3 (72 h)
SK-OV-3 (24 h)
CCD-18Co (24 h)
C
e
ll
 V
ia
b
il
it
y
 (
%
)
181 
 
Figure S6. Cytotoxicity assay of [WR]4-AuNP and [WR]4 compared with polyArg 
CR7, TAT (YGRKKRRQRRRC) (100 µM), and oligofectamine 2000 in CCD-18Co 
(48 h) (mean ± SD, n = 3). 
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Figure S7. Cellular uptake of cyclic F-[W5R4K] capped-AuNP compared with FAM 
(10 M) and linear F-(W5R4K) capped-AuNP in CCRF-CEM cells. 
 
 
 
 
 
 
 
 
 
 
 
0
100
200
300
400
500
600
M
e
a
n
 f
lu
o
re
s
c
e
n
c
e
 (
a
. u
.)
183 
 
Figure S8. ICP-MS of [WR]4-AuNPs (50 M) in SK-OV-3 cells after 3 h and 24 h 
incubation (mean ± SD, n = 3).  
 
 
 
Figure S9. Membrane integrity of SK-OV-3 cells in the presence of (50 µM) and 
control (cells with serum-free media without any treatment with AuNPs) (mean ± SD, 
n = 3). 
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Figure S10. Fluorescence of Dox in the presence of [WR]4-AuNPs (1:1 molar ratio) 
after 2 h incubation. 
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Figure S11. Differential interference contrast microscopy of fluorescence-labeled 
lamivudine (F-3TC) (5 M) in the absence of [WR]4-AuNP in SK-OV-3 cells.  
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Figure S12. Cellular uptake of [WR]4 capped-AuNP without a fluorescent label (10 
M) in CCRF-CEM and [WR]4 capped-AuNP (25 M) in SK-OV-3 cells. 
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Figure S13. Flow cytometry studies for F-3TC (5 M) in the presence or absence of 
[WR]4 or [WR]4-AuNPs (25 M) in SK-OV-3 cells, (mean ± SD, n = 3). 
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Figure S14. Flow cytometry studies for F-3TC (5 M) in the presence of linear 
(WR)4, cyclic [WR]4, linear [WR]4-AuNPs, and cyclic [WR]4-AuNPs (25 M) in 
CCRF-CEM cells, respectively (mean ± SD, n = 3).  
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Figure S15. Flow cytometry studies in SK-OV-3 cells for Dox alone (5 M) and in 
the presence of [WR]4 (25 M) or [WR]4-AuNPs (25 M) after 1 h (mean ± SD, n = 
3).  
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Figure S16. UV-Vis spectroscopy of peptide-capped gold nanoparticles.  
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Figure S17. Cytotoxicity of peptides and corresponding P-AuNPs.  
 
 
 
 
Figure S18. Membrane integrity of SK-OV-3 cells in the presence of P-AuNPs (50 
μM) (mean ± SD, n =3).  
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Figure S19. Fluorescence of CPT in the presence of c[KW]5-AuNPs and l[(KW)5-
AuNPs (1:1 molar ratio) after 4 h incubation.  
 
 
 
Figure S20. UV-Vis spectroscopy of c[KW]4-AuNPs and c[RW]4-AuNPs. 
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Scheme S1. Solid-phase synthesis of [WE]4 and linear (WR)4. 
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Scheme S2. Solid-phase synthesis of l(KW)4, c[KW]4, and F-l(KW)5. 
 
 
 
 
 
 
